

Tennessee HIV Epidemiological Profile, 2019

Tennessee Department of Health | February 2021



Table of contents

| Table of figures | 2 |
|--|----|
| Table of tables | |
| Executive summary | |
| Key findings | |
| Background | |
| Reporting laws and regulations | 10 |
| History of the epidemic | 11 |
| Persons newly diagnosed with HIV | 14 |
| Persons living with diagnosed HIV | 22 |
| Deaths among persons with diagnosed HIV | 29 |
| Perinatal HIV exposures | 32 |
| HIV Continuum of Care | 36 |
| Technical notes | 42 |
| Acknowledgements | 44 |
| Authors | 44 |
| Glossary | 45 |
| Abbreviations | 47 |
| References | 48 |
| Appendix A: Tennessee maps | 49 |
| Appendix B: Persons newly diagnosed with HIV | 51 |
| Appendix C: Persons living with diagnosed HIV | 53 |
| Appendix D: Deaths among persons living with diagnosed HIV | 55 |
| Appendix E: Perinatal HIV exposures | 56 |
| Appendix F: State data | 59 |
| Appendix G: Public health regional data | 60 |
| Appendix H: HIV community planning region data | 99 |

Table of figures

| Figure 1. HIV milestones, Tennessee, 1982–2019 | 11 |
|---|---------|
| Figure 2. Number of persons newly diagnosed with HIV by stage at diagnosis, | 12 |
| Tennessee, 1982–2019 | 12 |
| Figure 3. Number of persons living with HIV ever diagnosed with HIV Stages 0–2 and | 12 |
| Stage 3 (AIDS), Tennessee, 1982–2019 | 12 |
| Figure 4. Number of deaths among persons with diagnosed HIV, Tennessee, 1982–2018 | 13 |
| Figure 5. Persons newly diagnosed with HIV, Tennessee, 2015–2019 | 14 |
| Figure 6. Persons newly diagnosed with HIV by gender, Tennessee, 2015–2019 | |
| Figure 7. Persons newly diagnosed with HIV by age group, Tennessee, 2015–2019 | |
| Figure 8. Persons newly diagnosed with HIV by race/ethnicity, Tennessee, 2015–2019 | 16 |
| Figure 9. Cisgender males newly diagnosed with HIV by race/ethnicity, | 16 |
| Tennessee, 2015–2019 | 16 |
| Figure 10. Cisgender females newly diagnosed with HIV by race/ethnicity, | 17 |
| Tennessee, 2015–2019 | 17 |
| Figure 11. Number of cisgender males newly diagnosed with HIV who reported | 18 |
| male-to-male sexual contact by race/ethnicity, Tennessee, 2015–2019 | 18 |
| Figure 12. Number of cisgender males newly diagnosed with HIV by non-male-to-male sexual contact | |
| transmission risk, Tennessee, 2015–2019 | 19 |
| Figure 13. Number of cisgender females newly diagnosed with HIV who reported heterosexual sexual con | tact by |
| race/ethnicity, Tennessee, 2015–2019 | 19 |
| Figure 14. Cisgender females newly diagnosed with HIV by non-heterosexual sexual contact transmission | risk, |
| Tennessee 2015–2019 | 20 |
| Figure 15. Percentage of transgender persons newly diagnosed with HIV by transmission risk, Tennessee 2 | 2015- |
| 2019 | 20 |
| Figure 16. Rate of persons newly diagnosed with HIV per 100,000 persons by county, Tennessee, 2019 | 21 |
| Figure 18. Persons living with diagnosed HIV, Tennessee, 2015–2019 | 22 |
| Figure 19. Number of persons living with HIV Stages 0–2 and Stage 3 (AIDS) | 22 |
| Tennessee, 2015–2019 | 22 |
| Figure 20. Persons living with diagnosed HIV by gender, Tennessee, 2015–2019 | 23 |
| Figure 21. Persons living with diagnosed HIV by age group, Tennessee, 2015–2019 | 23 |
| Figure 22. Persons living with diagnosed HIV by race/ethnicity, Tennessee, 2015–2019 | 24 |
| Figure 23. Cisgender males living with diagnosed HIV by race/ethnicity, | 24 |
| Tennessee, 2015–2019 | 24 |
| Figure 24. Cisgender females living with diagnosed HIV by race/ethnicity, | 25 |
| Tennessee, 2015–2019 | |
| Figure 25. Number of cisgender males living with diagnosed HIV who reported male-to-male sexual conta | ict by |
| race/ethnicity, Tennessee, 2015–2019 | 25 |
| Figure 26. Number of cisgender males living with diagnosed HIV by non-male-to-male sexual contact | |
| transmission risk, Tennessee, 2015–2019 | 26 |
| Figure 27. Number of cisgender females living with diagnosed HIV who reported heterosexual sexual cont | act by |
| race/ethnicity Tennessee 2015–2019 | 26 |

| Figure 28. Number of cisgender females living with diagnosed HIV by non-heterosexual sexual contact | |
|---|-----|
| transmission risk, Tennessee 2015–2019 | 27 |
| Figure 29. Percentage of transgender persons living with diagnosed HIV by transmission risk, Tennessee, 20 | 15- |
| 2019 | 28 |
| Figure 30. Rate of persons living with diagnosed HIV per 100,000 persons by county, Tennessee, 2019 | 28 |
| Figure 31. Deaths among persons with diagnosed HIV, Tennessee, 2014–2018 | 29 |
| Figure 32. Deaths among persons with diagnosed HIV by gender, Tennessee, 2014–2018 | 29 |
| Figure 33. Deaths among persons with diagnosed HIV by age group, Tennessee, 2014–2018 | 30 |
| Figure 34. Deaths among persons with diagnosed HIV by race/ethnicity, | 30 |
| Tennessee, 2014–2018 | 30 |
| Figure 35. Death rate among persons with diagnosed HIV by county, Tennessee, 2018 | 31 |
| Figure 36. Births among pregnant persons with diagnosed HIV, Tennessee, 2014–2018 | 32 |
| Figure 37. Number of persons born to pregnant persons with diagnosed HIV, by HIV status, Tennessee, 2014 | 1– |
| 2018 | 33 |
| Figure 38. Time of HIV diagnoses among pregnant persons, Tennessee, 2014–2018 | 33 |
| Figure 39. Pregnant persons with diagnosed HIV by age group, Tennessee, 2014–2018 | 34 |
| Figure 40. Pregnant persons with diagnosed HIV by race/ethnicity, | 34 |
| Tennessee, 2014–2018 | 34 |
| Figure 41. Pregnant persons with diagnosed HIV by transmission risk, Tennessee 2014–2018 | |
| Figure 42. Continuum of Care, Tennessee, 2018 | 36 |
| Figure 43. Continuum of Care by Ryan White enrollment status, Tennessee, 2018 | 37 |
| Figure 44. Linkage to care by time to linkage and Ryan White enrollment status, | 38 |
| Tennessee, 2018 | 38 |
| Figure 45. Proportion of newly diagnosed individuals linked to care within 30 days, by select populations, | |
| Tennessee, 2014–2018 | 39 |
| Figure 46. Proportion of persons living with diagnosed HIV engaged in care, by select populations, Tennesse | e, |
| 2014–2018 | 40 |
| Figure 47. Proportion of persons living with diagnosed HIV with viral suppression, by select populations, | |
| Tennessee, 2014–2018 | 41 |
| Figure 48. Tennessee public health regions | 49 |
| Figure 49. Tennessee HIV community planning regions | 50 |

Table of tables

| Table 1. Persons newly diagnosed with HIV, Tennessee, 2015–2019 | 51 |
|--|-------|
| Table 2. Persons newly diagnosed with HIV by transmission risk, Tennessee, 2015–2019 | 52 |
| Table 3. Persons living with diagnosed HIV, Tennessee, 2015–2019 | 53 |
| Table 4. Persons living with diagnosed HIV by transmission risk, Tennessee, 2015–2019 | 54 |
| Table 8. Deaths among persons with diagnosed HIV, Tennessee, 2014–2018 | 55 |
| Table 5. Age group and race of pregnant persons diagnosed with HIV, Tennessee, 2014–2018 | 56 |
| Table 6. Characteristics of pregnant persons diagnosed with HIV, Tennessee, 2014–2018 | 57 |
| Table 7. Infants born to pregnant persons diagnosed with HIV, Tennessee, 2014–2018 | 58 |
| Table 9. Persons diagnosed with HIV, Tennessee, 2019 | 59 |
| Table 10. Persons newly diagnosed with HIV, Memphis/Shelby County, Tennessee, 2015–2019 | 60 |
| Table 11. Persons newly diagnosed with HIV, West public health region, Tennessee, 2015–2019 | 61 |
| Table 12. Persons newly diagnosed with HIV, Jackson/Madison County, Tennessee, 2015–2019 | 62 |
| Table 13. Persons newly diagnosed with HIV, South Central public health region, | 63 |
| Tennessee, 2015–2019 | 63 |
| Table 14. Persons newly diagnosed with HIV, Mid-Cumberland public health region, | 64 |
| Tennessee, 2015–2019 | 64 |
| Table 15. Persons newly diagnosed with HIV, Nashville/Davidson County, Tennessee, 2015–2019 | 65 |
| Table 16. Persons newly diagnosed with HIV, Upper Cumberland public health region, | 66 |
| Tennessee, 2015–2019 | 66 |
| Table 17. Persons newly diagnosed with HIV, Southeast public health region, Tennessee, 2015–2019 | 67 |
| Table 18. Persons newly diagnosed with HIV, Chattanooga/Hamilton County, Tennessee, 2015–2019 | 68 |
| Table 19. Persons newly diagnosed with HIV, East public health region, Tennessee, 2015–2019 | 69 |
| Table 20. Persons newly diagnosed with HIV, Knoxville/Knox County, Tennessee, 2015–2019 | 70 |
| Table 21. Persons newly diagnosed with HIV, Northeast public health region, Tennessee, 2015–2019 | 71 |
| Table 22. Persons newly diagnosed with HIV, Blountville/Sullivan County public health region, Tennessee, 201 | 15- |
| 2019 | 72 |
| Table 23. Persons concurrently diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of diagno | osis, |
| Memphis/Shelby County, Tennessee, 2015–2019 | 73 |
| Table 24. Persons concurrently diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of diagno | osis, |
| West public health region, Tennessee, 2015–2019 | 74 |
| Table 25. Persons concurrently diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of diagno | osis, |
| Jackson/Madison County, Tennessee, 2015–2019 | 75 |
| Table 26. Persons concurrently diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of diagno | osis, |
| South Central public health region, Tennessee, 2015–2019 | 76 |
| Table 27. Persons concurrently diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of diagno | osis, |
| Mid-Cumberland public health region, Tennessee, 2015–2019 | 77 |
| Table 28. Persons concurrently diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of diagno | osis, |
| Nashville/Davidson County, Tennessee, 2015–2019 | 78 |
| Table 29. Persons concurrently diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of diagno | osis, |
| Upper Cumberland public health region, Tennessee, 2015–2019 | 79 |
| Table 30. Persons concurrently diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of diagno | osis, |
| Southeast public health region, Tennessee, 2015–2019 | 80 |

| Table 31. Persons concurrently diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of di | _ |
|--|-----------|
| Chattanooga/Hamilton County, Tennessee, 2015–2019 | |
| Table 32. Persons concurrently diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of di | _ |
| East public health region, Tennessee, 2015–2019 | |
| Table 33. Persons concurrently diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of di | iagnosis, |
| Knoxville/Knox County, Tennessee, 2015–2019 | 83 |
| Table 34. Persons concurrently diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of di | iagnosis, |
| Northeast public health region, Tennessee, 2015–2019 | 84 |
| Table 35. Persons concurrently diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of diagnosed with HIV Stages 1 and 1 a | iagnosis, |
| Blountville/Sullivan County public health region, Tennessee, 2015–2019 | 85 |
| Table 36. Persons living with diagnosed HIV, Memphis/Shelby County, Tennessee, 2015–2019 | 86 |
| Table 37. Persons living with diagnosed HIV, West public health region, Tennessee, 2015–2019 | 87 |
| Table 38. Persons living with diagnosed HIV, Jackson/Madison County, Tennessee, 2015–2019 | 88 |
| Table 39. Persons living with diagnosed HIV, South Central public health region, | 89 |
| Tennessee, 2015–2019 | 89 |
| Table 40. Persons living with diagnosed HIV, Mid-Cumberland public health region, Tennessee, 2015–20 | 19 90 |
| Table 41. Persons living with diagnosed HIV, Nashville/Davidson County, Tennessee, 2015–2019 | 91 |
| Table 42. Persons living with diagnosed HIV, Upper Cumberland public health region, | 92 |
| Tennessee, 2015–2019 | 92 |
| Table 43. Persons living with diagnosed HIV, Southeast public health region, Tennessee, 2015–2019 | 93 |
| Table 44. Persons living with diagnosed HIV, Chattanooga/Hamilton County, Tennessee, 2015–2019 | 94 |
| Table 45. Persons living with diagnosed HIV, East public health region, Tennessee, 2015–2019 | 95 |
| Table 46. Persons living with diagnosed HIV, Knoxville/Knox County, Tennessee, 2015–2019 | 96 |
| Table 47. Persons living with diagnosed HIV, Northeast public health region, Tennessee, 2015–2019 | 97 |
| Table 48. Persons living with diagnosed HIV, Blountville/Sullivan County public health region, Tennessee, | 2015- |
| 2019 | 98 |
| Table 49. Persons newly diagnosed with HIV, Southwest HIV community planning region, | 99 |
| Tennessee, 2015–2019 | 99 |
| Table 50. Persons newly diagnosed with HIV, West HIV community planning region, | 100 |
| Tennessee, 2015–2019 | 100 |
| Table 51. Persons newly diagnosed with HIV, Middle HIV community planning region, | 101 |
| Tennessee, 2015–2019 | 101 |
| Table 52. Persons newly diagnosed with HIV, Southeast HIV community planning region, | 102 |
| Tennessee, 2015–2019 | 102 |
| Table 53. Persons newly diagnosed with HIV, East HIV community planning region, | 103 |
| Tennessee, 2015–2019 | 103 |
| Table 54. Persons concurrently diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of di | iagnosis, |
| Southwest HIV community planning region, Tennessee, 2015–2019 | 104 |
| Table 55. Persons concurrently diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of di | |
| West HIV community planning region, Tennessee, 2015–2019 | _ |
| Table 56. Persons concurrently diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of di | |
| Middle HIV community planning region, Tennessee, 2015–2019 | |

| able 57. Persons concurrently diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of diag | |
|---|-----------------|
| Southeast HIV community planning region, Tennessee, 2015–2019 | 107 |
| Table 58. Persons concurrently diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 month | s of diagnosis, |
| East HIV community planning region, Tennessee, 2015–2019 | 108 |
| Table 59. Persons living with diagnosed HIV, Southwest HIV community planning region, Tennessed | e, 2015–2019 |
| | 109 |
| Table 60. Persons living with diagnosed HIV, West HIV community planning region, | 110 |
| Tennessee, 2015–2019 | 110 |
| Table 61. Persons living with diagnosed HIV, Middle HIV community planning region, | 111 |
| Tennessee, 2015–2019 | 111 |
| Table 62. Persons living with diagnosed HIV, Southeast HIV community planning region, | 112 |
| Tennessee, 2015–2019 | 112 |
| Table 63. Persons living with diagnosed HIV, East HIV community planning region, | 113 |
| Tennessee, 2015–2019 | 113 |

Executive summary

This report presents 2019 surveillance data for human immunodeficiency virus (HIV) in Tennessee, focusing on persons newly diagnosed with HIV, those with concurrent late stage diagnosis (HIV Stage 3 or acquired immunodeficiency syndrome [AIDS]), persons living with diagnosed HIV (PLWH), deaths among persons diagnosed with HIV and HIV-related health outcomes among newly diagnosed individuals and PLWH (i.e., HIV Continuum of Care). The purpose of this report is to support HIV-related education, outcome monitoring and program planning.

All data presented are based on information received by Tennessee Department of Health (TDH) as of July 13, 2020. The data in this report reflect five-year trends between 2015 and 2019 for new diagnoses, late stage diagnoses and PLWH. Due to standard reporting delays, deaths among persons with diagnosed HIV and HIV Continuum of Care data are presented for 2015–2018

Data are presented in the form of total counts, rates per 100,000 persons, percentages of the total and percent change over time. Data are also stratified by various categories, including gender, race and ethnicity and age category. Rates are equal to counts divided by the total population and are presented alongside totals to account for differences in total population, such as between racial and ethnic groups. Percent change over time is presented to show the general trend over multiple years. Percent change is not presented when any yearly count is less than 20; it is difficult to draw meaningful conclusions concerning trends due to the instability of low counts.

Key findings

- Between 2015 and 2019, the number of persons newly diagnosed and PWLH increased. In 2019, 776 people were newly diagnosed with HIV, compared to 745 persons in 2015 (4% total increase). The number of PWLH also increased 4%, from 17,132 in 2015 to 17,864 in 2019.
- The majority of individuals newly diagnosed with HIV and PLWH were concentrated in a few geographic regions of the state. In 2019, Memphis/Shelby County accounted for 34.0% of new diagnoses and 36.6% of PLWH. Nashville/Davidson County accounted for 20.1% of new diagnoses and 21.2% of PLWH in the same year.
- The largest number (N=289) and highest rate (30.4 per 100,000) of new diagnoses in 2019 occurred among Tennesseans aged 25–34 years.
- Cisgender males between the ages of 15 and 34 years old were disproportionately affected by new HIV diagnoses. Among cisgender males newly diagnosed and living with HIV, maleto-male sexual contact (MMS) was the most commonly reported transmission risk. More than a quarter of newly diagnosed cisgender men in 2019 were non-Hispanic Black men who have sex with men (MSM) aged 15–34 years (27.2%).
- Among cisgender females newly diagnosed and living with HIV in 2019, heterosexual sexual contact was the most commonly reported transmission risk (49.3% and 38.0% respectively).
- Non-Hispanic Black individuals experienced the highest burden of HIV across all gender, age and transmission risk categories. In 2019, non-Hispanic Black individuals were diagnosed with HIV at a rate of 35.6 per 100,000 persons, compared to 18.7 among Hispanic individuals and 5.4 among non-Hispanic white individuals.
- In 2019, 7% of new diagnoses occurred among persons who inject drugs (PWID).

Background

Tennessee is a mid-sized state that consists of 95 counties and borders eight other states. TDH's Central Office, located in Nashville, partners with all of the state's counties, which are divided into 13 public health regions. Six of the most populous counties operate as stand-alone metropolitan public health regions, and the remaining 89 counties are combined into seven rural public health regions. The rural counties are considered an extension of TDH, whereas TDH partners with the metropolitan regions through contractual agreements. For community planning and HIV prevention and care funding purposes, the state is divided into five HIV community planning region (see Appendix A).

Population: Tennessee was home to 6,829,174 people in 2019, which accounts for approximately 2% of the population in the United States.¹ With a growth rate of 1%, similar to the national rate, the population of Tennessee increased by 234,118 people between 2015 and 2019.¹ The regional public health jurisdictions with the largest percentages of the population include the Mid-Cumberland Region (19.5%), Memphis/Shelby County (13.7%), East Tennessee Region (11.4%), and Nashville/Davidson County (10.2%).

Age: The median age in Tennessee in 2019 was 39 years, similar to that of the US median age (38 years). The age distribution in Tennessee roughly reflects that of the US population in general.²

Race and ethnicity: In 2019, 74% of the population in Tennessee was non-Hispanic white, followed by 17% Non-Hispanic Black and 6% Hispanic. Other racial groups make up the remaining 5% of the population, with the largest category in this fraction being Asian (2%).³

Income and poverty: The median household income in Tennessee in 2019 was \$53,320, compared to the US median income of \$62,843.^{4,5} Tennessee continues to experience racial and ethnic disparities in household income, with white households reporting higher median income (\$56,725) compared to Black and Hispanic households (\$38,791 and \$43,885, respectively).⁵ The statewide poverty rate in 2019 was 15%; the highest proportions of households living in poverty, ranging from 20% to 29%, were concentrated in the rural Northeast and West public health regions.⁵

Viral hepatitis (VH): In Tennessee, the number and rate of newly reported cases of confirmed and probable acute hepatitis B virus (HBV), acute hepatitis C virus (HCV), and chronic HCV increased from 2014 to 2018. In 2018, there were 388 (5.7 per 100,000 persons) acute HBV infections, 273 (4.0 per 100,000 persons) acute HCV infections and 20,066 (296.4 per 100,000 persons) chronic HCV infections. Throughout 2014–2018, non-Hispanic white persons had the highest rates of acute HBV, acute HCV and chronic HCV compared to non-Hispanic Black and Hispanic individuals. Northeastern Tennessee has the highest rates of acute and chronic infection. In 2018 individuals aged 30 years and older accounted for 95% of all newly reported acute HBV infections. Lower rates of infection in persons less than 30 years of age are likely due to increased vaccine coverage from routine childhood vaccination against HBV. Intravenous drug use was the most frequently reported transmission risk among newly reported acute HCV infections in 2018 (34.4%).

Sexually transmitted infections (STIs): In Tennessee, the number and rate of reported cases of chlamydia, gonorrhea and primary and secondary (P&S) syphilis increased from 2015–2019. In 2019, 41,501 (607.7 per 100,000 persons) chlamydia infections, 16,183 (237.0 per 100,000 persons)

gonorrhea infections and 683 (10.0 per 100,000 persons) P&S syphilis infections were r,eported. Throughout 2015–2019, non-Hispanic Black persons had the highest rates of chlamydia, gonorrhea and P&S syphilis compared to non-Hispanic white and Hispanic individuals. In 2019, Memphis/Shelby County had the highest rate of chlamydia (1096.9 per 100,000 persons) and gonorrhea infections (454.8 per 100,000 persons). The Memphis Metropolitan Statistical Area (MSA) was ranked number one for rates of chlamydia and gonorrhea among US MSAs in 2018.^{6,7} Nashville/Davidson County had the highest rate of P&S syphilis infections in Tennessee (26.7 per 100,000 persons). Male-to-male sexual contact (MMS) was the most frequently reported transmission risk among persons diagnosed with P&S syphilis (44%). Additionally, 28% of persons diagnosed with P&S syphilis were co-infected with HIV in 2019.

Opioid use: In 2019, the rate of filled opioid pain prescriptions in Tennessee was 793 per 1,000 persons compared to the national rate of 514 per 1,000 persons. The number of drug overdose deaths involving opioids in Tennessee increased 26% from 2015–2018. Over 1,300 persons died as a result of an opioid overdose in 2018 in Tennessee. Knoxville/Knox County had the highest rate of drug overdose deaths involving opioids followed by Nashville/Davidson County (48 and 27 per 100,000 persons, respectively).⁸

Reporting laws and regulations

The TDH HIV Surveillance and Epidemiology Program manages the Tennessee HIV surveillance system. AIDS became reportable in TN in 1982, followed by HIV in 1992. Because HIV and AIDS are reportable conditions by law (T.C.A. §1200-14-01-.02), medical labs are required to send all HIV-related laboratory reports to TDH; this includes diagnostic tests, CD4 lymphocyte counts and HIV viral load results. HIV-1 genotype nucleotide sequences are reportable by laboratories with Electronic Laboratory Reporting (ELR) ability. Laboratory results are reported by providers and laboratories either by paper, electronic files (e.g., Excel files via email) and/or via ELR. These are reported to TDH within one week of identification.

In addition to the laboratory results, case report forms containing demographic characteristics, HIV transmission risk and treatment information are collected by regional public health field staff. This information is then stored in the enhanced HIV/AIDS Reporting System (eHARS). TDH's Reportable Disease regulations can be found at https://www.tn.gov/health/cedep/reportable-diseases.html.

In accordance with T.C.A. §37-1-403, any physician or other person diagnosing or treating any sexually transmitted disease or venereal herpes in children 13 years of age or younger should immediately make a confidential written report of the case to TDH.

History of the epidemic





Figure 1. HIV milestones, Tennessee, 1982-2019


Reporting requirements and surveillance practices have evolved since the beginning of the HIV crisis in the early 1980s. These enhanced practices altered the way persons diagnosed and living with diagnosed HIV are counted. Medical advancements and prevention practices (e.g., highly active antiretroviral therapy [HAART], pre-exposure prophylaxis [PrEP], treatment as prevention [TasP]) reduced the number of new HIV infections and increased lifespans of persons diagnosed with HIV.

Figure 2. Number of persons newly diagnosed with HIV by stage at diagnosis, Tennessee, 1982–2019



Since 1992, the number of persons with Stage 3 HIV (AIDS) at the time of their diagnosis has decreased significantly (Figure 2). Starting in 2008, more individuals were newly diagnosed with HIV at Stages 0–2 than Stage 3 (AIDS). This trend has continued through 2019.

Figure 3. Number of persons living with HIV ever diagnosed with HIV Stages 0–2 and Stage 3 (AIDS), Tennessee, 1982–2019



The number of persons living with diagnosed HIV continues to increase due to advances in treatment that improve health and prolong the lives of PLWH (Figure 3). Data for 2014 represent one exception to this trend; new surveillance activities, including enhanced death ascertainment and the use of Accurint, a subscription-based database compiling publicly available address information, to update current address for all persons in the TDH eHARS database, accounted for the artificial decrease in PLWH. These methods have not changed since 2014.



Figure 4. Number of deaths among persons with diagnosed HIV, Tennessee, 1982–2018

The number of deaths among PLWH decreased significantly since 1995 when highly active antiretroviral therapy (HAART) was introduced in Tennessee (Figure 4). Prior to 2012, the death data presented were based on residence at the time of diagnosis. Starting with 2012 data, death data are presented based on the residence at the time of death. The number of deaths among persons with diagnosed HIV increased by 13% from 299 to 339 from 2016 to 2018.

0

Persons newly diagnosed with HIV

The following data are presented for persons newly diagnosed with HIV. For more information on persons newly diagnosed with HIV by gender, age, race/ethnicity and transmission risk, please refer to the data tables in Appendix B. For additional data on persons newly diagnosed with HIV, please visit the HIV data dashboards (https://www.tn.gov/health/health-program-areas/statistics/health-data/hiv-data.html).




Figure 5. Persons newly diagnosed with HIV, Tennessee, 2015–2019

The number of persons newly diagnosed with HIV increased from 745 to 776, a change of 4% between 2015 and 2019 (Figure 5). The increase in the number of persons newly diagnosed with HIV between 2016 and 2019 is hypothesized to be, in part, the result of improved surveillance, including more complete and timely reporting from testing sites. This improvement is coupled with increased, earlier and more targeted testing in areas where increased transmission is identified, particularly among at-risk groups (i.e., PWID).

Number of persons Rate per 100,000 persons 800 20 +5% +2% 15 600 10 400 200

0%

2017

Cisgender males

2018

2015

2016

Figure 6. Persons newly diagnosed with HIV by gender, Tennessee, 2015–2019

Similar to US trends, cisgender males were diagnosed with HIV at a higher rate than cisgender females (Figure 6). Between 2015 and 2019, the rate of persons newly diagnosed with HIV increased from 18.2 to 18.5 per 100,000 persons among cisgender men and decreased from 4.4 to 4.2 per 100,000 among cisgender women. Rates of persons newly diagnosed with HIV cannot be calculated for transgender persons because the total population of persons who identify as transgender individuals is not established for Tennessee.

2015

2016

2017

Transgender persons

2018

2019

2019

Cisgender females





Figure 7. Persons newly diagnosed with HIV by age group, Tennessee, 2015–2019


During 2015 to 2019, 25–34 year olds represented the largest proportion of persons newly diagnosed with HIV (Figure 7). The greatest declines in new diagnoses were observed among persons 15-24 and 45-54 years old. The greatest increase in new diagnoses was observed among persons 55+ years old.

Figure 8. Persons newly diagnosed with HIV by race/ethnicity, Tennessee, 2015–2019



Despite annual decreases over the five-year period, non-Hispanic Black individuals represented the highest numbers and rates of persons newly diagnosed with HIV (Figure 8). Notably, in 2019, non-Hispanic Black individuals had a rate of 35.6 diagnoses per 100,000 persons and accounted for 52% of all persons newly diagnosed with HIV yet comprised only 17% of the total Tennessee population in 2019. Despite having the lowest number of new HIV diagnoses, Hispanic individuals had the second highest rate of new diagnoses in 2019 (18.7 diagnoses per 100,000 persons). The rate of persons newly diagnosed with HIV among Hispanic individuals increased 27% between 2015 and 2019.


Figure 9. Cisgender males newly diagnosed with HIV by race/ethnicity, Tennessee. 2015–2019



Non-Hispanic Black cisgender males, who represent 16% of the male population in Tennessee in


2019 account for more than half of cisgender males newly diagnosed with HIV in 2019 (Figure 9). Overall, the number of cisgender men newly diagnosed with HIV increased between 2015 and 2019 from 586 to 618.

Figure 10. Cisgender females newly diagnosed with HIV by race/ethnicity, Tennessee, 2015–2019




Non-Hispanic Black cisgender females, who represent 17% of all females in Tennessee in 2019, represented nearly three-fifths (58%) of all cisgender females newly diagnosed with HIV in 2019 (Figure 10). During 2015 to 2019, the rate of new HIV diagnoses among non-Hispanic Black cisgender females decreased from 15.1 to 13.9 per 100,000. Because small numbers of cases among Hispanic cisgender women make drawing meaningful conclusions about changes over time difficult, no percent change is displayed.

Figure 11. Number of cisgender males newly diagnosed with HIV who reported male-to-male sexual contact by race/ethnicity, Tennessee, 2015–2019



Between 2015 and 2019, MMS was the most commonly reported transmission risk by cisgender males newly diagnosed with HIV and accounted for more than half of new diagnoses among cisgender males (N=419; Figure 11). The majority of cisgender males newly diagnosed with HIV who reported MMS were non-Hispanic Black though the number of new diagnoses in this population decreased 13% over this time period. The number of newly diagnosed non-Hispanic white cisgender men who reported MMS increased 15% during the same time period.


Figure 12. Number of cisgender males newly diagnosed with HIV by non-male-to-male sexual contact transmission risk, Tennessee, 2015–2019



IDU: Injection drug use, MMS + IDU: Male-to-male sexual contact with injection drug use, HET: Heterosexual sexual contact

During 2015 to 2019, reported heterosexual sexual contact among cisgender males newly diagnosed with HIV decreased 24% (Figure 12). Approximately one in every seven cisgender males newly diagnosed with HIV in 2019 had no reported transmission risk.


Figure 13. Number of cisgender females newly diagnosed with HIV who reported heterosexual sexual contact by race/ethnicity, Tennessee, 2015–2019



Between 2015 and 2019, about half of cisgender women newly diagnosed with HIV reported heterosexual sexual contact as a transmission risk (N=72; Figure 13). The majority of these individuals were non-Hispanic Black (68%). Over the 5-year period, the number of new diagnoses

in non-Hispanic Black cisgender women with reported heterosexual sexual contact decreased 19% and 50% for non-Hispanic white cisgender women.


Figure 14. Cisgender females newly diagnosed with HIV by non-heterosexual sexual contact transmission risk, Tennessee 2015–2019



IDU: Injection drug use


In 2019, transmission risk categories other than heterosexual sexual contact were reported by 51% (N=74) newly diagnosed cisgender women (Figure 14). The number of people newly diagnosed who reported injection drug use or no known transmission risk increased over the time period while the number exposed in utero (perinatal exposure) decreased consistently.

Figure 15. Percentage of transgender persons newly diagnosed with HIV by transmission risk, Tennessee 2015–2019




The most commonly reported transmission risk among transgender persons newly diagnosed with HIV was any sexual contact between 2015 and 2019 (Figure 15).

Figure 16. Rate of persons newly diagnosed with HIV per 100,000 persons by county, Tennessee, 2019



The highest concentration of new diagnoses in Tennessee was identified in the metropolitan areas of the state. More than half of Tennessee's counties had an estimated rate of new diagnoses between 0.5 and 11.4 per 100,000 persons (light blue shading) and a more than one third of counties did not have a newly diagnosed person (white). The highest rates (dark blue) continue to be concentrated in metropolitan areas, including Memphis/Shelby County (28.2 per 100,000 persons) and Nashville/Davidson County (22.5 per 100,000 persons). The overall state rate of new HIV diagnoses in 2019 was 11.4 per 100,000 persons (Figure 16).

Figure 17. Number of persons newly diagnosed with HIV, by stage within 12 months of diagnosis, Tennessee, 2015–2019



Individuals diagnosed with Stage 3 HIV (AIDS) within 12 months of a new HIV diagnosis are considered a concurrent or late diagnosis and indicate a delayed awareness of HIV status. Over time, the proportion of people concurrently diagnosed with HIV and Stage 3 HIV (AIDS) has decreased: between 2015 and 2019, the percent receiving late diagnoses of HIV improved from 20.7% to 18.8% (Figure 17).

Persons living with diagnosed HIV

The following data are presented for persons living with diagnosed HIV. For more information on persons living with diagnosed HIV by gender, age, race/ethnicity and transmission risk, please refer to the data tables in Appendix C. For additional data on PLWH, please visit the HIV data dashboards (https://www.tn.gov/health/health-program-areas/statistics/health-data/hiv-data.html).




Figure 18. Persons living with diagnosed HIV, Tennessee, 2015–2019

The number of PLWH increased over time from 17,132 in 2015 to 17,864 in 2019 (Figure 18). It is expected that the number of PLWH, as well as rates per 100,000 persons, will continue to increase due to new diagnoses and aging of PLWH.





Figure 19. Number of persons living with HIV Stages 0-2 and Stage 3 (AIDS)

Tennessee 2015-2019


During 2015 to 2019, the proportion of PLWH with a history of HIV Stage 3 (AIDS) diagnosis decreased slightly (50.8% to 48.4%; Figure 19).

Figure 20. Persons living with diagnosed HIV by gender, Tennessee, 2015–2019



During 2015 to 2019, the rate of PLWH was approximately 3.2 times higher among cisgender men compared to cisgender women (Figure 20). This gender disparity reflects national trends. Rates of transgender PLWH cannot be calculated for transgender persons because the total population size of transgender individuals is not known.

Figure 21. Persons living with diagnosed HIV by age group, Tennessee, 2015–2019



Between 2015 and 2019, the highest number and rate of PLWH were consistently among persons aged 45–54 years (Figure 21). However, in 2019, the number of PLWH aged 55 years and older surpassed the number of PLWH aged 45–54 years after increasing by 29% over this time period (3,848 to 5,419). This is likely driven by improvements in care for PLWH that have extended life expectancy.

Number of persons Rate per 100,000 persons +4% 0% +2% +12% +1%

Figure 22. Persons living with diagnosed HIV by race/ethnicity, Tennessee, 2015-2019

Multi-year trends by race and ethnicity among PLWH are similar to those seen among persons newly diagnosed with HIV, including the significant disparity seen among non-Hispanic Black persons who have the HIV highest rates in the state (Figure 22).

Non-Hispanic Black





Figure 23. Cisgender males living with diagnosed HIV by race/ethnicity, Tennessee, 2015–2019

Non-Hispanic white

Hispanic


Over the five-year period, rates for all three racial and ethnic groups increased. Though non-Hispanic white individuals represent the largest numbers of cisgender men living with an HIV diagnosis, the highest rates for cisgender males are among non-Hispanic Black individuals (Figure 23).

Figure 24. Cisgender females living with diagnosed HIV by race/ethnicity, Tennessee, 2015–2019



Though the numbers of Hispanic cisgender women living the HIV increased over the five-year period, the rate decreased due to high population growth. Additionally, the highest rates of cisgender women living the HIV continue to be seen among non-Hispanic Black cisgender women, decreasing from 520.5 per 100,000 persons in 2015 to 507.6 per 100,000 in 2019 (Figure 24).


Figure 25. Number of cisgender males living with diagnosed HIV who reported male-to-male sexual contact by race/ethnicity, Tennessee, 2015–2019



MMS contact was consistently reported by the largest number of cisgender males living with diagnosed HIV in Tennessee; 67.3% of cisgender men living with diagnosed HIV reported MMS contact in 2019 (Figure 25). Though more cisgender men of non-Hispanic Black race were living with HIV than their non-Hispanic white counterparts, almost equal numbers in each group

reported MMS contact.


Figure 26. Number of cisgender males living with diagnosed HIV by non-male-to-male sexual contact transmission risk, Tennessee, 2015–2019



IDU: Injection drug use, MMS + IDU: Male-to-male sexual contact with injection drug use, HET: Heterosexual sexual contact

Among cisgender men living with diagnosed HIV, the transmission risk with the greatest reported decrease was injection drug use (Figure 26). However, the number people who reported heterosexual sexual contact and unknown risk, respectively, increased 5% and 6% over the past five years.


Figure 27. Number of cisgender females living with diagnosed HIV who reported heterosexual sexual contact by race/ethnicity, Tennessee, 2015–2019



Between 2015 and 2019, heterosexual sexual contact was the most commonly reported

transmission risk by cisgender females living with diagnosed HIV, accounting for more than 70% of cisgender women living with HIV in 2019 (N=3,153; Figure 27). Most cisgender females living with diagnosed HIV who reported heterosexual sexual contact were non-Hispanic Black; the number of cisgender females living with diagnosed HIV among this population increased 3% between 2015 and 2019. The number of Hispanic cisgender females living with diagnosed HIV who reported heterosexual sexual contact was substantially smaller but increased 11% in the same time period.


Figure 28. Number of cisgender females living with diagnosed HIV by non-heterosexual sexual contact transmission risk, Tennessee 2015–2019



IDU: Injection drug use

The number of cisgender women living with diagnosed HIV who reported injection drug use decreased 3% between 2015 and 2019. In the same time period, the number of cisgender women who were exposed in utero (perinatal exposure) increased 11% (Figure 28).


Figure 29. Percentage of transgender persons living with diagnosed HIV by transmission risk, Tennessee, 2015–2019



IDU: Injection drug use

Throughout the reporting period, the majority of transgender persons living with diagnosed HIV reported sexual contact. Four percent of transgender persons living with diagnosed HIV were identified as having transmission risk of any sexual contact and IDU in 2019 (N=9; Figure 29).

Figure 30. Rate of persons living with diagnosed HIV per 100,000 persons by county, Tennessee, 2019



The overall state rate of PLWH was 261.6 per 100,000 persons (Figure 30). In 2019, highest rates of PLWH continued to be seen in metropolitan areas, such as Memphis/Shelby County (698.2 per 100,000 persons) and Nashville/Davidson County (546.6 per 100,000 persons).

Deaths among persons with diagnosed HIV

The following data are presented for all-cause deaths among persons with diagnosed HIV, which, due to standard reporting delays, data are presented for 2014–2018. For more information on deaths among persons with diagnosed HIV by gender, age, race/ethnicity and transmission risk, please refer to the data tables in Appendix D.




Figure 31. Deaths among persons with diagnosed HIV, Tennessee, 2014–2018

The number of deaths among persons with diagnosed HIV increased by 14% from 291 to 339 from 2014 to 2018 (Figure 31).





Figure 32. Deaths among persons with diagnosed HIV by gender, Tennessee, 2014–2018


The majority of deaths are seen in cisgender males because numbers and rates of new diagnoses and PLWH are so much higher for cisgender males than for cisgender females. This disparity is seen in the 2014–2018 reporting period (Figure 32).

Figure 33. Deaths among persons with diagnosed HIV by age group, Tennessee, 2014–2018




Persons diagnosed with HIV are living longer. As expected, the largest number of deaths occurred consistently among persons aged 45 years and older over the five-year period (Figure 33). This shift is further evidenced in the large decrease in the number of deaths observed among 35–44 years old over the same time frame.

Figure 34. Deaths among persons with diagnosed HIV by race/ethnicity, Tennessee, 2014–2018



Non-Hispanic Black individuals had the highest rates of death among people with diagnosed HIV (Figure 34). This rate increased 4% from 15.8 to 16.4 deaths per 100,000 persons over the five-year period.

Figure 35. Death rate among persons with diagnosed HIV by county, Tennessee, 2018



In 2018, the overall state death rate among people with diagnosed HIV was 5.0 per 100,000 persons. The lightest blue counties represent those with a death rate between 0.5 and 5.0 per 100,000 persons. Consistent with previous reports, the highest death rates among people with a diagnosis of HIV continued to be concentrated in the metropolitan areas, including Nashville/Davidson County (8.8 per 100,000 persons), Memphis/Shelby County (10.8 per 100,000 persons) and Madison/Jackson County (8.2 per 100,000 persons). High rates were also seen in the rural counties such as Benton (12.3 per 100,000 persons), Bledsoe (13.4 per 100,000 persons), Grainger (8.6 per 100,000 persons), Haywood (34.6 per 100,000 persons), Houston (12.1 per 100,000 persons), Meigs (8.1 per 100,000 persons), Overton (13.6 per 100,000 persons), Trousdale (27.2 per 100,000 persons), and Wayne (12.0 per 100,000 persons), counties (Figure 35).

Perinatal HIV exposures

Parent to child transmission of HIV can be prevented through universal testing of all pregnant persons and use of anti-retroviral medication. After birth, any child with perinatal HIV exposure via their birth parent is tested for HIV to determine the child's HIV status. For more information of HIV testing among perinatally exposed children go to

(https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/diagnosis-hiv-infection-infants-and-children?view=full).


The following data are presented for live births among pregnant PLWH, which, due to standard reporting delays, data are presented for 2014–2018. For more information on perinatal HIV exposures by age, race/ethnicity, transmission risk, delivery type, viral suppression, birth weight and gestational age please refer to the data tables in Appendix E.

Number of births Rate per 100,000 births 85 105.3 76 93.8 53 64.9 42 52 36 44.2 2015 2014 2016 2017 2018 2014 2015 2016 2017 2018

Figure 36. Births among pregnant persons with diagnosed HIV, Tennessee, 2014-2018


The number of reported live births to pregnant PLWH increased from 53 in 2014 to 85 in 2018. The lowest number of reported perinatal HIV exposures was in 2015 with 36 live births. Please note that the number of perinatal HIV exposures is lower than expected during years 2014–2016 because an annual match between TDH vital status birth files and eHARS was not performed. A retrospective match conducted in 2020 revealed the number of potential perinatal HIV exposures in 2014-2016 were similar to those observed for 2017 and 2018.

Figure 37. Number of persons born to pregnant persons with diagnosed HIV, by HIV status, Tennessee, 2014–2018



The majority of persons born to parents living with diagnosed HIV did not contract HIV. In 2018, two babies were diagnosed with HIV after documented perinatal exposure; another 12 babies were lost to follow-up or have an indeterminate HIV status. Prevention of perinatal HIV transmission works: the number of persons born to pregnant PLWH who did not become HIV positive increased between 2014 and 2018 while the percent of persons diagnosed with HIV decreased from 7.4% in 2014 to 2.5% in 2018.

Figure 38. Time of HIV diagnoses among pregnant persons, Tennessee, 2014–2018



Most pregnant PLWH were diagnosed before their delivery with a growing number diagnosed before becoming pregnant. Less than two pregnant persons were diagnosed at or after delivery each year between 2014 and 2018.

Number of pregnant persons Rate per 10,000 persons 5-24 **2**5-34 **3**5-44 **4**5-54

Figure 39. Pregnant persons with diagnosed HIV by age group, Tennessee, 2014–2018

Most pregnant PLWH are 25–34 years old. The number of pregnant PLWH 25–34 years old identified increased 89% from 28 in 2014 to 53 in 2018. The highest rate of pregnant PLWH was consistently in 25–34 years old persons in the last five years except for 2016.




Figure 40. Pregnant persons with diagnosed HIV by race/ethnicity, Tennessee, 2014–2018

The highest number and rate of pregnant PLWH was among non-Hispanic Black persons; the number increased 42% from 2014–2018. The number of pregnant PLWH among non-Hispanic white persons increased from 6 to 18 in the same period.

60
40
20
2014 2015 2016 2017 2018
HET IDU Perinatal exposure Unknown

Figure 41. Pregnant persons with diagnosed HIV by transmission risk, Tennessee 2014–2018

IDU: Injection drug use, **HET**: Heterosexual sexual contact

The most frequently reported transmission risk among pregnant PLWH was heterosexual sexual contact. In 2018, transmission risk was unknown for 24 persons in 2018.

HIV Continuum of Care

The HIV Continuum of Care outlines the stages of HIV medical care from initial diagnosis through viral suppression. The continuum displays the proportion of individuals living with diagnosed HIV who are engaged at each stage of their care: diagnosis of HIV, linkage to care, engagement in care and achievement of viral suppression. By setting goals for the continuum and monitoring each of these outcomes, HIV programs can identify where program improvements are needed. Due to standard reporting delays, these data are presented for 2014–2018. For additional data on the Continuum of Care, please visit the HIV data dashboards (https://www.tn.gov/health/health-program-areas/statistics/health-data/hiv-data.html).




Figure 42. Continuum of Care, Tennessee, 2018

Diagnosed: Persons living with diagnosed HIV in Tennessee at the end of the evaluation year.

Linked to care, 30 days: Persons newly diagnosed with HIV and during the evaluation year with at least one CD4 or viral load result reported within 30 days after diagnosis.

Engaged in care: Persons with diagnosed with HIV before the evaluation year and living with diagnosed HIV in Tennessee at the end of the evaluation year, who had at least 2 CD4 or viral load results reported at least three months apart during the evaluation year. **Virally suppressed**: Persons living with diagnosed HIV who had at least one viral load result during the evaluation year and whose last viral load measurement was less than or equal to 200 copies/mL.

In 2018, of the persons newly diagnosed with HIV, 64% were linked to HIV medical care within 30 days of their initial date of diagnosis (Figure 42). Of PLWH diagnosed on or before December 31, 2017 and believed to be alive and residing in Tennessee as of December 31, 2018, 57% were engaged in HIV medical care and 62% were virally suppressed.

Linked to care, 30 days

Engaged in care

Overall

Enrolled in Ryan White

Not enrolled in Ryan White


Figure 43. Continuum of Care by Ryan White enrollment status, Tennessee, 2018

Linked to care, 30 days: Persons newly diagnosed with HIV and during the evaluation year with at least one CD4 or viral load result reported within 30 days after diagnosis.

Engaged in care: Persons with diagnosed with HIV before the evaluation year and living with diagnosed HIV in Tennessee at the end of the evaluation year, who had at least 2 CD4 or viral load results reported at least three months apart during the evaluation year. **Virally suppressed**: Persons living with diagnosed HIV who had at least one viral load result during the evaluation year and whose last viral load measurement was less than or equal to 200 copies/mL.

In 2018, of the persons newly diagnosed with HIV, there was a significant difference in linkage to care rates between Ryan White enrollment statuses; 67% of persons enrolled in Ryan White and 59% of persons not enrolled in Ryan White were linked to HIV medical care within 30 days of their initial date of diagnosis (Figure 43). Differences were also seen in continued engagement in care and, likely a direct result of this retention, in rates of the achievement of suppression of the viral loads. Of Ryan White clients diagnosed with HIV on or before December 31, 2017 and believed to be alive and residing in Tennessee as of December 31, 2018, 64% were engaged in HIV medical care and 67% were virally suppressed versus the 44% and 50% respectively of persons not enrolled in the Ryan White Program. A number of factors (e.g., access to transportation, HIV and mental health care and health literacy) improved engagement in care and viral suppression regardless of Ryan White enrollment status.¹⁰


Figure 44. Linkage to care by time to linkage and Ryan White enrollment status, Tennessee, 2018



Linked to care: Persons newly diagnosed with HIV and during the evaluation year with at least one CD4 or viral load result reported within the specified number days after diagnosis.

In 2018, Ryan White clients newly diagnosed with HIV were more frequently linked to care than non-Ryan White clients (Figure 44). A number of factors (e.g., access to transportation, HIV and mental health care and health literacy) improved linkage to care regardless of Ryan White enrollment status.¹⁰

Figure 45. Proportion of newly diagnosed individuals linked to care within 30 days, by select populations, Tennessee, 2014–2018




Linked to care, 30 days: Persons newly diagnosed with HIV and during the evaluation year with at least one CD4 or viral load result reported within 30 days after diagnosis.

MMS: Male-to-male sexual contact

The overall percentage of newly diagnosed individuals linked to care within 30 days of diagnosis increased 25% between 2014 and 2018. In 2018, 64% of newly diagnosed individuals were linked to care within 30 days compared to 51% in 2014 (Figure 45). Certain populations, including non-Hispanic Black individuals, MSM and young individuals had consistently lower rates of linkage to care as compared to all individuals newly diagnosed with HIV. Notably persons aged 15–24 years at diagnosis increased by 12% from 2014 to 2018, 46% and 57%, respectively.

Changes to surveillance practices improved the timeliness of laboratory result data entry. However, it is likely that there are gaps in laboratory result reporting that may artificially decrease linkage to care outcome percentages.


Figure 46. Proportion of persons living with diagnosed HIV engaged in care, by select populations, Tennessee, 2014–2018



Engaged in care: Persons with diagnosed with HIV before the evaluation year and living with diagnosed HIV in Tennessee at the end of the evaluation year, who had at least 2 CD4 or viral load results reported at least three months apart during the evaluation year. **MMS**: Male-to-male sexual contact

The overall percentage of PLWH engaged in care remained generally stable between 2014 and 2018 (Figure 46). There was a 13% increase among persons aged 15–24 years between 2014 and 2018. A lower percentage of Hispanic persons continued to be engaged in care than other populations shown.

Figure 47. Proportion of persons living with diagnosed HIV with viral suppression, by select populations, Tennessee, 2014–2018



Virally suppressed: Persons living with diagnosed HIV who had at least one viral load result during the evaluation year and whose last viral load measurement was less than or equal to 200 copies/mL.

MMS: Male-to-male sexual contact

The overall percentage of PLWH who were virally suppressed remained stable between 2014 and 2018, with 62% of PLWH virally suppressed in 2018 (Figure 47). The percentage of 15–24 years old PLWH who were virally suppressed increased 48% between 2014 and 2018 (44% and 65%, respectively).

Technical notes

Data suppression: Data are suppressed based on a mutual agreement between TDH and CDC. If the population of the specified geographic area is greater than or equal to 500,000 persons, data is never suppressed. If the population of the specified geographic area is less than 500,000 persons, data between one and four will be suppressed. However, additional data may be suppressed to ensure data remain secure and not calculable.

Date of diagnosis: This date represents the date an individual was first diagnosed with HIV, regardless of the stage of disease progression. However, in many instances the initial diagnosis of infection does not occur until several years after the initial infection. As a result, the trends in persons diagnosed with HIV can only approximate actual trends in new HIV infections.

HIV surveillance/reporting system: TDH's HIV Epidemiology and Surveillance Program manages the HIV surveillance system. Tennessee established reporting of persons diagnosed with HIV stage 3 (AIDS) in 1982, persons diagnosed with HIV in 1992, all HIV-related laboratory reports in 2005, CD4 lymphocyte counts and HIV viral load laboratory results in 2012 and HIV-1 genotype nucleotide sequences (only from laboratories capable of electronic lab reporting) in 2019. Demographic information, vital status (whether a person is known to be living or deceased), transmission risk, laboratory results and treatment are collected on standardized case report forms and laboratory reports. These data are stored in the TDH eHARS database. Data collected are based on the date of diagnoses rather than the time of infection. The diagnosis can be made at any clinical stage of the disease. The surveillance system only includes data on individuals who are tested confidentially and reported. Members of certain subpopulations may be more or less likely to be tested and therefore they could be over- or under-represented among persons diagnosed and reported with HIV.

Place of residence: Newly reported HIV diagnoses are presented based on an individual's residence at the time of the most recent diagnosis of HIV or HIV Stage 3 (AIDS). Persons living with diagnosed HIV are presented based on an individual's residence as of December 31 of the year the data is presented. For example, when viewing persons living with diagnosed HIV in 2019 data, the residence is based on the residence as of December 31, 2019. Death data is presented based on the individual's residence at the time of death.

Starting in 2014, enhancements were made to verify the vital status and current address information for persons in the TDH eHARS database. Changes included the enhancement of death ascertainment procedures and the use of Accurint, a subscription-based database compiling publicly available address information, to update current address for all persons, which accounted for an artificial decrease in the estimate of PLWH with a Tennessee residence.

Starting with 2019 data, changes were made to the process for assigning counties when a person's residential zip code crossed county lines. If a county is not otherwise assigned, the county with the highest population within the zip code boundary is used.

Public health regions: Tennessee's 95 counties are divided into thirteen public health regions. Six of the most populous counties operate as stand-alone metropolitan public health regions that conduct standardized surveillance activities under agreements with TDH. The remaining 89

counties are combined into seven rural health regions and are direct extensions of TDH. A map of the public health regions is in Appendix A.

Reporting delay: Delays exist between the time HIV infection is diagnosed and the time the infection is reported to TDH. As a result, case number for the most recent years of diagnoses may not be complete. Data from the most recent year should be considered provisional. **The data in this report represent all information reported to TDH through July 13, 2020.**

Perinatal data: Perinatal HIV exposures are not reportable in TN. Infants are primarily identified by other methods such as reports in the state STD surveillance system, TDH Vital Statistics birth files, and laboratory reports. Identification from these methods can cause a lag in reporting perinatal exposures in eHARS compared to instances when medical providers report such exposures. This data should be considered provisional due to delays in reporting.

Reporting HIV Stages 0–2 and HIV Stage 3 (AIDS): TDH form PH-1600 must be completed for the following events: new diagnosis of HIV (i.e., acute HIV infection or the first report of an antibody positive test result); new diagnosis of HIV Stage 3 (AIDS); or patient with a previously diagnosed HIV diagnosis on the first provider visit. Providers are required to report such events within seven days. Reporting forms are located at: https://apps.health.tn.gov/ReportableDiseases/Common/PH-1600.pdf.

HIV community planning regions: Tennessee's 95 counties are divided into five HIV community planning regions. The HIV community planning regions are used by Ryan White Part B and HIV Prevention staff to analyze and report on HIV outcomes as well as by local community planning groups to allocate funds and resources to end the HIV epidemic. A map of the HIV community planning regions is in Appendix A.

Small numbers: Data release limitations are set to ensure that the information cannot be used to identify any individual. Caution should be used when interpreting rates where the numerators are less than 20 persons as estimates based on small numbers are subject to significant fluctuation.

Transmission risk: Transmission risk refers to the way in which an individual is reported to have acquired HIV. Despite possible existence of multiple transmission risks through which HIV can be transmitted, individuals are assigned a single most likely transmission risk based on a hierarchy developed by CDC. The most commonly reported transmission risks are: male-to-male sexual contact, heterosexual sexual contact, injection drug use and male-to-male sexual contact combined with injection drug use. "Other" transmission risks include blood transfusion. A limitation of the surveillance system is the large number of individuals reported with an undetermined transmission risk.

Vital status: Persons are presumed to be alive unless the TDH has received notification of death. Current vital status information for PLWH is ascertained through reports of death from other jurisdictions' surveillance programs and routine matches with TDH Vital Statistics, National Death Index Office and the Social Security Death Master File. The most recent available death data are for calendar year 2017.

Acknowledgements

The authors would like to thank the central office and public health regional HIV surveillance staff throughout the state of Tennessee, without whom, an accurate accounting of the HIV epidemic in Tennessee would not be possible. Additionally, we would like to thank Tennessee Department of Health's HIV Epidemiology and Surveillance, Ryan White Part B and HIV Prevention programs for providing valuable data collection, management and support.

Authors

- Jack Marr, MPH
- Samantha A. Mathieson, MPH
- Melanie Ratliff, MPH
- Laurie Maurer, PhD, MA
- Robb L. Garman, MPH
- Meredith Brantley, PhD, MPH
- Rose Devasia, MD, MPH
- Pamela Talley, MD, MPH

Suggested Citation:

Tennessee Department of Health, HIV Epidemiology and Surveillance Program. Tennessee HIV Epidemiological Profile, 2019. Nashville, TN: Tennessee Department of Health; February 2021.

Glossary

Case rate: The frequency of a defined event in a specified population for a given time period, usually expressed as the number of cases per 100,000 persons. Case rate is calculated by dividing the number of cases in the population of interest by the total number of people in the population. Then multiply by 100,000 to get the rate per 100,000 people.

Cisgender: All persons whose sex assigned at birth is the same as their current gender.

Concurrent Stage 3 HIV (AIDS) diagnosis: Any HIV diagnosis that occurs 12 months or less before an individual is diagnosed as Stage 3 HIV (AIDS).

Continuum of Care: The HIV Continuum of Care displays the proportion of individuals living with diagnosed HIV who are engaged at each stage of HIV medical care: diagnosis of HIV, linkage to care, engagement in care and achievement of viral suppression. Goals are set for each stage and surveillance is conducted to evaluate progress.

Date of diagnosis: The date of diagnosis refers to the specimen collection date on the earliest lab result indicating HIV infection. If a laboratory test result is unavailable, the diagnosis date recorded in a medical record by a physician is used rather than the date that the physician wrote the note.

Death rate: The number of deaths in a specified population for a given time period, usually expressed as the number of deaths per 100,000 persons. The death rate is calculated by dividing the number of deaths in the population of interest by the total number of people in the population then multiplying by 100,000 to get the rate per 100,000 people.

Engaged in care: Persons with diagnosed HIV who had at least two CD4 or viral load results reported at least three months apart during the evaluation year.

Enrolled in Ryan White: Individuals who met the Ryan White Part B services eligibility criteria and were certified as eligible for Ryan White Part B services. Click here to learn more about Ryan White Part B eligibility.

HIV case: All individuals who have been diagnosed with HIV. Cases can be sub-classified into either HIV cases or HIV stage 3 (AIDS) cases.

HIV Stages 0–2: This refers to an individual who has been infected with HIV that is in the early stages of the disease process and has not met the case definition for HIV stage 3 (AIDS). Click here to learn more about HIV stages.

HIV Stage 3 (AIDS): This refers to an individual who has been infected with HIV that is in the later stages of the disease process and has met the case definition for HIV stage 3 (AIDS). Click <u>here</u> to learn more about HIV stages.

Linked to care, 30 days: Persons newly diagnosed with HIV with at least one CD4 or viral load result reported within 30 days after the diagnosis date.

Metropolitan Statistical Area: Geographical area consisting of an urban center with a minimum population of 50,000 persons and any relevant surrounding counties.⁹ For example, the Memphis

MSA includes eight counties in three states: Shelby, Tipton and Fayette Counties in Tennessee; Tunica, Tate, DeSoto and Marshall Counties in Mississippi; and Crittenden County in Arkansas.

Not enrolled in Ryan White: Individuals who were not certified as eligible for Ryan White Part B services because they did not apply or qualify for Ryan White Part B services. Click here to learn more about Ryan White Part B eligibility.

Perinatal exposure: Exposure of a child to HIV from an HIV-infected mother during pregnancy, labor or breastfeeding (through breast milk).

Ryan White HIV/AIDS Program Part B: The Ryan White HIV/AIDS Program is a federal program designed to provide HIV medical care, medication and other support to low-income people living with HIV. Part B specifically provides funds to states to improve quality and accessibility of HIV care. Click here to learn more about the Ryan White HIV/AIDS Program.

Transgender: Adjective describing persons whose gender is different than the sex they were assigned at birth. Transgender persons can be men or women, but for the purpose of this report, transgender individuals are categorized separately from non-transgender (or cisgender) men and women.

Treatment as prevention (TasP): Use of medical treatment options for those living with HIV as a way of preventing transmission to those who are HIV-negative. TasP usually refers to antiretroviral (ARV) treatment used to treat people living with HIV that reduces one's viral load and likelihood of transmitting the virus.

Virally suppressed: Persons with diagnosed HIV who had at least one viral load measurement during the evaluation year and whose last viral load measurement was less than or equal to 200 copies/mL.

Abbreviations

AIDS: Acquired immunodeficiency syndrome

ARV: Antiretroviral

CDC: Centers for Disease Control and Prevention

eHARS: Enhanced HIV/AIDS reporting system

HAART: Highly active antiretroviral therapy

HET: Heterosexual sexual contact

HIV: Human immunodeficiency virus

IDU: Injection drug use

MMS: Male-to-male sexual contact

MSA: Metropolitan statistical area

MSM: Men who have sex with men

MMS + IDU: Male-to-male sexual contact and injection drug use

NIR: No identified risk

NRR: No reportable risk

PLWH: Persons living with diagnosed HIV

PrEP: Pre-exposure prophylaxis

PWID: Persons who inject drugs

TasP: Treatment as prevention

TDH: Tennessee Department of Health


US: United States

References

- 1. US Census Bureau, Population Division. Annual Estimates of the Resident Population for the United States, Regions, States, and Puerto Rico: April 1, 2010 to July 1, 2019 (NST-EST2019-01). In: National Population Totals and Components of Change: 2010–2019. Washington, DC: US Census Bureau; 2019.
- 2. US Census Bureau, Population Division. Annual Estimates of the Resident Population for Selected Age Groups by Sex for the United States, States, Counties and Puerto Rico Commonwealth and Municipios: April 1, 2010 to July 1, 2019. Washington, DC: US Census Bureau; 2020.
- 3. US Census Bureau, Population Division. Annual Estimates of the Resident Population by Sex, Age, Race, and Hispanic Origin for the United States and States: April 1, 2010 to July 1, 2019. Washington, DC: US Census Bureau; 2020.
- 4. United States Census Bureau. Annual Estimates of the Resident Population by Sex, Age, Race, and Hispanic Origin for the United States and States: April 1, 2010 to July 1, 2019. Washington, DC: US Census Bureau; 2020.
- 5. US Census Bureau, Population Division. 2019 American Community Survey 5-Year Estimates. Washington, DC: US Census Bureau; 2020.
- Centers for Disease Control and Prevention, Division of STD Prevention. Sexually
 Transmitted Disease Surveillance 2019: Table 6. Chlamydia Reported Cases and Rates of
 Reported Cases in Selected Metropolitan Statistical Areas (MSAs) in Alphabetical Order,
 United States, 2015–2019. Atlanta, GA: Centers for Disease Control and Prevention; 20
 August 2020, https://www.cdc.gov/std/stats18/tables/6.htm.
- 7. Centers for Disease Control and Prevention, Division of STD Prevention. Sexually Transmitted Disease Surveillance 2019: Table 17. Gonorrhea Reported Cases and Rates of Reported Cases in Selected Metropolitan Statistical Areas (MSAs) in Alphabetical Order, United States, 2015–2019, Atlanta, GA: Centers for Disease Control and Prevention; 20 August 2019, https://www.cdc.gov/std/stats18/tables/17.htm.
- 8. Tennessee Department of Health, Tennessee Drug Overdose Dashboard. Nashville, TN: Tennessee Department of Health; 2019, https://www.tn.gov/health/health-program-areas/pdo/pdo/data-dashboard.html.
- 9. Office of Management and Budget. OMB Bulletin No. 13–01. Washington, DC: Office of Management and Budget; 28 February 2013, https://www.whitehouse.gov/sites/whitehouse.gov/files/omb/bulletins/2013/b13-01.pdf.
- 10. Centers for Disease Control and Prevention, Division of HIV/AIDS. Treatment, Care, and Prevention for People with HIV. Atlanta, GA: Centers for Disease Control and Prevention; 15 October 2019, https://www.cdc.gov/hiv/clinicians/treatment/treatment-clinicians.html.

Appendix A: Tennessee maps

Figure 48. Tennessee public health regions






Figure 49. Tennessee HIV community planning regions

Appendix B: Persons newly diagnosed with HIV

Table 1. Persons newly diagnosed with HIV, Tennessee, 2015–2019

| | 2015 | | 201 | 6 | 201 | 7 | 201 | 8 | 201 | 9 |
|---------------------------------|-------------|------|-----|------|-----|------|-----|------|-----|------|
| | No. | Rate | No. | Rate | No. | Rate | No. | Rate | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 586 | 18.2 | 580 | 17.9 | 587 | 17.9 | 600 | 18.2 | 618 | 18.5 |
| Cisgender female | 147 | 4.4 | 126 | 3.7 | 130 | 3.8 | 137 | 4.0 | 146 | 4.2 |
| Transgender person | 12 | _ | 13 | _ | 8 | _ | 20 | _ | 12 | _ |
| Age group (at diagnosis, years) | | | | | | | | | | |
| <15 | 9 | 0.7 | 6 | 0.5 | 4 | 0.3 | 4 | 0.3 | 2 | 0.2 |
| 15-24 | 192 | 21.9 | 195 | 22.3 | 188 | 21.6 | 175 | 20.1 | 165 | 19.0 |
| 25-34 | 255 | 29.1 | 240 | 26.8 | 245 | 26.7 | 295 | 31.6 | 289 | 30.4 |
| 35–44 | 126 | 15.1 | 126 | 15.2 | 120 | 14.4 | 132 | 15.7 | 138 | 16.3 |
| 45-54 | 111 | 12.4 | 101 | 11.3 | 94 | 10.6 | 87 | 9.9 | 106 | 12.2 |
| ≥55 | 52 | 2.8 | 51 | 2.7 | 74 | 3.8 | 64 | 3.2 | 76 | 3.7 |
| Race/ethnicity by gender | | | | | | | | | | |
| Overall | | | | | | | | | | |
| Non-Hispanic Black | 435 | 39.3 | 424 | 38.0 | 416 | 37.0 | 436 | 38.4 | 407 | 35.6 |
| Non-Hispanic white | 248 | 5.1 | 242 | 4.9 | 258 | 5.2 | 237 | 4.7 | 272 | 5.4 |
| Hispanic | 46 | 13.6 | 36 | 10.3 | 35 | 9.6 | 55 | 14.5 | 73 | 18.7 |
| Other | 16 | 6.7 | 17 | 6.9 | 16 | 6.2 | 29 | 10.9 | 24 | 8.7 |
| Cisgender male | | | | | | | | | | |
| Non-Hispanic Black | 337 | 64.5 | 325 | 61.7 | 334 | 62.9 | 324 | 60.5 | 315 | 58.5 |
| Non-Hispanic white | 199 | 8.3 | 211 | 8.8 | 214 | 8.8 | 210 | 8.6 | 223 | 9.1 |
| Hispanic | 40 | 22.3 | 30 | 16.2 | 26 | 13.5 | 47 | 23.6 | 60 | 29.2 |
| Other | 10 | 8.6 | 14 | 11.7 | 13 | 10.5 | 19 | 14.8 | 20 | 15.0 |
| Cisgender female | | | | | | | | | | |
| Non-Hispanic Black | 88 | 15.1 | 89 | 15.1 | 77 | 13.0 | 95 | 15.9 | 84 | 13.9 |
| Non-Hispanic white | 48 | 1.9 | 28 | 1.1 | 42 | 1.7 | 26 | 1.0 | 47 | 1.8 |
| Hispanic | 5 | 3.1 | 6 | 3.6 | 8 | 4.6 | 7 | 3.9 | 11 | 5.9 |
| Other | 6 | 4.8 | 3 | 2.3 | 3 | 2.3 | 9 | 6.5 | 4 | 2.8 |
| Transgender person | | | | | | | | | | |
| Non-Hispanic Black | 10 | _ | 10 | _ | 5 | _ | 17 | _ | 8 | _ |
| Non-Hispanic white | 1 | _ | 3 | _ | 2 | _ | 1 | _ | 2 | _ |
| Hispanic | 1 | _ | 0 | _ | 1 | _ | 1 | _ | 2 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 1 | _ | 0 | _ |
| Overall | 745 | 11.3 | 719 | 10.8 | 725 | 10.8 | 757 | 11.2 | 776 | 11.4 |

Source: Tennessee enhanced HIV/AIDS Reporting System (eHARS), accessed July 13, 2020.

Newly diagnosed: persons diagnosed with HIV during January 1—December 31 of the year of interest and resided in Tennessee at the time of diagnosis Hispanics can be of any race.

[—] represents data not available.

Table 2. Persons newly diagnosed with HIV by transmission risk, Tennessee, 2015–2019

| | 2015 | | 2016 | | 2017 | • | 2018 | 3 | 2019 | , |
|-----------------------------------|------|------|------|------|------|-------|------|------|------|------|
| | No. | % | No. | % | No. | % | No. | % | No. | % |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 401 | 68.4 | 394 | 67.9 | 412 | 70.2 | 384 | 64.0 | 419 | 67.8 |
| Non-Hispanic Black | 230 | _ | 226 | _ | 243 | _ | 197 | _ | 200 | _ |
| Non-Hispanic white | 136 | _ | 143 | _ | 138 | _ | 145 | _ | 157 | _ |
| Hispanic | 29 | _ | 19 | _ | 21 | _ | 30 | _ | 47 | _ |
| Other | 6 | _ | 6 | _ | 10 | _ | 12 | _ | 15 | _ |
| Injection drug use (IDU) | 18 | 3.1 | 12 | 2.1 | 17 | 2.9 | 12 | 2.0 | 23 | 3.7 |
| MMS + IDU | 17 | 2.9 | 24 | 4.1 | 16 | 2.7 | 21 | 3.5 | 17 | 2.8 |
| Heterosexual sexual contact | 78 | 13.3 | 113 | 19.5 | 62 | 10.6 | 92 | 15.3 | 63 | 10.2 |
| Perinatal exposure | 1 | 0.2 | 2 | 0.3 | 0 | 0.0 | 2 | 0.3 | 1 | 0.2 |
| Other | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Unknown | 71 | 12.1 | 35 | 6.0 | 80 | 13.6 | 89 | 14.8 | 95 | 15.4 |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | 97 | 66.0 | 110 | 87.3 | 83 | 63.8 | 93 | 67.9 | 72 | 49.3 |
| Injection drug use (IDU) | 17 | 11.6 | 9 | 7.1 | 10 | 7.7 | 8 | 5.8 | 33 | 22.6 |
| Perinatal exposure | 5 | 3.4 | 4 | 3.2 | 3 | 2.3 | 2 | 1.5 | 1 | 0.7 |
| Other | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Unknown | 28 | 19.0 | 3 | 2.4 | 34 | 26.2 | 34 | 24.8 | 40 | 27.4 |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 11 | 91.7 | 12 | 92.3 | 8 | 100.0 | 17 | 85.0 | 8 | 66.7 |
| Injection drug use (IDU) | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 8.3 |
| Any sexual contact + IDU | 1 | 8.3 | 1 | 7.7 | 0 | 0.0 | 0 | 0.0 | 1 | 8.3 |
| Perinatal exposure | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Other | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Unknown | 0 | 0.0 | 1 | 7.7 | 1 | 12.5 | 3 | 15.0 | 2 | 16.7 |
| Overall | 745 | _ | 719 | _ | 725 | _ | 757 | _ | 776 | _ |

Newly diagnosed: persons diagnosed with HIV during January 1–December 31 of the year of interest and resided in Tennessee at the time of diagnosis

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

[%] is the percentage of each subgroup; percentages for subgroups with less than 10 (e.g., transgender persons) should be interpreted with caution.

[—] represents data not available.

Appendix C: Persons living with diagnosed HIV

Table 3. Persons living with diagnosed HIV, Tennessee, 2015–2019

| | 201 | 5 | 2010 | 6 | 201 | 7 | 201 | 8 | 201 | 9 |
|--------------------------------|-------|--------|-------|--------|-------|--------|-------|--------|-------|--------|
| | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 12610 | 392.2 | 12861 | 396.7 | 12904 | 394.1 | 13364 | 404.4 | 13247 | 397.5 |
| Cisgender female | 4356 | 129.0 | 4419 | 129.8 | 4425 | 128.8 | 4476 | 129.1 | 4413 | 126.2 |
| Transgender person | 166 | _ | 178 | _ | 181 | _ | 216 | _ | 204 | _ |
| Age group (current age, years) | | | | | | | | | | |
| <15 | 94 | 7.6 | 89 | 7.2 | 80 | 6.4 | 86 | 6.9 | 79 | 6.3 |
| 15–24 | 777 | 88.5 | 750 | 85.9 | 711 | 81.6 | 701 | 80.5 | 650 | 74.8 |
| 25-34 | 2987 | 340.9 | 3053 | 340.5 | 3099 | 338.1 | 3251 | 348.5 | 3230 | 340.1 |
| 35-44 | 3892 | 465.8 | 3802 | 457.9 | 3717 | 445.9 | 3742 | 445.2 | 3648 | 430.4 |
| 45-54 | 5534 | 619.3 | 5452 | 610.1 | 5257 | 590.3 | 5134 | 581.5 | 4838 | 555.3 |
| ≥55 | 3848 | 206.2 | 4312 | 225.9 | 4646 | 238.3 | 5142 | 258.0 | 5419 | 265.9 |
| Race/ethnicity by gender | | | | | | | | | | |
| Overall | | | | | | | | | | |
| Non-Hispanic Black | 9556 | 863.9 | 9795 | 878.7 | 9851 | 875.6 | 10157 | 895.6 | 9998 | 875.6 |
| Non-Hispanic white | 6280 | 128.0 | 6357 | 128.9 | 6344 | 127.9 | 6507 | 130.4 | 6408 | 127.7 |
| Hispanic | 798 | 235.4 | 813 | 231.9 | 805 | 220.6 | 849 | 224.1 | 910 | 232.5 |
| Other | 498 | 207.8 | 493 | 198.9 | 510 | 198.5 | 543 | 203.6 | 548 | 198.2 |
| Cisgender male | | | | | | | | | | |
| Non-Hispanic Black | 6407 | 1225.8 | 6585 | 1251.0 | 6640 | 1249.8 | 6891 | 1286.3 | 6793 | 1260.8 |
| Non-Hispanic white | 5234 | 218.4 | 5295 | 219.6 | 5281 | 217.7 | 5439 | 222.8 | 5354 | 218.2 |
| Hispanic | 622 | 346.2 | 635 | 342.9 | 623 | 323.8 | 657 | 329.5 | 712 | 346.5 |
| Other | 347 | 300.1 | 346 | 289.6 | 360 | 290.2 | 377 | 292.7 | 388 | 290.1 |
| Cisgender female | | | | | | | | | | |
| Non-Hispanic Black | 3037 | 520.5 | 3088 | 524.8 | 3089 | 520.3 | 3118 | 521.1 | 3061 | 507.6 |
| Non-Hispanic white | 1008 | 40.2 | 1020 | 40.4 | 1019 | 40.2 | 1019 | 39.9 | 1012 | 39.4 |
| Hispanic | 169 | 106.0 | 171 | 103.4 | 175 | 101.5 | 182 | 101.4 | 188 | 101.1 |
| Other | 142 | 114.5 | 140 | 109.1 | 142 | 106.8 | 157 | 113.8 | 152 | 106.5 |
| Transgender person | | | | | | | | | | |
| Non-Hispanic Black | 112 | _ | 122 | _ | 122 | _ | 148 | _ | 144 | _ |
| Non-Hispanic white | 38 | _ | 42 | _ | 44 | _ | 49 | _ | 42 | _ |
| Hispanic | 7 | _ | 7 | _ | 7 | _ | 10 | _ | 10 | _ |
| Other | 9 | _ | 7 | _ | 8 | _ | 9 | _ | 8 | _ |
| Overall | 17132 | 259.9 | 17458 | 262.7 | 17510 | 261.0 | 18056 | 266.6 | 17864 | 261.6 |

Source: Tennessee enhanced HIV/AIDS Reporting System (eHARS), accessed July 13, 2020.

Living with diagnosed HIV: persons diagnosed with HIV on or before December 31 and resided in Tennessee on December 31 of the year of interest Hispanics can be of any race.

[—] represents data not available.

Table 4. Persons living with diagnosed HIV by transmission risk, Tennessee, 2015–2019

| | 2015 | 2015 | | | 2017 | • | 2018 | 3 | 2019 |) |
|-----------------------------------|-------|-------------|-------|------|-------|------|-------|------|-------|------|
| | No. | % | No. | % | No. | % | No. | % | No. | % |
| Transmission risk | | | | | | | | | | |
| Cisgender Male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 8398 | 66.6 | 8547 | 66.5 | 8643 | 67.0 | 8943 | 66.9 | 8921 | 67.3 |
| Non-Hispanic Black | 3815 | _ | 3937 | _ | 4025 | _ | 4205 | _ | 4166 | _ |
| Non-Hispanic white | 4013 | _ | 4045 | _ | 4029 | _ | 4127 | _ | 4084 | _ |
| Hispanic | 346 | _ | 351 | _ | 354 | _ | 374 | _ | 420 | _ |
| Other | 224 | _ | 214 | _ | 226 | _ | 237 | _ | 251 | _ |
| Injection drug use (IDU) | 652 | 5.2 | 656 | 5.1 | 637 | 4.9 | 624 | 4.7 | 599 | 4.5 |
| MMS + IDU | 546 | 4.3 | 558 | 4.3 | 527 | 4.1 | 566 | 4.2 | 532 | 4.0 |
| Heterosexual sexual contact | 1591 | 12.6 | 1669 | 13.0 | 1665 | 12.9 | 1719 | 12.9 | 1679 | 12.7 |
| Perinatal exposure | 70 | 0.6 | 72 | 0.6 | 72 | 0.6 | 77 | 0.6 | 81 | 0.6 |
| Other | 51 | 0.4 | 51 | 0.4 | 48 | 0.4 | 46 | 0.3 | 43 | 0.3 |
| Unknown | 1304 | 10.3 | 1308 | 10.2 | 1321 | 10.2 | 1389 | 10.4 | 1392 | 10.5 |
| Cisgender Female | | | | | | | | | | |
| Heterosexual sexual contact | 3153 | 72.4 | 3216 | 72.8 | 3224 | 72.9 | 3242 | 72.4 | 3153 | 71.4 |
| Injection drug use (IDU) | 443 | 10.2 | 445 | 10.1 | 438 | 9.9 | 424 | 9.5 | 429 | 9.7 |
| Perinatal exposure | 91 | 2.1 | 92 | 2.1 | 93 | 2.1 | 101 | 2.3 | 102 | 2.3 |
| Other | 15 | 0.3 | 15 | 0.3 | 14 | 0.3 | 15 | 0.3 | 13 | 0.3 |
| Unknown | 654 | 15.0 | 651 | 14.7 | 656 | 14.8 | 694 | 15.5 | 716 | 16.2 |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 137 | 82.5 | 148 | 83.1 | 152 | 84.0 | 182 | 84.3 | 171 | 83.8 |
| Injection drug use (IDU) | 1 | 0.6 | 1 | 0.6 | 1 | 0.6 | 1 | 0.5 | 2 | 1.0 |
| Any sexual contact + IDU | 9 | 5.4 | 9 | 5.1 | 8 | 4.4 | 10 | 4.6 | 9 | 4.4 |
| Perinatal exposure | 1 | 0.6 | 1 | 0.6 | 1 | 0.6 | 1 | 0.5 | 1 | 0.5 |
| Other | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Unknown | 18 | 10.8 | 19 | 10.7 | 19 | 10.5 | 22 | 10.2 | 21 | 10.3 |
| Overall | 17132 | _ | 17458 | _ | 17510 | _ | 18056 | _ | 17864 | _ |

Living with diagnosed HIV: persons diagnosed with HIV on or before December 31 and resided in Tennessee on December 31 of the year of interest

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

[%] is the percentage of each subgroup; percentages for subgroups with less than 10 (e.g., transgender persons) should be interpreted with caution.

⁻ represents data not available.

Appendix D: Deaths among persons living with diagnosed HIV

Table 8. Deaths among persons with diagnosed HIV, Tennessee, 2014–2018

| | 20 | 14 | 20 | 15 | 20 | 16 | 20 | 17 | 20 | 18 |
|-----------------------------|-----|------|-----|------|-----|------|-----|------|-----|------|
| | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 206 | 6.5 | 222 | 6.9 | 220 | 6.8 | 225 | 6.9 | 237 | 7.2 |
| Cisgender female | 83 | 2.5 | 96 | 2.8 | 78 | 2.3 | 77 | 2.2 | 100 | 2.9 |
| Transgender person | 1 | _ | 1 | _ | 1 | _ | 2 | _ | 2 | _ |
| Age group (at death, years) | | | | | | | | | | |
| <15 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| 15-24 | 6 | 0.7 | 7 | 0.8 | 3 | 0.3 | 5 | 0.6 | 2 | 0.2 |
| 25-34 | 19 | 2.2 | 31 | 3.5 | 24 | 2.7 | 17 | 1.9 | 23 | 2.5 |
| 35-44 | 49 | 5.8 | 61 | 7.3 | 37 | 4.5 | 46 | 5.5 | 43 | 5.1 |
| 45-54 | 92 | 10.3 | 116 | 13.0 | 97 | 10.9 | 90 | 10.1 | 100 | 11.3 |
| ≥55 | 125 | 6.9 | 104 | 5.6 | 138 | 7.2 | 146 | 7.5 | 171 | 8.6 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 173 | 15.8 | 184 | 16.6 | 165 | 14.8 | 175 | 15.6 | 186 | 16.4 |
| Non-Hispanic white | 106 | 2.2 | 116 | 2.4 | 118 | 2.4 | 122 | 2.5 | 142 | 2.8 |
| Hispanic | 5 | 1.5 | 7 | 2.1 | 8 | 2.3 | 2 | 0.5 | 6 | 1.6 |
| Other | 7 | 3.0 | 12 | 5.0 | 8 | 3.2 | 5 | 1.9 | 5 | 1.9 |
| Overall | 291 | 4.4 | 319 | 4.8 | 299 | 4.5 | 304 | 4.5 | 339 | 5.0 |

Source: Tennessee enhanced HIV/AIDS Reporting System (eHARS), accessed July 13, 2020.

Deaths among persons with diagnosed HIV: deaths among persons who resided in Tennessee at the time of death Hispanics can be of any race.

[—] represents data not available.

Appendix E: Perinatal HIV exposures

Table 5. Age group and race of pregnant persons diagnosed with HIV, Tennessee, 2014–2018

| · | 201 | 4 | 201 | 15 | 201 | 16 | 201 | 17 | 201 | 18 |
|--------------------------------|-----|------|-----|------|-----|------|-----|------|-----|------|
| | No. | Rate |
| Age group (at delivery, years) | | | | | | | | | | |
| <15 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| 15–24 | 13 | 4.9 | 5 | 2.0 | 8 | 3.3 | 10 | 4.3 | 15 | 6.7 |
| 25–34 | 28 | 6.4 | 19 | 4.3 | 25 | 5.5 | 47 | 10.3 | 53 | 11.6 |
| 35-44 | 12 | 11.4 | 12 | 11.0 | 8 | 7.0 | 19 | 16.3 | 17 | 13.9 |
| 45-54 | 0 | 0.0 | 0 | 0.0 | 1 | 69.0 | 0 | 0.0 | 0 | 0.0 |
| ≥55 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 36 | 21.3 | 24 | 14.5 | 32 | 19.7 | 55 | 33.5 | 51 | 31.2 |
| Non-Hispanic white | 6 | 1.1 | 6 | 1.1 | 7 | 1.3 | 13 | 2.4 | 18 | 3.4 |
| Hispanic | 9 | 19.1 | 4 | 7.8 | 3 | 6.1 | 3 | 6.4 | 5 | 10.8 |
| Other | 2 | 4.3 | 2 | 4.0 | 0 | 0 | 5 | 7.8 | 11 | 16.6 |
| Overall | 53 | 6.5 | 36 | 4.4 | 42 | 5.2 | 76 | 9.4 | 85 | 10.5 |

Sources: Tennessee enhanced HIV/AIDS Reporting System (eHARS), accessed July 13, 2020.

Pregnant persons diagnosed with HIV: persons living with diagnosed with a live birth during January 1–December 31 of the year of interest and resided in Tennessee at the time of diagnosis

Hispanics can be of any race.

Rates per 10,000 persons. Rates were calculated using Tennessee Department of Health Birth Statistical File 2014–2018.

Table 6. Characteristics of pregnant persons diagnosed with HIV, Tennessee, 2014–2018

| | 2014 | l . | 2015 | 5 | 201 | 6 | 201 | 7 | 201 | 8 |
|--|------|------|------|------|-----|------|-----|------|-----|------|
| | No. | % | No. | % | No. | % | No. | % | No. | % |
| Transmission risk | | | | | | | | | | |
| Heterosexual sexual contact | 40 | 75.5 | 23 | 63.9 | 28 | 66.7 | 55 | 72.4 | 51 | 60.0 |
| Injection drug use (IDU) | 2 | 3.8 | 4 | 11.1 | 1 | 2.4 | 4 | 5.3 | 3 | 3.5 |
| Perinatal exposure | 2 | 3.8 | 1 | 2.8 | 4 | 9.5 | 4 | 5.3 | 7 | 8.2 |
| Other | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Unknown | 9 | 17.0 | 8 | 22.2 | 9 | 21.4 | 13 | 17.1 | 24 | 28.2 |
| Delivery type | | | | | | | | | | |
| Vaginal | 19 | 35.8 | 21 | 58.3 | 18 | 42.9 | 39 | 51.3 | 36 | 42.4 |
| Elective cesarean | 5 | 9.4 | 1 | 2.8 | 8 | 19.0 | 1 | 1.3 | 4 | 4.7 |
| Non-elective cesarean | 3 | 5.7 | 0 | 0.0 | 1 | 2.4 | 0 | 0.0 | 0 | 0.0 |
| Cesarean, unknown type | 26 | 49.1 | 14 | 38.9 | 14 | 33.3 | 35 | 46.1 | 45 | 52.9 |
| Unknown | 0 | 0.0 | 0 | 0.0 | 1 | 2.4 | 1 | 1.3 | 0 | 0.0 |
| Viral suppression (before/at delivery) | | | | | | | | | | |
| Virally suppressed | 32 | 60.4 | 23 | 63.9 | 26 | 61.9 | 54 | 71.1 | 61 | 71.8 |
| Not virally suppressed | 15 | 28.3 | 9 | 25.0 | 8 | 19.0 | 17 | 22.4 | 19 | 22.4 |
| Unknown | 6 | 11.3 | 4 | 11.1 | 8 | 19.0 | 5 | 6.6 | 5 | 5.9 |
| Overall | 53 | _ | 36 | _ | 42 | _ | 76 | _ | 85 | _ |

Pregnant persons diagnosed with HIV: persons living with diagnosed with a live birth during January 1–December 31 of the year of interest and resided in Tennessee at the time of diagnosis

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

[%] is the percentage of each subgroup; percentages for subgroups with less than 10 (e.g., transgender persons) should be interpreted with caution.

Table 7. Infants born to pregnant persons diagnosed with HIV, Tennessee, 2014–2018

| | 2014 | 1 | 201 | 2015 | | 5 | 2017 | | 2018 | |
|--------------------------|------|------|-----|------|-----|------|------|------|------|------|
| | No. | % | No. | % | No. | % | No. | % | No. | % |
| Birth weight | | | | | | | | | | |
| Low (<2500 grams) | 14 | 26.4 | 7 | 19.4 | 7 | 16.7 | 10 | 13.2 | 18 | 21.2 |
| Normal (≥2500 grams) | 39 | 73.6 | 29 | 80.6 | 35 | 83.3 | 65 | 85.5 | 67 | 78.8 |
| Unknown | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 1.3 | 0 | 0.0 |
| Gestational age | | | | | | | | | | |
| Preterm (<37 weeks) | 12 | 22.6 | 12 | 33.3 | 6 | 14.3 | 13 | 17.1 | 16 | 18.8 |
| Early term (37–38 weeks) | 24 | 45.3 | 13 | 36.1 | 18 | 42.9 | 34 | 44.7 | 45 | 52.9 |
| Full term (≥39 weeks) | 16 | 30.2 | 11 | 30.6 | 17 | 40.5 | 28 | 36.8 | 24 | 28.2 |
| Unknown | 1 | 1.9 | 0 | 0.0 | 1 | 2.4 | 1 | 1.3 | 0 | 0.0 |
| Overall | 53 | _ | 36 | _ | 42 | _ | 76 | _ | 85 | _ |

Pregnant persons diagnosed with HIV: persons living with diagnosed with a live birth during January 1–December 31 of the year of interest and resided in Tennessee at the time of diagnosis

% is the percentage of each subgroup; percentages for subgroups with less than 10 (e.g., transgender persons) should be interpreted with caution.

Appendix F: State data

Table 9. Persons diagnosed with HIV, Tennessee, 2019

| | New HIV di | agnoses | Concurrent Sta diagno | | All persons li diagnose | |
|-----------------------------------|------------|---------|--------------------------|------|----------------------------|-------|
| | No. | Rate | No. | Rate | No. | Rate |
| Gender | | | | | | |
| Cisgender male | 618 | 18.5 | 120 | 3.6 | 13247 | 397.5 |
| Cisgender female | 146 | 4.2 | 26 | 0.7 | 4413 | 126.2 |
| Transgender person | 12 | _ | 0 | _ | 204 | _ |
| Age group (years) | | | | | | |
| <15 | 2 | 0.2 | 0 | 0.0 | 79 | 6.3 |
| 15–24 | 165 | 19.0 | 11 | 1.3 | 650 | 74.8 |
| 25–34 | 289 | 30.4 | 44 | 4.6 | 3230 | 340.1 |
| 35-44 | 138 | 16.3 | 30 | 3.5 | 3648 | 430.4 |
| 45-54 | 106 | 12.2 | 29 | 3.3 | 4838 | 555.3 |
| ≥55 | 76 | 3.7 | 32 | 1.6 | 5419 | 265.9 |
| Race/ethnicity | | | | | | |
| Non-Hispanic Black | 407 | 35.6 | 70 | 6.1 | 9998 | 875.6 |
| Non-Hispanic white | 272 | 5.4 | 52 | 1.0 | 6408 | 127.7 |
| Hispanic | 73 | 18.7 | 18 | 4.6 | 910 | 232.5 |
| Other | 24 | 8.7 | 6 | 2.2 | 548 | 198.2 |
| Transmission risk | | | | | | |
| Cisgender male | | | | | | |
| Male-to-male sexual contact (MMS) | 419 | _ | 75 | _ | 8921 | _ |
| Injection drug use (IDU) | 23 | _ | 4 | _ | 599 | _ |
| MMS and IDU | 17 | _ | 0 | _ | 532 | _ |
| Heterosexual sexual contact | 63 | _ | 21 | _ | 1679 | _ |
| Perinatal exposure | 1 | _ | 0 | _ | 81 | _ |
| Other | 0 | _ | 0 | _ | 43 | _ |
| Unknown | 95 | _ | 20 | _ | 1392 | |
| Cisgender female | 33 | | 20 | | 1332 | |
| Heterosexual sexual contact | 72 | _ | 18 | _ | 3153 | _ |
| Injection drug use (IDU) | 33 | _ | 4 | _ | 429 | |
| Perinatal exposure | 1 | _ | 0 | _ | 102 | |
| Other | 0 | _ | 0 | _ | 13 | |
| Unknown | 40 | _ | 4 | _ | 716 | |
| Transgender person | 40 | | 7 | | 710 | |
| Any sexual contact | 8 | _ | 0 | _ | 171 | _ |
| Injection drug use (IDU) | 1 | _ | 0 | _ | 2 | _ |
| Any sexual contact and IDU | 1 | _ | 0 | _ | 9 | _ |
| Perinatal exposure | 0 | _ | 0 | | 1 | |
| Other | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 2 | _ | 0 | _ | 21 | _ |
| Overall | ∠ 776 | 11.4 | 146 | 2.1 | 17,864 | 261.6 |

Source: Tennessee enhanced HIV/AIDS Reporting System (eHARS), accessed July 13, 2020.

New HIV diagnoses: persons diagnosed with HIV during January 1–December 31, 2019 and resided in Tennessee at the time of diagnosis

Concurrent diagnoses: persons who were diagnosed with HIV 12 months or less before being diagnosed as Stage 3 HIV (AIDS) Living with diagnosed HIV: persons diagnosed with HIV on or before December 31 and resided in Tennessee on December 31, 2019 For new diagnoses and concurrent diagnoses, age group refers to the age at the time of HIV diagnosis. For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

[—] represents data not available.

Appendix G: Public health regional data

Table 10. Persons newly diagnosed with HIV, Memphis/Shelby County, Tennessee, 2015–2019

| | 20 ⁻ | 15 | 20 ⁻ | 16 | 20 ⁻ | 17 | 201 | 18 | 20 | 19 |
|-----------------------------------|-----------------|------|-----------------|------|-----------------|------|-----|------|-----|------|
| | No. | Rate | No. | Rate | No. | Rate | No. | Rate | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 212 | 47.5 | 206 | 46.3 | 211 | 47.5 | 228 | 51.3 | 207 | 46.6 |
| Cisgender female | 62 | 12.6 | 54 | 11.0 | 46 | 9.4 | 58 | 11.8 | 52 | 10.6 |
| Transgender person | 5 | _ | 5 | _ | 2 | _ | 11 | _ | 5 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 3 | 1.5 | 2 | 1.0 | 0 | 0.0 | 3 | 1.5 | 1 | 0.5 |
| 15–24 | 84 | 63.2 | 76 | 58.5 | 76 | 60.0 | 86 | 69.2 | 81 | 66.5 |
| 25–34 | 87 | 64.7 | 92 | 67.7 | 84 | 61.2 | 105 | 75.4 | 83 | 58.8 |
| 35-44 | 43 | 36.2 | 42 | 35.9 | 39 | 33.5 | 46 | 39.4 | 37 | 31.7 |
| 45–54 | 41 | 33.5 | 31 | 25.6 | 31 | 26.1 | 32 | 27.5 | 35 | 30.7 |
| ≥55 | 21 | 9.1 | 22 | 9.3 | 29 | 12.1 | 25 | 10.3 | 27 | 10.9 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 239 | 47.9 | 242 | 48.4 | 224 | 44.7 | 253 | 50.4 | 207 | 41.1 |
| Non-Hispanic white | 27 | 7.9 | 12 | 3.5 | 22 | 6.5 | 26 | 7.8 | 29 | 8.8 |
| Hispanic | 11 | 19.3 | 6 | 10.3 | 11 | 18.5 | 15 | 24.6 | 23 | 37.0 |
| Other | 2 | 5.3 | 5 | 13.0 | 2 | 5.1 | 3 | 7.5 | 5 | 12.1 |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 126 | _ | 127 | _ | 140 | _ | 123 | _ | 113 | _ |
| Injection drug use (IDU) | 2 | _ | 0 | _ | 1 | _ | 1 | _ | 1 | _ |
| MMS and IDU | 0 | _ | 0 | _ | 1 | _ | 4 | _ | 1 | _ |
| Heterosexual sexual contact | 41 | _ | 62 | _ | 33 | _ | 35 | _ | 13 | _ |
| Perinatal exposure | 1 | _ | 0 | _ | 0 | _ | 2 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 42 | _ | 17 | _ | 36 | _ | 63 | _ | 79 | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | 40 | _ | 50 | _ | 30 | _ | 31 | _ | 19 | _ |
| Injection drug use (IDU) | 5 | _ | 1 | _ | 1 | _ | 1 | _ | 3 | _ |
| Perinatal exposure | 2 | _ | 2 | _ | 0 | _ | 1 | _ | 1 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 15 | _ | 1 | _ | 15 | _ | 25 | _ | 29 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 5 | _ | 5 | _ | 2 | _ | 10 | _ | 3 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | | 0 | | 0 | | 1 | | 2 | |
| Overall | 279 | 29.8 | 265 | 28.3 | 259 | 27.7 | 297 | 31.7 | 264 | 28.2 |

Source: Tennessee enhanced HIV/AIDS Reporting System (eHARS), accessed July 13, 2020.

New HIV diagnoses: persons diagnosed with HIV during January 1–December 31, 2019 and resided in Tennessee at the time of diagnosis For new diagnoses and concurrent diagnoses, age group refers to the age at the time of HIV diagnosis.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

[—] represents data not available.

Table 11. Persons newly diagnosed with HIV, West public health region, Tennessee, 2015–2019

| | 2015 | | 2016 | · · | 2017 | | 2018 | - | 2019 | |
|-----------------------------------|------|------|------|------|------|------|------|------|------|------|
| | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 24 | 9.2 | 27 | 10.4 | 27 | 10.4 | 18 | 6.9 | 19 | 7.3 |
| Cisgender female | 4 | 1.5 | 5 | 1.9 | 9 | 3.4 | 4 | 1.5 | 4 | 1.5 |
| Transgender person | 1 | _ | 2 | _ | 0 | _ | 0 | _ | 0 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| 15–24 | 6 | 8.8 | 9 | 13.4 | 12 | 18.0 | 4 | 6.1 | 6 | 9.2 |
| 25–34 | 11 | 17.9 | 13 | 21.2 | 13 | 20.9 | 7 | 11.2 | 8 | 12.7 |
| 35–44 | 4 | 6.2 | 6 | 9.6 | 7 | 11.3 | 6 | 9.7 | 6 | 9.7 |
| 45–54 | 5 | 6.9 | 3 | 4.2 | 1 | 1.4 | 4 | 5.8 | 2 | 3.0 |
| ≥55 | 3 | 1.8 | 3 | 1.8 | 3 | 1.8 | 1 | 0.6 | 1 | 0.6 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 14 | 16.0 | 20 | 23.2 | 19 | 21.9 | 11 | 12.7 | 13 | 15.1 |
| Non-Hispanic white | 14 | 3.4 | 12 | 2.9 | 17 | 4.1 | 10 | 2.4 | 7 | 1.7 |
| Hispanic | 1 | 6.7 | 2 | 13.1 | 0 | 0.0 | 1 | 6.1 | 2 | 11.9 |
| Other | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 7.5 |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 16 | _ | 21 | _ | 17 | _ | 10 | _ | 13 | _ |
| Injection drug use (IDU) | 2 | _ | 0 | _ | 2 | _ | 1 | _ | 2 | _ |
| MMS and IDU | 1 | _ | 0 | _ | 1 | _ | 2 | _ | 1 | _ |
| Heterosexual sexual contact | 2 | _ | 5 | _ | 4 | _ | 3 | _ | 1 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 3 | _ | 1 | _ | 3 | _ | 2 | _ | 2 | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | 4 | _ | 4 | _ | 6 | _ | 4 | _ | 3 | _ |
| Injection drug use (IDU) | 0 | _ | 1 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other . | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 3 | _ | 0 | _ | 1 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 0 | _ | 2 | _ | 0 | _ | 0 | _ | 0 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 1 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Overall | 29 | 3.1 | 34 | 3.6 | 36 | 3.8 | 22 | 2.3 | 23 | 2.5 |

New HIV diagnoses: persons diagnosed with HIV during January 1–December 31, 2019 and resided in Tennessee at the time of diagnosis For new diagnoses and concurrent diagnoses, age group refers to the age at the time of HIV diagnosis.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

[—] represents data not available.

Table 12. Persons newly diagnosed with HIV, Jackson/Madison County, Tennessee, 2015–2019

| | 20 ⁻ | 15 | 20 ⁻ | 16 | 20 ⁻ | 17 | 201 | 18 | 20 ⁻ | 19 |
|-----------------------------------|-----------------|------|-----------------|------|-----------------|------|-----|------|-----------------|------|
| | No. | Rate | No. | Rate | No. | Rate | No. | Rate | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 14 | 30.3 | 11 | 23.8 | Χ | Х | 13 | 28.1 | 7 | 15.1 |
| Cisgender female | Χ | Χ | Χ | Χ | Χ | Χ | X | Χ | X | Χ |
| Transgender person | 0 | _ | 0 | _ | Χ | _ | 0 | _ | X | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| 15–24 | 5 | 34.4 | 5 | 35.0 | Χ | Х | X | Х | Χ | Χ |
| 25-34 | 5 | 41.4 | 6 | 49.7 | Χ | Х | 9 | 72.6 | Χ | Χ |
| 35-44 | 5 | 43.9 | X | X | Χ | Х | X | Х | Χ | Χ |
| 45-54 | Χ | X | X | X | Χ | Х | X | Х | X | Χ |
| ≥55 | 0 | 0.0 | 0 | 0.0 | Χ | Χ | 0 | 0.0 | 0 | 0.0 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 12 | 33.1 | 8 | 22.0 | 9 | 24.6 | 12 | 32.8 | 8 | 21.8 |
| Non-Hispanic white | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Χ |
| Hispanic | Χ | Χ | Χ | Χ | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Other | Χ | Χ | 0 | 0.0 | 0 | 0.0 | Χ | Χ | Χ | Χ |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 10 | _ | 7 | _ | 8 | _ | 10 | _ | 5 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| MMS and IDU | 0 | _ | Χ | _ | 0 | _ | 0 | _ | 0 | _ |
| Heterosexual sexual contact | Χ | _ | Χ | _ | Χ | _ | X | _ | Χ | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | Χ | _ | 0 | _ | 0 | _ | X | _ | X | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | Χ | _ | Χ | _ | Χ | _ | Χ | _ | Χ | _ |
| Injection drug use (IDU) | Χ | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 0 | _ | 0 | _ | Χ | _ | 0 | _ | Χ | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Overall | Х | Х | Х | Х | Х | Х | Х | Х | 10 | 10.2 |

New HIV diagnoses: persons diagnosed with HIV during January 1–December 31, 2019 and resided in Tennessee at the time of diagnosis For new diagnoses and concurrent diagnoses, age group refers to the age at the time of HIV diagnosis.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

— represents data not available.

Table 13. Persons newly diagnosed with HIV, South Central public health region, Tennessee, 2015–2019

| | 20° | 15 | 201 | 16 | 201 | 17 | 201 | 18 | 201 | 9 |
|-----------------------------------|-----|------|-----------|------|----------|------|----------|------|------------|------|
| | No. | Rate | No. | Rate | No. | Rate | No. | Rate | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 13 | 6.7 | 21 | 10.7 | 16 | 8.0 | 15 | 7.4 | 19 | 9.3 |
| Cisgender female | Χ | Χ | 5 | 2.5 | Χ | Χ | Χ | X | Χ | Χ |
| Transgender person | 0 | _ | 0 | _ | Χ | _ | 0 | _ | Χ | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| 15-24 | 0 | 0.0 | Χ | Χ | Χ | X | Χ | Χ | Χ | Χ |
| 25-34 | 8 | 16.7 | 8 | 16.1 | 6 | 11.7 | 7 | 13.4 | 12 | 22.4 |
| 35-44 | Χ | Χ | Χ | Χ | 6 | 12.2 | Χ | Χ | Χ | X |
| 45-54 | Χ | X | 5 | 9.3 | 6 | 11.1 | 0 | 0.0 | Χ | Х |
| ≥55 | Χ | Χ | 6 | 4.9 | 0 | 0.0 | Χ | Χ | Χ | Х |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 6 | 22.7 | 9 | 33.6 | 7 | 25.5 | 5 | 17.9 | 10 | 35.2 |
| Non-Hispanic white | 9 | 2.7 | 13 | 3.8 | 11 | 3.2 | 8 | 2.3 | 10 | 2.9 |
| Hispanic | X | X | X | X | Χ | Х | X | X | X | Х |
| Other | 0 | 0.0 | X | X | Х | Х | Х | X | Х | Х |
| Transmission risk | - | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 8 | _ | 9 | _ | 9 | _ | 8 | _ | 12 | _ |
| Injection drug use (IDU) | X | _ | X | _ | 0 | _ | 0 | _ | X | _ |
| MMS and IDU | X | _ | X | _ | X | _ | X | _ | 0 | _ |
| Heterosexual sexual contact | X | _ | 7 | _ | X | _ | X | _ | X | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | X | _ | X | _ | X | _ | X | _ |
| Cisgender female | | | ,, | | , | | ,, | | ,, | |
| Heterosexual sexual contact | Х | _ | 5 | _ | Х | _ | Х | _ | Χ | _ |
| Injection drug use (IDU) | X | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Transgender person | J | | | | | | | | · · | |
| Any sexual contact | 0 | _ | 0 | _ | Х | _ | 0 | _ | Х | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 0 | _ | 0 | _ | 0 | _ | 0 | _ | X | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| | X | X | 26 | | X | | X | | 2 5 | |
| Overall | | | | 6.6 | | Х | Х | Х | 25 | 6.0 |

New HIV diagnoses: persons diagnosed with HIV during January 1–December 31, 2019 and resided in Tennessee at the time of diagnosis For new diagnoses and concurrent diagnoses, age group refers to the age at the time of HIV diagnosis.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

- represents data not available.

Table 14. Persons newly diagnosed with HIV, Mid-Cumberland public health region, Tennessee, 2015–2019

| | 201 | 15 | 201 | 16 | 201 | 7 | 201 | 8 | 201 | 9 |
|-----------------------------------|-----|------|-----|------|-----|------|-----|------|-----|------|
| | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 56 | 9.4 | 52 | 8.5 | 65 | 10.3 | 81 | 12.6 | 77 | 11.7 |
| Cisgender female | 10 | 1.6 | 11 | 1.7 | 18 | 2.8 | 14 | 2.1 | 24 | 3.6 |
| Transgender person | 0 | _ | 2 | _ | 0 | _ | 0 | _ | 0 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 1 | 0.4 | 1 | 0.4 | 2 | 0.8 | 1 | 0.4 | 0 | 0.0 |
| 15–24 | 19 | 11.2 | 24 | 13.9 | 20 | 11.4 | 20 | 11.2 | 18 | 10.0 |
| 25-34 | 23 | 14.3 | 19 | 11.4 | 25 | 14.4 | 36 | 20.3 | 31 | 17.1 |
| 35-44 | 10 | 6.0 | 13 | 7.7 | 9 | 5.2 | 20 | 11.2 | 15 | 8.2 |
| 45-54 | 11 | 6.5 | 6 | 3.5 | 19 | 10.8 | 12 | 6.8 | 19 | 10.7 |
| ≥55 | 2 | 0.7 | 2 | 0.7 | 8 | 2.5 | 6 | 1.8 | 18 | 5.3 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 30 | 25.7 | 24 | 19.7 | 29 | 22.5 | 37 | 27.3 | 41 | 28.9 |
| Non-Hispanic white | 29 | 3.0 | 33 | 3.3 | 43 | 4.3 | 43 | 4.2 | 52 | 5.0 |
| Hispanic | 4 | 5.6 | 4 | 5.3 | 9 | 11.3 | 6 | 7.1 | 4 | 4.5 |
| Other | 3 | 5.3 | 4 | 6.7 | 2 | 3.1 | 9 | 13.4 | 4 | 5.6 |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 46 | _ | 37 | _ | 45 | _ | 53 | _ | 61 | _ |
| Injection drug use (IDU) | 3 | _ | 1 | _ | 1 | _ | 2 | _ | 3 | _ |
| MMS and IDU | 1 | _ | 4 | _ | 2 | _ | 2 | _ | 0 | _ |
| Heterosexual sexual contact | 5 | _ | 5 | _ | 7 | _ | 15 | _ | 9 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other . | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 1 | _ | 5 | _ | 10 | _ | 9 | _ | 4 | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | 9 | _ | 8 | _ | 12 | _ | 9 | _ | 13 | _ |
| Injection drug use (IDU) | 0 | _ | 1 | _ | 1 | _ | 0 | _ | 5 | _ |
| Perinatal exposure | 1 | _ | 1 | _ | 1 | _ | 1 | _ | 0 | _ |
| Other . | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 1 | _ | 4 | _ | 4 | _ | 6 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 0 | _ | 1 | _ | 0 | _ | 0 | _ | 0 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 0 | _ | 1 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Overall | 66 | 5.4 | 65 | 5.2 | 83 | 6.5 | 95 | 7.3 | 101 | 7.6 |

New HIV diagnoses: persons diagnosed with HIV during January 1–December 31, 2019 and resided in Tennessee at the time of diagnosis For new diagnoses and concurrent diagnoses, age group refers to the age at the time of HIV diagnosis.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

- represents data not available.

Table 15. Persons newly diagnosed with HIV, Nashville/Davidson County, Tennessee, 2015-2019

| | 20 ⁻ | 15 | 201 | 16 | 20 | 17 | 20° | 18 | 201 | 19 |
|-----------------------------------|-----------------|------|-----|------|-----|------|-----|------|-----|------|
| | No. | Rate | No. | Rate | No. | Rate | No. | Rate | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 134 | 40.9 | 114 | 34.5 | 125 | 37.7 | 106 | 31.9 | 139 | 41.6 |
| Cisgender female | 27 | 7.7 | 23 | 6.5 | 12 | 3.4 | 22 | 6.2 | 14 | 3.9 |
| Transgender person | 5 | _ | 3 | _ | 2 | _ | 6 | _ | 3 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 3 | 2.4 | 0 | 0.0 | 1 | 0.8 | 0 | 0.0 | 0 | 0.0 |
| 15–24 | 45 | 50.2 | 36 | 40.2 | 32 | 36.2 | 31 | 35.2 | 23 | 26.1 |
| 25-34 | 64 | 48.4 | 49 | 36.2 | 61 | 44.3 | 55 | 39.2 | 79 | 55.3 |
| 35-44 | 24 | 25.8 | 29 | 31.2 | 23 | 24.6 | 27 | 28.5 | 27 | 28.1 |
| 45-54 | 18 | 21.5 | 21 | 25.2 | 13 | 15.8 | 11 | 13.7 | 16 | 20.4 |
| ≥55 | 12 | 7.7 | 5 | 3.1 | 9 | 5.6 | 10 | 6.1 | 11 | 6.6 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 87 | 46.6 | 75 | 39.8 | 77 | 41.0 | 70 | 37.4 | 75 | 40.2 |
| Non-Hispanic white | 57 | 14.8 | 54 | 14.0 | 48 | 12.4 | 36 | 9.3 | 53 | 13.6 |
| Hispanic | 13 | 19.1 | 9 | 13.0 | 8 | 11.4 | 17 | 23.8 | 23 | 31.8 |
| Other | 9 | 22.5 | 2 | 4.8 | 6 | 14.3 | 11 | 25.3 | 5 | 11.2 |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 113 | _ | 92 | _ | 108 | _ | 82 | _ | 120 | _ |
| Injection drug use (IDU) | 0 | _ | 1 | _ | 1 | _ | 1 | _ | 3 | _ |
| MMS and IDU | 4 | _ | 2 | _ | 0 | _ | 4 | _ | 3 | _ |
| Heterosexual sexual contact | 10 | _ | 13 | _ | 2 | _ | 14 | _ | 9 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 7 | _ | 6 | _ | 14 | _ | 5 | _ | 4 | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | 20 | _ | 20 | _ | 7 | _ | 20 | _ | 8 | _ |
| Injection drug use (IDU) | 0 | _ | 3 | _ | 0 | _ | 0 | _ | 5 | _ |
| Perinatal exposure | 2 | _ | 0 | _ | 1 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 5 | _ | 0 | _ | 4 | _ | 2 | _ | 1 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 5 | _ | 3 | _ | 2 | _ | 5 | _ | 3 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 1 | _ | 0 | _ |
| Overall | 166 | 24.4 | 140 | 20.4 | 139 | 20.2 | 134 | 19.4 | 156 | 22.5 |

New HIV diagnoses: persons diagnosed with HIV during January 1–December 31, 2019 and resided in Tennessee at the time of diagnosis For new diagnoses and concurrent diagnoses, age group refers to the age at the time of HIV diagnosis. For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

[—] represents data not available.

Table 16. Persons newly diagnosed with HIV, Upper Cumberland public health region, Tennessee, 2015–2019

| | 20° | 15 | 201 | 16 | 201 | 17 | 201 | 18 | 201 | 9 |
|-----------------------------------|-----|------|-----|------|-----|------|-----|------|----------|------|
| | No. | Rate | No. | Rate | No. | Rate | No. | Rate | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 15 | 8.8 | Χ | Χ | 13 | 7.5 | 8 | 4.6 | Х | Х |
| Cisgender female | Χ | Χ | 0 | 0.0 | Χ | Χ | Χ | Χ | Х | Х |
| Transgender person | 0 | _ | 0 | _ | Χ | _ | Χ | _ | 0 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| 15–24 | 6 | 13.5 | Χ | Χ | Χ | Χ | Χ | Χ | 0 | 0.0 |
| 25-34 | 7 | 18.0 | Χ | Χ | Χ | Χ | 5 | 12.0 | Χ | X |
| 35-44 | Χ | Χ | Χ | Χ | Χ | Χ | 0 | 0.0 | Χ | X |
| 45-54 | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Χ | X |
| ≥55 | 0 | 0.0 | 0 | 0.0 | Χ | Χ | Χ | Χ | Χ | Х |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | Х | Х | 0 | 0.0 | Х | Х | Χ | Х | Х | Х |
| Non-Hispanic white | 14 | 4.4 | 12 | 3.8 | 13 | 4.0 | 10 | 3.1 | Х | Х |
| Hispanic | Χ | Х | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Other | 0 | 0.0 | Χ | Χ | Х | Χ | 0 | 0.0 | 0 | 0.0 |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 6 | _ | 10 | _ | 8 | _ | 8 | _ | Х | _ |
| Injection drug use (IDU) | X | _ | X | _ | 0 | _ | 0 | _ | 0 | _ |
| MMS and IDU | Х | _ | Х | _ | X | _ | 0 | _ | X | _ |
| Heterosexual sexual contact | Х | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | X | _ | 0 | _ | X | _ | 0 | _ | 0 | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | Х | _ | 0 | _ | Х | _ | Х | _ | 0 | _ |
| Injection drug use (IDU) | X | _ | 0 | _ | X | _ | 0 | _ | X | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | X | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Transgender person | ,, | | | | | | | | | |
| Any sexual contact | 0 | _ | 0 | _ | Х | _ | 0 | _ | 0 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | X | _ | 0 | _ |
| Overall | x | X | X | X | 16 | 4.5 | X | X | <u>5</u> | 1.4 |

New HIV diagnoses: persons diagnosed with HIV during January 1–December 31, 2019 and resided in Tennessee at the time of diagnosis For new diagnoses and concurrent diagnoses, age group refers to the age at the time of HIV diagnosis. For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

- represents data not available.

Table 17. Persons newly diagnosed with HIV, Southeast public health region, Tennessee, 2015–2019

| | 201 | 15 | 201 | 6 | 201 | 17 | 201 | 8 | 201 | 9 |
|-----------------------------------|-----|------|-----|------|-----|------|-----|------|-----|------|
| | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 13 | 8.0 | 13 | 7.9 | 12 | 7.3 | 12 | 7.2 | 15 | 8.9 |
| Cisgender female | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Χ |
| Transgender person | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | Χ | Х | Χ | Х | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| 15–24 | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Χ |
| 25-34 | Χ | Χ | 5 | 13.0 | Χ | Χ | 6 | 15.1 | 7 | 17.2 |
| 35-44 | 6 | 14.7 | Χ | Χ | 5 | 12.5 | Χ | Χ | 5 | 12.6 |
| 45-54 | Χ | Χ | Χ | Χ | 0 | 0.0 | Χ | Χ | Χ | Χ |
| ≥55 | 0 | 0.0 | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Χ |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 5 | 42.4 | Х | Х | Х | Х | Χ | Χ | Х | Х |
| Non-Hispanic white | 6 | 2.0 | 15 | 5.1 | 9 | 3.0 | 10 | 3.3 | 14 | 4.7 |
| Hispanic | Χ | X | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | Χ | X |
| Other | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 7 | _ | 5 | _ | 6 | _ | 7 | _ | 9 | _ |
| Injection drug use (IDU) | Χ | _ | X | _ | Χ | _ | 0 | _ | X | _ |
| MMS and IDU | Χ | _ | Χ | _ | Χ | _ | Χ | _ | Χ | _ |
| Heterosexual sexual contact | Χ | _ | Х | _ | Χ | _ | Χ | _ | Χ | _ |
| Perinatal exposure | 0 | _ | Х | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | X | _ | X | _ | Χ | _ | X | _ | 0 | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | Χ | _ | Х | _ | Χ | _ | Χ | _ | Х | _ |
| Injection drug use (IDU) | 0 | _ | Х | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | X | _ | 0 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Overall | X | Х | X | Х | X | Х | X | Х | X | Х |

New HIV diagnoses: persons diagnosed with HIV during January 1–December 31, 2019 and resided in Tennessee at the time of diagnosis For new diagnoses and concurrent diagnoses, age group refers to the age at the time of HIV diagnosis. For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

[—] represents data not available.

Table 18. Persons newly diagnosed with HIV, Chattanooga/Hamilton County, Tennessee, 2015-2019

| | 20 ⁻ | 15 | 201 | 16 | 201 | 17 | 201 | 18 | 201 | 9 |
|-----------------------------------|-----------------|------|-----|------|-----|------|-----|------|-----|------|
| | No. | Rate | No. | Rate | No. | Rate | No. | Rate | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 37 | 21.7 | 42 | 24.3 | 33 | 18.9 | 36 | 20.5 | 38 | 21.4 |
| Cisgender female | 7 | 3.8 | Χ | Χ | Χ | Χ | Χ | Χ | 10 | 5.3 |
| Transgender person | X | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | Х | Х |
| 15–24 | 8 | 18.0 | 13 | 29.4 | 9 | 20.4 | Χ | Χ | 6 | 13.6 |
| 25–34 | 18 | 36.4 | 13 | 25.4 | 17 | 32.5 | 20 | 37.6 | 20 | 36.9 |
| 35–44 | 7 | 15.9 | 15 | 34.0 | 5 | 11.3 | 6 | 13.4 | 12 | 26.5 |
| 45-54 | 9 | 19.1 | 10 | 21.2 | 8 | 17.1 | 5 | 10.8 | 6 | 13.1 |
| ≥55 | Χ | Χ | Χ | Χ | Χ | Χ | 9 | 8.0 | Χ | Х |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 22 | 31.9 | 23 | 33.2 | 19 | 27.3 | 21 | 30.1 | 24 | 34.3 |
| Non-Hispanic white | 18 | 7.1 | 24 | 9.4 | 24 | 9.3 | 21 | 8.1 | 19 | 7.3 |
| Hispanic | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Χ | X |
| Other | 0 | 0.0 | Χ | Χ | 0 | 0.0 | 0 | 0.0 | Χ | Х |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 19 | _ | 31 | _ | 21 | _ | 23 | _ | 25 | _ |
| Injection drug use (IDU) | Χ | _ | Χ | _ | Χ | _ | Χ | _ | Χ | _ |
| MMS and IDU | Χ | _ | Χ | _ | 0 | _ | Χ | _ | Χ | _ |
| Heterosexual sexual contact | 6 | _ | Χ | _ | Χ | _ | 5 | _ | 7 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | Χ | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 7 | _ | Χ | _ | 8 | _ | Χ | _ | Χ | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | Х | _ | 9 | _ | Χ | _ | 5 | _ | Χ | _ |
| Injection drug use (IDU) | Χ | _ | 0 | _ | Χ | _ | Χ | _ | 5 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | Χ | _ | Χ | _ | Χ | _ | Χ | _ | Χ | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | Х | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Overall | X | Х | X | Х | X | Х | X | Х | 48 | 13.1 |

New HIV diagnoses: persons diagnosed with HIV during January 1–December 31, 2019 and resided in Tennessee at the time of diagnosis For new diagnoses and concurrent diagnoses, age group refers to the age at the time of HIV diagnosis. For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

⁻ represents data not available.

Table 19. Persons newly diagnosed with HIV, East public health region, Tennessee, 2015–2019

| _ | 201 | 15 | 201 | 6 | 201 | 17 | 201 | 8 | 201 | 9 |
|-----------------------------------|-----|------|-----|------|-----|------|-----|------|-----|------|
| | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 19 | 5.1 | 22 | 5.9 | 22 | 5.8 | 22 | 5.8 | 26 | 6.8 |
| Cisgender female | 5 | 1.3 | 2 | 0.5 | 6 | 1.5 | 8 | 2.0 | 5 | 1.3 |
| Transgender person | 0 | _ | 0 | _ | 0 | _ | 1 | _ | 0 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 0 | 0.0 | 1 | 0.8 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| 15–24 | 3 | 3.4 | 6 | 6.8 | 8 | 9.1 | 9 | 10.2 | 7 | 8.0 |
| 25–34 | 4 | 4.8 | 6 | 7.0 | 7 | 8.0 | 10 | 11.2 | 11 | 12.0 |
| 35-44 | 6 | 6.6 | 2 | 2.2 | 5 | 5.7 | 5 | 5.7 | 7 | 8.0 |
| 45-54 | 6 | 5.6 | 5 | 4.7 | 5 | 4.7 | 6 | 5.6 | 5 | 4.8 |
| ≥55 | 5 | 2.0 | 4 | 1.5 | 3 | 1.1 | 1 | 0.4 | 1 | 0.4 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 1 | 6.2 | 3 | 18.4 | 2 | 12.1 | 3 | 18.0 | 1 | 5.9 |
| Non-Hispanic white | 20 | 2.9 | 16 | 2.3 | 23 | 3.3 | 24 | 3.4 | 23 | 3.3 |
| Hispanic | 3 | 9.9 | 4 | 12.7 | 3 | 9.1 | 3 | 8.8 | 7 | 19.7 |
| Other | 0 | 0.0 | 1 | 5.2 | 0 | 0.0 | 1 | 4.9 | 0 | 0.0 |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 12 | _ | 12 | _ | 11 | _ | 10 | _ | 18 | _ |
| Injection drug use (IDU) | 1 | _ | 3 | _ | 2 | _ | 3 | _ | 0 | _ |
| MMS and IDU | 0 | _ | 2 | _ | 3 | _ | 2 | _ | 3 | _ |
| Heterosexual sexual contact | 5 | _ | 4 | _ | 4 | _ | 5 | _ | 3 | _ |
| Perinatal exposure | 0 | _ | 1 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 1 | _ | 0 | _ | 2 | _ | 2 | _ | 2 | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | 3 | _ | 2 | _ | 5 | _ | 5 | _ | 3 | _ |
| Injection drug use (IDU) | 2 | _ | 0 | _ | 1 | _ | 3 | _ | 1 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 1 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 0 | _ | 0 | _ | 0 | _ | 1 | _ | 0 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other . | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Overall | 24 | 3.2 | 24 | 3.2 | 28 | 3.7 | 31 | 4.0 | 31 | 4.0 |

New HIV diagnoses: persons diagnosed with HIV during January 1–December 31, 2019 and resided in Tennessee at the time of diagnosis For new diagnoses and concurrent diagnoses, age group refers to the age at the time of HIV diagnosis. For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

[—] represents data not available.

Table 20. Persons newly diagnosed with HIV, Knoxville/Knox County, Tennessee, 2015–2019

| | 20 ⁻ | 15 | 201 | 16 | 20° | 17 | 201 | 18 | 201 | 19 |
|-----------------------------------|-----------------|------|-----|------|-----|------|-----|------|-----|------|
| | No. | Rate | No. | Rate | No. | Rate | No. | Rate | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 30 | 13.7 | 41 | 18.5 | 35 | 15.6 | 37 | 16.3 | Х | Х |
| Cisgender female | Χ | Χ | 10 | 4.3 | 15 | 6.3 | Χ | Χ | 25 | 10.3 |
| Transgender person | 0 | _ | Χ | _ | Χ | _ | X | _ | Χ | _ |
| Age group (years) | | | | | | | | | | |
| <15 | Χ | Χ | Χ | Х | Χ | Χ | 0 | 0.0 | 0 | 0.0 |
| 15–24 | 7 | 9.8 | 11 | 15.3 | 11 | 15.3 | 6 | 8.3 | 16 | 22.2 |
| 25-34 | 12 | 19.9 | 20 | 32.6 | 15 | 23.9 | 24 | 37.7 | 30 | 46.3 |
| 35-44 | 9 | 15.9 | 7 | 12.3 | 14 | 24.4 | 9 | 15.4 | 20 | 33.8 |
| 45-54 | 8 | 13.4 | 9 | 15.1 | Χ | X | 7 | 11.9 | 9 | 15.5 |
| ≥55 | Χ | Χ | Χ | Χ | 6 | 4.7 | X | Χ | Χ | Χ |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 12 | 30.3 | 15 | 37.6 | 16 | 39.7 | 17 | 41.9 | 24 | 58.6 |
| Non-Hispanic white | 28 | 7.5 | 33 | 8.7 | 32 | 8.4 | 26 | 6.8 | 48 | 12.5 |
| Hispanic | Χ | Χ | Χ | Χ | Χ | Χ | 6 | 29.0 | X | Χ |
| Other | 0 | 0.0 | Χ | Χ | Χ | Χ | X | Χ | 5 | 22.3 |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 23 | _ | 30 | _ | 26 | _ | 29 | _ | 33 | _ |
| Injection drug use (IDU) | Χ | _ | Χ | _ | Χ | _ | X | _ | 9 | _ |
| MMS and IDU | Χ | _ | Χ | _ | Χ | _ | X | _ | X | _ |
| Heterosexual sexual contact | Χ | _ | 6 | _ | Χ | _ | 6 | _ | 11 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | Χ | _ | 0 | _ | Χ | _ | 0 | _ | 0 | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | 8 | _ | 7 | _ | 9 | _ | 11 | _ | 12 | _ |
| Injection drug use (IDU) | Χ | _ | Χ | _ | Χ | _ | X | _ | 13 | _ |
| Perinatal exposure | 0 | _ | Χ | _ | Χ | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | Χ | _ | 0 | _ | 0 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 0 | _ | Χ | _ | Χ | _ | Χ | _ | 0 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | Χ | _ |
| Any sexual contact and IDU | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Overall | Х | Х | Х | Х | Х | Х | Х | Х | Х | Х |

New HIV diagnoses: persons diagnosed with HIV during January 1–December 31, 2019 and resided in Tennessee at the time of diagnosis For new diagnoses and concurrent diagnoses, age group refers to the age at the time of HIV diagnosis. For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

⁻ represents data not available.

Table 21. Persons newly diagnosed with HIV, Northeast public health region, Tennessee, 2015–2019

| | 20 ⁻ | 15 | 20 | 16 | 201 | 17 | 201 | 18 | 20 | 19 |
|-----------------------------------|-----------------|------|--------|------|--------|------|--------|------|-----|------|
| | No. | Rate | No. | Rate | No. | Rate | No. | Rate | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 15 | 8.7 | 12 | 6.9 | 14 | 8.1 | 13 | 7.5 | 8 | 4.6 |
| Cisgender female | Χ | X | Χ | Χ | Χ | Χ | Χ | Χ | Χ | X |
| Transgender person | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| 15-24 | 5 | 11.0 | 5 | 11.1 | Χ | Χ | Χ | Χ | 0 | 0.0 |
| 25-34 | 10 | 24.8 | Х | Х | 7 | 16.9 | 6 | 14.3 | Χ | Χ |
| 35-44 | Χ | Х | Χ | Х | 0 | 0.0 | Х | Χ | Χ | Х |
| 45–54 | Χ | Х | Х | Х | X | Χ | Х | Χ | Х | Х |
| ≥55 | 0 | 0.0 | X | X | Χ | Х | X | X | X | X |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | Х | Χ | Х | Х | Х | Х | 0 | 0.0 | 0 | 0.0 |
| Non-Hispanic white | 21 | 6.5 | 9 | 2.8 | 11 | 3.4 | 11 | 3.4 | 7 | 2.2 |
| Hispanic | 0 | 0.0 | 0 | 0.0 | X | X | X | X | X | Χ.Σ |
| Other | 0 | 0.0 | 0 | 0.0 | X | X | 0 | 0.0 | 0 | 0.0 |
| Transmission risk | | 0.0 | | 0.0 | ,, | | | 0.0 | | 0.0 |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 12 | _ | 9 | _ | 10 | _ | 11 | _ | 6 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | X | _ | X | _ | 0 | _ |
| MMS and IDU | X | _ | X | _ | 0 | _ | 0 | _ | X | _ |
| Heterosexual sexual contact | 0 | _ | X | _ | X | _ | X | _ | X | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | X | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Cisgender female | ^ | | U | | U | | U | | U | |
| Heterosexual sexual contact | 5 | | Х | | 0 | | 0 | | Х | |
| Injection drug use (IDU) | X | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | X | _ | 0 | _ | X | _ | X | _ | 0 | _ |
| | ^ | | U | _ | ^ | _ | ^ | _ | U | _ |
| Transgender person | ^ | | 0 | | 0 | | 0 | | 0 | |
| Any sexual contact | 0 0 | _ | 0 0 | _ | 0 0 | _ | 0 0 | _ | 0 | _ |
| Injection drug use (IDU) | | _ | | _ | | _ | | _ | | _ |
| Any sexual contact and IDU | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | | 0 | | 0 | | 0 | | 0 | |
| Overall | Х | Х | Х | Х | Х | Х | Х | Х | Х | Х |

New HIV diagnoses: persons diagnosed with HIV during January 1–December 31, 2019 and resided in Tennessee at the time of diagnosis For new diagnoses and concurrent diagnoses, age group refers to the age at the time of HIV diagnosis. For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

[—] represents data not available.

Table 22. Persons newly diagnosed with HIV, Blountville/Sullivan County public health region, Tennessee, 2015–2019

| | 201 | 15 | 201 | 6 | 201 | 7 | 2018 | 3 | 2019 | |
|-----------------------------------|-----|------|-----|------|-----|------|------|------|------|------|
| | No. | Rate | No. | Rate | No. | Rate | No. | Rate | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | Х | Χ | 6 | 7.9 | 5 | 6.6 | Х | Х | Х | Х |
| Cisgender female | X | Χ | 0 | 0.0 | Χ | Χ | 0 | 0.0 | Χ | Χ |
| Transgender person | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| 15-24 | X | Χ | Χ | Χ | Χ | Χ | Χ | Χ | 0 | 0.0 |
| 25-34 | X | Χ | Χ | Χ | Χ | Χ | 5 | 27.1 | 0 | 0.0 |
| 35-44 | X | Χ | 0 | 0.0 | Χ | Χ | Χ | Χ | Χ | X |
| 45-54 | 0 | 0.0 | Χ | Χ | Χ | Х | 0 | 0.0 | Х | Х |
| ≥55 | 0 | 0.0 | Χ | Χ | Χ | Х | Χ | Х | Х | Х |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | Х | Χ | 0 | 0.0 | Х | Х | Х | Х | 0 | 0.0 |
| Non-Hispanic white | X | Χ | 6 | 4.1 | Χ | Х | 9 | 6.1 | 5 | 3.4 |
| Hispanic | X | Χ | 0 | 0.0 | 0 | 0.0 | Χ | Х | 0 | 0.0 |
| Other | 0 | 6.7 | 0 | 0.0 | Χ | Х | 0 | 0.0 | 0 | 0.0 |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | Χ | _ | Х | _ | Χ | _ | 10 | _ | Х | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | Χ | _ | 0 | _ | 0 | _ |
| MMS and IDU | 0 | _ | Χ | _ | Χ | _ | 0 | _ | Χ | _ |
| Heterosexual sexual contact | 0 | _ | Χ | _ | 0 | _ | Х | _ | Х | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | X | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | 0 | _ | 0 | _ | Χ | _ | 0 | _ | Х | _ |
| Injection drug use (IDU) | Χ | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Overall | 6 | 3.8 | 6 | 3.8 | X | Х | X | Х | 5 | 3.2 |

New HIV diagnoses: persons diagnosed with HIV during January 1–December 31, 2019 and resided in Tennessee at the time of diagnosis For new diagnoses and concurrent diagnoses, age group refers to the age at the time of HIV diagnosis. For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

- represents data not available.

Table 23. Persons concurrently diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of diagnosis, Memphis/Shelby County, Tennessee, 2015–2019

| | 20° | 15 | 201 | 16 | 201 | 17 | 201 | 8 | 201 | 9 |
|-----------------------------------|-----|------|-----|------|-----|------|-----|------|-----|------|
| | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 37 | 8.3 | 38 | 8.5 | 43 | 9.7 | 52 | 11.7 | 38 | 8.5 |
| Cisgender female | 6 | 1.2 | 9 | 1.8 | 12 | 2.4 | 12 | 2.4 | 10 | 2.0 |
| Transgender person | 1 | _ | 1 | _ | 1 | _ | 0 | _ | 0 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 1 | 0.5 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| 15–24 | 6 | 4.5 | 7 | 5.4 | 6 | 4.7 | 10 | 8.0 | 6 | 4.9 |
| 25–34 | 10 | 7.4 | 13 | 9.6 | 17 | 12.4 | 19 | 13.6 | 14 | 9.9 |
| 35–44 | 10 | 8.4 | 9 | 7.7 | 13 | 11.2 | 13 | 11.1 | 9 | 7.7 |
| 45–54 | 12 | 9.8 | 11 | 9.1 | 13 | 10.9 | 13 | 11.2 | 7 | 6.1 |
| ≥55 | 5 | 2.2 | 8 | 3.4 | 7 | 2.9 | 9 | 3.7 | 12 | 4.8 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 34 | 6.8 | 40 | 8.0 | 47 | 9.4 | 49 | 9.8 | 33 | 6.6 |
| Non-Hispanic white | 4 | 1.2 | 3 | 0.9 | 4 | 1.2 | 8 | 2.4 | 7 | 2.1 |
| Hispanic | 5 | 8.8 | 2 | 3.4 | 5 | 8.4 | 6 | 9.8 | 5 | 8.0 |
| Other | 1 | 2.6 | 3 | 7.8 | 0 | 0.0 | 1 | 2.5 | 3 | 7.3 |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 18 | _ | 18 | _ | 21 | _ | 25 | _ | 17 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 1 | _ |
| MMS and IDU | 0 | _ | 0 | _ | 0 | _ | 3 | _ | 0 | _ |
| Heterosexual sexual contact | 10 | _ | 14 | _ | 13 | _ | 11 | _ | 4 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 9 | _ | 6 | _ | 9 | _ | 13 | _ | 16 | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | 3 | _ | 9 | _ | 10 | _ | 7 | _ | 5 | _ |
| Injection drug use (IDU) | 1 | _ | 0 | _ | 0 | _ | 0 | _ | 1 | _ |
| Perinatal exposure | 1 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 1 | _ | 0 | _ | 2 | _ | 5 | _ | 4 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 1 | _ | 1 | _ | 1 | _ | 0 | _ | 0 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Overall | 44 | 4.7 | 48 | 5.1 | 56 | 6.0 | 64 | 6.8 | 48 | 5.1 |

Concurrent diagnoses: persons who were diagnosed with HIV 12 months or less before being diagnosed as Stage 3 HIV (AIDS)

For new diagnoses and concurrent diagnoses, age group refers to the age at the time of HIV diagnosis. For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

⁻ represents data not available.

Table 24. Persons concurrently diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of diagnosis, West public health region, Tennessee, 2015–2019

| | 201 | 15 | 201 | 6 | 201 | 7 | 201 | 8 | 2019 | 9 |
|-----------------------------------|-----|------|-----|------|-----|------|-----|------|------|------|
| | No. | Rate | No. | Rate | No. | Rate | No. | Rate | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 6 | 2.3 | 6 | 2.3 | 4 | 1.5 | 3 | 1.2 | 4 | 1.5 |
| Cisgender female | 0 | 0.0 | 3 | 1.1 | 3 | 1.1 | 2 | 0.7 | 0 | 0.0 |
| Transgender person | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| 15–24 | 1 | 1.5 | 2 | 3.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| 25–34 | 1 | 1.6 | 2 | 3.3 | 4 | 6.4 | 1 | 1.6 | 1 | 1.6 |
| 35-44 | 0 | 0.0 | 2 | 3.2 | 1 | 1.6 | 2 | 3.2 | 1 | 1.6 |
| 45-54 | 2 | 2.7 | 1 | 1.4 | 0 | 0.0 | 2 | 2.9 | 1 | 1.5 |
| ≥55 | 2 | 1.2 | 2 | 1.2 | 2 | 1.2 | 0 | 0.0 | 1 | 0.6 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 5 | 5.7 | 6 | 7.0 | 3 | 3.5 | 4 | 4.6 | 2 | 2.3 |
| Non-Hispanic white | 1 | 0.2 | 2 | 0.5 | 4 | 1.0 | 1 | 0.2 | 1 | 0.2 |
| Hispanic | 0 | 0.0 | 1 | 6.6 | 0 | 0.0 | 0 | 0.0 | 1 | 5.9 |
| Other | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 4 | _ | 5 | _ | 3 | _ | 2 | _ | 3 | _ |
| Injection drug use (IDU) | 1 | _ | 0 | _ | 0 | _ | 0 | _ | 1 | _ |
| MMS and IDU | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Heterosexual sexual contact | 1 | _ | 1 | _ | 0 | _ | 1 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 1 | _ | 0 | _ | 0 | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | 0 | _ | 2 | _ | 2 | _ | 2 | _ | 0 | _ |
| Injection drug use (IDU) | 0 | _ | 1 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 1 | _ | 0 | _ | 0 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Overall | 6 | 1.1 | 9 | 1.7 | 7 | 1.3 | 5 | 0.9 | 4 | 0.8 |

Concurrent diagnoses: persons who were diagnosed with HIV 12 months or less before being diagnosed as Stage 3 HIV (AIDS)

For new diagnoses and concurrent diagnoses, age group refers to the age at the time of HIV diagnosis. For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

⁻ represents data not available.

Table 25. Persons concurrently diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of diagnosis, Jackson/Madison County, Tennessee, 2015–2019

| · | 201 | 15 | 201 | 16 | 201 | 7 | 201 | 8 | 2019 | 9 |
|-----------------------------------|-----|------|-----|------|-----|------|-----|------|------|------|
| | No. | Rate | No. | Rate | No. | Rate | No. | Rate | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | Χ | Х | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Χ |
| Cisgender female | Χ | Χ | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | Χ | Χ |
| Transgender person | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| 15-24 | Χ | Χ | Χ | Χ | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| 25–34 | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Χ |
| 35–44 | Χ | Χ | 0 | 0.0 | 0 | 0.0 | X | Χ | Χ | Χ |
| 45-54 | 0 | 0.0 | 0 | 0.0 | Χ | Χ | Χ | Χ | 0 | 0.0 |
| ≥55 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Х | Х | Х |
| Non-Hispanic white | 0 | 0.0 | Χ | Χ | Χ | Χ | Χ | Χ | 0 | 0.0 |
| Hispanic | Χ | X | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Other | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | Χ | _ | Χ | _ | Χ | _ | Χ | _ | 0 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| MMS and IDU | 0 | _ | Χ | _ | 0 | _ | 0 | _ | 0 | _ |
| Heterosexual sexual contact | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | Χ | _ | Χ | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | Χ | _ | 0 | _ | 0 | _ | 0 | _ | Χ | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Overall | Х | Х | X | Х | Х | Х | Х | Х | Х | Х |

Concurrent diagnoses: persons who were diagnosed with HIV 12 months or less before being diagnosed as Stage 3 HIV (AIDS)

For new diagnoses and concurrent diagnoses, age group refers to the age at the time of HIV diagnosis. For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

- represents data not available.

Table 26. Persons concurrently diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of diagnosis, South Central public health region, Tennessee, 2015–2019

| | 20° | 15 | 20° | 16 | 20° | 17 | 20 | 18 | 20 | 19 |
|-----------------------------------|-----|------|-----|------|-----|------|-----|------|-----|------|
| | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | Χ | Х | Χ | Χ | Χ | Χ | 5 | 2.5 | 7 | 3.4 |
| Cisgender female | Χ | Χ | 0 | 0.0 | Χ | Χ | 0 | 0.0 | 0 | 0.0 |
| Transgender person | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| 15–24 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | Χ | X |
| 25–34 | Χ | Χ | 0 | 0.0 | 0 | 0.0 | Χ | Χ | Χ | Х |
| 35-44 | Χ | Х | Χ | X | Χ | Χ | Χ | X | Χ | Х |
| 45-54 | Χ | Χ | 0 | 0.0 | Χ | Χ | 0 | 0.0 | Χ | Х |
| ≥55 | Χ | Χ | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | Χ | X |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | Χ | Х | 0 | 0.0 | Х | Х | Χ | Χ | Χ | Х |
| Non-Hispanic white | Χ | Χ | X | Χ | Χ | Χ | Χ | Χ | Χ | Х |
| Hispanic | Χ | Х | Χ | X | 0 | 0.0 | 0 | 0.0 | Χ | Х |
| Other | 0 | 0.0 | 0 | 0.0 | Χ | Χ | 0 | 0.0 | 0 | 0.0 |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | Χ | _ | 0 | _ | Χ | _ | Χ | _ | Χ | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| MMS and IDU | Χ | _ | X | _ | 0 | _ | 0 | _ | 0 | _ |
| Heterosexual sexual contact | Χ | _ | Χ | _ | Χ | _ | Χ | _ | Χ | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | Χ | _ | Χ | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | Χ | _ | 0 | _ | Χ | _ | 0 | _ | 0 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Overall | 5 | 1.3 | Х | Х | 5 | 1.2 | 5 | 1.2 | 7 | 1.7 |

Concurrent diagnoses: persons who were diagnosed with HIV 12 months or less before being diagnosed as Stage 3 HIV (AIDS)

For new diagnoses and concurrent diagnoses, age group refers to the age at the time of HIV diagnosis. For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

[—] represents data not available.

Table 27. Persons concurrently diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of diagnosis, Mid-Cumberland public health region, Tennessee, 2015–2019

| | 201 | 15 | 201 | 6 | 201 | 7 | 201 | 8 | 201 | 9 |
|-----------------------------------|-----|------|-----|------|-----|------|-----|------|-----|------|
| | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 20 | 3.3 | 4 | 0.7 | 14 | 2.2 | 18 | 2.8 | 14 | 2.1 |
| Cisgender female | 5 | 8.0 | 2 | 0.3 | 1 | 0.2 | 4 | 0.6 | 7 | 1.0 |
| Transgender person | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 0.4 | 0 | 0.0 |
| 15–24 | 2 | 1.2 | 3 | 1.7 | 1 | 0.6 | 2 | 1.1 | 0 | 0.0 |
| 25-34 | 9 | 5.6 | 0 | 0.0 | 5 | 2.9 | 9 | 5.1 | 4 | 2.2 |
| 35-44 | 3 | 1.8 | 1 | 0.6 | 3 | 1.7 | 6 | 3.4 | 5 | 2.7 |
| 45-54 | 9 | 5.3 | 2 | 1.2 | 6 | 3.4 | 1 | 0.6 | 6 | 3.4 |
| ≥55 | 2 | 0.7 | 0 | 0.0 | 0 | 0.0 | 3 | 0.9 | 6 | 1.8 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 9 | 7.7 | 3 | 2.5 | 5 | 3.9 | 10 | 7.4 | 8 | 5.6 |
| Non-Hispanic white | 13 | 1.3 | 1 | 0.1 | 7 | 0.7 | 8 | 0.8 | 9 | 0.9 |
| Hispanic | 3 | 4.2 | 1 | 1.3 | 3 | 3.8 | 1 | 1.2 | 2 | 2.2 |
| Other | 0 | 0.0 | 1 | 1.7 | 0 | 0.0 | 3 | 4.5 | 2 | 2.8 |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 14 | _ | 3 | _ | 10 | _ | 10 | _ | 11 | _ |
| Injection drug use (IDU) | 2 | _ | 0 | _ | 1 | _ | 0 | _ | 0 | _ |
| MMS and IDU | 1 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Heterosexual sexual contact | 3 | _ | 1 | _ | 1 | _ | 8 | _ | 3 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 2 | _ | 0 | _ | 0 | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | 5 | _ | 1 | _ | 1 | _ | 3 | _ | 7 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 1 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 1 | _ | 0 | _ | 0 | _ | 0 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other . | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Overall | 25 | 2.1 | 6 | 0.5 | 15 | 1.2 | 22 | 1.7 | 21 | 1.6 |

Concurrent diagnoses: persons who were diagnosed with HIV 12 months or less before being diagnosed as Stage 3 HIV (AIDS)

For new diagnoses and concurrent diagnoses, age group refers to the age at the time of HIV diagnosis. For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

- represents data not available.

Table 28. Persons concurrently diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of diagnosis, Nashville/Davidson County, Tennessee, 2015–2019

| | 201 | 15 | 201 | 16 | 201 | 7 | 201 | 8 | 201 | 9 |
|-----------------------------------|-----|------|-----|------|-----|------|-----|------|-----|------|
| | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 23 | 7.0 | 23 | 7.0 | 15 | 4.5 | 17 | 5.1 | 23 | 6.9 |
| Cisgender female | 5 | 1.4 | 5 | 1.4 | 3 | 0.8 | 2 | 0.6 | 1 | 0.3 |
| Transgender person | 1 | _ | 0 | _ | 0 | _ | 1 | _ | 0 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 1 | 0.8 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| 15–24 | 3 | 3.3 | 2 | 2.2 | 4 | 4.5 | 3 | 3.4 | 2 | 2.3 |
| 25–34 | 8 | 6.1 | 9 | 6.7 | 6 | 4.4 | 11 | 7.8 | 8 | 5.6 |
| 35–44 | 8 | 8.6 | 10 | 10.8 | 3 | 3.2 | 3 | 3.2 | 8 | 8.3 |
| 45-54 | 5 | 6.0 | 6 | 7.2 | 3 | 3.6 | 3 | 3.7 | 1 | 1.3 |
| ≥55 | 4 | 2.6 | 1 | 0.6 | 2 | 1.2 | 0 | 0.0 | 5 | 3.0 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 15 | 8.0 | 16 | 8.5 | 9 | 4.8 | 12 | 6.4 | 13 | 7.0 |
| Non-Hispanic white | 12 | 3.1 | 9 | 2.3 | 5 | 1.3 | 2 | 0.5 | 7 | 1.8 |
| Hispanic | 1 | 1.5 | 3 | 4.3 | 2 | 2.8 | 4 | 5.6 | 4 | 5.5 |
| Other | 1 | 2.5 | 0 | 0.0 | 2 | 4.8 | 2 | 4.6 | 0 | 0.0 |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 18 | _ | 16 | _ | 13 | _ | 13 | _ | 19 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 1 | _ |
| MMS and IDU | 0 | _ | 0 | _ | 0 | _ | 2 | _ | 0 | _ |
| Heterosexual sexual contact | 1 | _ | 6 | _ | 1 | _ | 2 | _ | 3 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 4 | _ | 1 | _ | 1 | _ | 0 | _ | 0 | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | 3 | _ | 5 | _ | 2 | _ | 2 | _ | 1 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 2 | _ | 0 | _ | 1 | _ | 0 | _ | 0 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 1 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 1 | _ | 0 | _ |
| Overall | 29 | 4.3 | 28 | 4.1 | 18 | 2.6 | 20 | 2.9 | 24 | 3.5 |

Concurrent diagnoses: persons who were diagnosed with HIV 12 months or less before being diagnosed as Stage 3 HIV (AIDS)

For new diagnoses and concurrent diagnoses, age group refers to the age at the time of HIV diagnosis. For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

⁻ represents data not available.

Table 29. Persons concurrently diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of diagnosis, Upper Cumberland public health region, Tennessee, 2015–2019

| | 20 | 15 | 201 | 16 | 201 | 17 | 201 | 8 | 201 | 9 |
|-----------------------------------|-----|------|-----|------|-----|------|-----|------|-----|------|
| | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | Χ | Х | 5 | 2.9 | Χ | Х | Χ | Χ | Х | Х |
| Cisgender female | Χ | X | 0 | 0.0 | 0 | 0.0 | Χ | Χ | Χ | Χ |
| Transgender person | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| 15-24 | 0 | 0.0 | Χ | Χ | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| 25-34 | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Χ | 0 | 0.0 |
| 35-44 | 0 | 0.0 | 0 | 0.0 | Χ | Χ | 0 | 0.0 | Χ | X |
| 45-54 | Χ | Х | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Х |
| ≥55 | 0 | 0.0 | 0 | 0.0 | Χ | Χ | Χ | Χ | 0 | 0.0 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | Χ | Х | 0 | 0.0 | Х | Х | 0 | 0.0 | 0 | 0.0 |
| Non-Hispanic white | Χ | Х | 5 | 1.6 | Χ | Χ | Χ | Χ | Χ | Х |
| Hispanic | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Other | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 0 | _ | Х | _ | Χ | _ | Χ | _ | Χ | _ |
| Injection drug use (IDU) | Χ | _ | Χ | _ | 0 | _ | 0 | _ | 0 | _ |
| MMS and IDU | 0 | _ | Χ | _ | Χ | _ | 0 | _ | 0 | _ |
| Heterosexual sexual contact | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | Χ | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | 0 | _ | 0 | _ | 0 | _ | Х | _ | 0 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | Х | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | Χ | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Overall | X | Х | 5 | 1.4 | X | Х | X | Х | X | Х |

Concurrent diagnoses: persons who were diagnosed with HIV 12 months or less before being diagnosed as Stage 3 HIV (AIDS)

For new diagnoses and concurrent diagnoses, age group refers to the age at the time of HIV diagnosis. For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

- represents data not available.

Table 30. Persons concurrently diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of diagnosis, Southeast public health region, Tennessee, 2015–2019

| | 20 | 15 | 201 | 16 | 20 ⁻ | 17 | 20 ⁻ | 18 | 201 | 19 |
|-----------------------------------|-----|------|-----|------|-----------------|------|-----------------|------|-----|------|
| | No. | Rate | No. | Rate | No. | Rate | No. | Rate | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | Χ | Χ | 5 | 3.1 | Χ | Χ | Χ | Χ | Χ | Х |
| Cisgender female | Χ | Χ | X | X | 0 | 0.0 | 0 | 0.0 | Χ | Χ |
| Transgender person | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| 15-24 | 0 | 0.0 | 0 | 0.0 | Χ | Χ | 0 | 0.0 | 0 | 0.0 |
| 25-34 | 0 | 0.0 | X | X | Χ | Χ | 0 | 0.0 | Χ | Χ |
| 35–44 | Χ | Χ | X | Χ | Χ | Χ | X | Χ | 0 | 0.0 |
| 45-54 | Χ | Χ | Χ | Χ | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| ≥55 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | Χ | Χ | Χ | Χ |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | Х | Х | 0 | 0.0 | Х | Χ | 0 | 0.0 | 0 | 0.0 |
| Non-Hispanic white | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Χ |
| Hispanic | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Other | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | Х | _ | Χ | _ | Χ | _ | Χ | _ | Х | _ |
| Injection drug use (IDU) | 0 | _ | Χ | _ | Χ | _ | 0 | _ | 0 | _ |
| MMS and IDU | Χ | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Heterosexual sexual contact | Χ | _ | Χ | _ | 0 | _ | Χ | _ | Χ | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other . | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | Χ | _ | 0 | _ | Χ | _ | 0 | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | Χ | _ | Χ | _ | 0 | _ | 0 | _ | Χ | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Overall | X | Х | Х | Х | Х | Х | Х | Х | Х | Х |

Concurrent diagnoses: persons who were diagnosed with HIV 12 months or less before being diagnosed as Stage 3 HIV (AIDS)

For new diagnoses and concurrent diagnoses, age group refers to the age at the time of HIV diagnosis. For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

⁻ represents data not available.

Table 31. Persons concurrently diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of diagnosis, Chattanooga/Hamilton County, Tennessee, 2015–2019

| | 201 | 15 | 201 | 16 | 201 | 17 | 201 | 8 | 2019 | |
|-----------------------------------|-----|------|-----|------|-----|------|-----|------|------|-------------|
| | No. | Rate | No. | Rate | No. | Rate | No. | Rate | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | Χ | Χ | 11 | 6.4 | 7 | 4.0 | 7 | 4.0 | 10 | 5.6 |
| Cisgender female | 0 | 0.0 | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Х |
| Transgender person | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| 15-24 | Χ | Χ | Χ | Χ | Χ | Χ | 0 | 0.0 | Χ | Х |
| 25-34 | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Χ | 6 | 11.1 |
| 35-44 | Χ | Χ | Χ | Χ | Χ | Χ | 0 | 0.0 | Χ | Х |
| 45-54 | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Х |
| ≥55 | 0 | 0.0 | Χ | Χ | Χ | Χ | 5 | 4.4 | Χ | Х |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 5 | 7.3 | 5 | 7.2 | Χ | Х | 5 | 7.2 | 6 | 8.6 |
| Non-Hispanic white | Χ | Χ | 6 | 2.4 | 7 | 2.7 | Χ | Χ | Χ | Х |
| Hispanic | Χ | Χ | Χ | Χ | 0 | 0.0 | Χ | Χ | Χ | Х |
| Other | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | Х | _ | 9 | _ | Χ | _ | Х | _ | 7 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| MMS and IDU | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Heterosexual sexual contact | 0 | _ | Χ | _ | Χ | _ | Χ | _ | Χ | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 5 | _ | Χ | _ | Χ | _ | Χ | _ | Х | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | 0 | _ | Χ | _ | 0 | _ | Χ | _ | 0 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | Х | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | Χ | _ | 0 | _ | 0 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Overall | X | Х | X | Х | X | Х | X | Х | X | Х |

Concurrent diagnoses: persons who were diagnosed with HIV 12 months or less before being diagnosed as Stage 3 HIV (AIDS)

For new diagnoses and concurrent diagnoses, age group refers to the age at the time of HIV diagnosis. For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

- represents data not available.

Table 32. Persons concurrently diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of diagnosis, East public health region, Tennessee, 2015–2019

| | 201 | 15 | 201 | 6 | 201 | 7 | 201 | 8 | 2019 | • |
|-----------------------------------|-----|------|-----|------|-----|------|-----|------|------|------|
| | No. | Rate | No. | Rate | No. | Rate | No. | Rate | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 7 | 1.9 | 9 | 2.4 | 6 | 1.6 | 8 | 2.1 | 6 | 1.6 |
| Cisgender female | 2 | 0.5 | 1 | 0.3 | 1 | 0.3 | 2 | 0.5 | 0 | 0.0 |
| Transgender person | 0 | _ | 0 | _ | 0 | _ | 1 | _ | 0 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| 15-24 | 0 | 0.0 | 1 | 1.1 | 0 | 0.0 | 2 | 2.3 | 0 | 0.0 |
| 25–34 | 0 | 0.0 | 2 | 2.3 | 1 | 1.1 | 2 | 2.2 | 2 | 2.2 |
| 35–44 | 4 | 4.4 | 0 | 0.0 | 1 | 1.1 | 3 | 3.4 | 0 | 0.0 |
| 45-54 | 1 | 0.9 | 4 | 3.7 | 4 | 3.7 | 3 | 2.8 | 3 | 2.9 |
| ≥55 | 4 | 1.6 | 3 | 1.2 | 1 | 0.4 | 1 | 0.4 | 1 | 0.4 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 6.0 | 0 | 0.0 |
| Non-Hispanic white | 8 | 1.2 | 9 | 1.3 | 6 | 0.9 | 7 | 1.0 | 6 | 0.9 |
| Hispanic | 1 | 3.3 | 1 | 3.2 | 1 | 3.0 | 2 | 5.9 | 0 | 0.0 |
| Other | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 4.9 | 0 | 0.0 |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 3 | _ | 5 | _ | 3 | _ | 3 | _ | 3 | _ |
| Injection drug use (IDU) | 1 | _ | 1 | _ | 1 | _ | 1 | _ | 0 | _ |
| MMS and IDU | 0 | _ | 1 | _ | 0 | _ | 0 | _ | 0 | _ |
| Heterosexual sexual contact | 3 | _ | 2 | _ | 1 | _ | 3 | _ | 2 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 1 | _ | 1 | _ | 1 | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | 1 | _ | 1 | _ | 1 | _ | 1 | _ | 0 | _ |
| Injection drug use (IDU) | 1 | _ | 0 | _ | 0 | _ | 1 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 0 | _ | 0 | _ | 0 | _ | 1 | _ | 0 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Overall | 9 | 1.2 | 10 | 1.3 | 7 | 0.9 | 11 | 1.4 | 6 | 0.8 |

Concurrent diagnoses: persons who were diagnosed with HIV 12 months or less before being diagnosed as Stage 3 HIV (AIDS)

For new diagnoses and concurrent diagnoses, age group refers to the age at the time of HIV diagnosis. For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

- represents data not available.

Table 33. Persons concurrently diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of diagnosis, Knoxville/Knox County, Tennessee, 2015–2019

| | 20 ⁻ | 15 | 201 | 6 | 201 | 7 | 201 | 8 | 2019 | |
|-----------------------------------|-----------------|------|-----|------|-----|------|-----|------|------|-------------|
| | No. | Rate | No. | Rate | No. | Rate | No. | Rate | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | Χ | Χ | Χ | Χ | 6 | 2.7 | 11 | 4.9 | 11 | 4.8 |
| Cisgender female | Χ | Χ | Χ | Χ | 5 | 2.1 | Χ | Χ | Χ | Χ |
| Transgender person | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| 15–24 | X | Χ | Χ | Χ | Χ | Χ | 0 | 0.0 | Χ | X |
| 25–34 | X | Χ | Χ | Χ | Χ | Χ | 7 | 11.0 | 6 | 9.3 |
| 35-44 | X | Χ | Χ | Χ | Χ | Χ | Χ | Χ | 0 | 0.0 |
| 45-54 | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Χ | X |
| ≥55 | 0 | 0.0 | Χ | Χ | Χ | Χ | Χ | Χ | Χ | X |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | Х | Х | Χ | Χ | Х | Х | 5 | 12.3 | Х | Х |
| Non-Hispanic white | 7 | 1.9 | 6 | 1.6 | 7 | 1.8 | 7 | 1.8 | 9 | 2.3 |
| Hispanic . | 0 | 0.0 | Χ | Χ | Χ | Χ | Χ | Χ | 0 | 0.0 |
| Other | 0 | 0.0 | 0 | 0.0 | Χ | Χ | 0 | 0.0 | Χ | Х |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 7 | _ | 6 | _ | 6 | _ | 8 | _ | 7 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | Χ | _ | Χ | _ |
| MMS and IDU | Χ | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Heterosexual sexual contact | 0 | _ | Χ | _ | 0 | _ | Χ | _ | Χ | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | Х | _ | Χ | _ | Х | _ | Χ | _ | 0 | _ |
| Injection drug use (IDU) | 0 | _ | Χ | _ | Χ | _ | 0 | _ | Χ | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Overall | X | Х | 9 | 2.0 | 11 | 2.4 | X | Х | Х | Х |

Concurrent diagnoses: persons who were diagnosed with HIV 12 months or less before being diagnosed as Stage 3 HIV (AIDS)

For new diagnoses and concurrent diagnoses, age group refers to the age at the time of HIV diagnosis. For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

⁻ represents data not available.

Table 34. Persons concurrently diagnosed with HIV Stages 0-2 and Stage 3 (AIDS) within 12 months of diagnosis, Northeast public health region, Tennessee, 2015-2019

| | 201 | 15 | 201 | 16 | 201 | 17 | 201 | 8 | 201 | 9 |
|-----------------------------------|-----|------|-----|------|-----|------|-----|------|-----|------|
| | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 5 | 2.9 | Χ | Χ | Χ | Х | Χ | Χ | Χ | Χ |
| Cisgender female | Χ | Χ | 0 | 0.0 | Χ | Χ | Χ | Χ | Χ | Χ |
| Transgender person | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| 15–24 | 0 | 0.0 | Χ | Χ | 0 | 0.0 | Χ | Χ | 0 | 0.0 |
| 25–34 | Χ | Χ | 0 | 0.0 | Χ | Χ | Χ | Χ | 0 | 0.0 |
| 35-44 | Χ | X | Χ | Χ | 0 | 0.0 | 0 | 0.0 | Χ | Χ |
| 45-54 | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Χ |
| ≥55 | 0 | 0.0 | 0 | 0.0 | Х | Χ | Χ | Χ | 0 | 0.0 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | Χ | Х | Χ | Χ | Х | Х | 0 | 0.0 | 0 | 0.0 |
| Non-Hispanic white | 5 | 1.5 | Χ | Χ | Χ | Х | X | X | X | X |
| Hispanic | 0 | 0.0 | 0 | 0.0 | Х | Х | Χ | Х | Χ | Х |
| Other | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Transmission risk | - | | | | - | | - | | - | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | Χ | _ | Х | _ | Х | _ | Х | _ | Х | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | X | _ | 0 | _ |
| MMS and IDU | X | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Heterosexual sexual contact | 0 | _ | X | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | X | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Cisgender female | , | | | | J | | | | · · | |
| Heterosexual sexual contact | Х | _ | 0 | _ | 0 | _ | 0 | _ | Х | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | | 0 | _ | 0 | _ |
| Other | 0 | | 0 | | 0 | | 0 | | 0 | |
| Unknown | X | | 0 | | X | _ | X | | 0 | |
| Transgender person | ^ | _ | U | _ | ^ | _ | ^ | _ | U | _ |
| Any sexual contact | 0 | _ | 0 | | 0 | _ | 0 | _ | 0 | |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure Other | 0 | _ | | _ | | _ | | _ | | _ |
| | - | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | | 0 | | 0 | | 0 | | 0 | |
| Overall | Х | X | Х | Х | 6 | 1.7 | 5 | 1.4 | Х | Х |

Concurrent diagnoses: persons who were diagnosed with HIV 12 months or less before being diagnosed as Stage 3 HIV (AIDS)

For new diagnoses and concurrent diagnoses, age group refers to the age at the time of HIV diagnosis. For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

- represents data not available.

Table 35. Persons concurrently diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of diagnosis, Blountville/Sullivan County public health region, Tennessee, 2015–2019

| | 20 ⁻ | 15 | 201 | 16 | 201 | 17 | 201 | 8 | 2019 | |
|-----------------------------------|-----------------|------|-----|------|-----|------|-----|------|------|-------------|
| | No. | Rate | No. | Rate | No. | Rate | No. | Rate | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | Х | Х | Χ | Χ | Χ | Х | Χ | Χ | Χ | Х |
| Cisgender female | 0 | 0.0 | 0 | 0.0 | Χ | Χ | 0 | 0.0 | Χ | Х |
| Transgender person | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| 15-24 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| 25-34 | Χ | Χ | 0 | 0.0 | 0 | 0.0 | Χ | Χ | 0 | 0.0 |
| 35-44 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| 45-54 | 0 | 0.0 | Χ | Χ | Χ | Χ | 0 | 0.0 | Χ | Х |
| ≥55 | 0 | 0.0 | 0 | 0.0 | Χ | Χ | Χ | Χ | Χ | Х |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 0 | 0.0 | 0 | 0.0 | Х | Х | 0 | 0.0 | 0 | 0.0 |
| Non-Hispanic white | 0 | 0.0 | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Х |
| Hispanic | Х | Х | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Other | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | Х | _ | Х | _ | 0 | _ | Х | _ | 0 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | Χ | _ | 0 | _ | 0 | _ |
| MMS and IDU | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Heterosexual sexual contact | 0 | _ | 0 | _ | 0 | _ | Χ | _ | Χ | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | 0 | _ | 0 | _ | Χ | _ | 0 | _ | Х | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Overall | X | Х | X | Х | X | Х | X | Х | Х | Х |

Concurrent diagnoses: persons who were diagnosed with HIV 12 months or less before being diagnosed as Stage 3 HIV (AIDS)

For new diagnoses and concurrent diagnoses, age group refers to the age at the time of HIV diagnosis. For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

⁻ represents data not available.

Table 36. Persons living with diagnosed HIV, Memphis/Shelby County, Tennessee, 2015-2019

| | 201 | 15 | 201 | 6 | 2017 | 1 | 2018 | - | 2019 | |
|-----------------------------------|------|--------|------|--------|------|--------|------|--------|------|--------|
| | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 4323 | 969.2 | 4405 | 989.6 | 4406 | 992.1 | 4604 | 1035.9 | 4506 | 1013.4 |
| Cisgender female | 1982 | 403.6 | 2006 | 408.6 | 1974 | 401.9 | 2008 | 408.2 | 1943 | 394.5 |
| Transgender person | 70 | _ | 82 | _ | 79 | _ | 98 | _ | 94 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 36 | 18.2 | 37 | 18.8 | 29 | 14.8 | 32 | 16.3 | 29 | 14.8 |
| 15–24 | 360 | 270.9 | 330 | 253.8 | 330 | 260.5 | 323 | 260.0 | 310 | 254.4 |
| 25–34 | 1331 | 989.8 | 1364 | 1004.1 | 1318 | 959.6 | 1384 | 993.6 | 1297 | 918.7 |
| 35-44 | 1595 | 1343.3 | 1556 | 1330.4 | 1528 | 1311.2 | 1569 | 1344.7 | 1505 | 1288.6 |
| 45–54 | 1793 | 1465.1 | 1788 | 1478.9 | 1757 | 1478.6 | 1748 | 1500.9 | 1679 | 1472.6 |
| ≥55 | 1260 | 546.3 | 1418 | 602.1 | 1497 | 624.8 | 1654 | 678.7 | 1723 | 695.9 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 5291 | 1059.7 | 5430 | 1084.9 | 5410 | 1080.1 | 5621 | 1119.3 | 5483 | 1089.6 |
| Non-Hispanic white | 706 | 206.0 | 688 | 203.0 | 672 | 200.1 | 696 | 208.9 | 662 | 200.3 |
| Hispanic | 161 | 281.8 | 165 | 283.5 | 167 | 281.0 | 177 | 290.3 | 194 | 312.3 |
| Other | 217 | 573.1 | 210 | 546.6 | 210 | 538.0 | 216 | 539.6 | 204 | 494.0 |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 2707 | _ | 2750 | _ | 2769 | _ | 2872 | _ | 2816 | _ |
| Injection drug use (IDU) | 108 | _ | 106 | _ | 98 | _ | 101 | _ | 102 | _ |
| MMS and IDU | 99 | _ | 96 | _ | 92 | _ | 96 | _ | 84 | _ |
| Heterosexual sexual contact | 733 | _ | 772 | _ | 773 | _ | 804 | _ | 754 | _ |
| Perinatal exposure | 29 | _ | 29 | _ | 28 | _ | 29 | _ | 31 | _ |
| Other | 13 | _ | 12 | _ | 12 | _ | 11 | _ | 10 | _ |
| Unknown | 634 | _ | 640 | _ | 634 | _ | 691 | _ | 709 | |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | 1527 | _ | 1550 | _ | 1527 | _ | 1529 | _ | 1449 | _ |
| Injection drug use (IDU) | 70 | _ | 71 | _ | 71 | _ | 73 | _ | 70 | _ |
| Perinatal exposure | 48 | _ | 48 | _ | 49 | _ | 52 | _ | 51 | |
| Other | 2 | _ | 2 | _ | 2 | _ | 2 | _ | 2 | |
| Unknown | 335 | _ | 335 | _ | 325 | _ | 352 | _ | 371 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 59 | _ | 70 | _ | 66 | _ | 84 | _ | 79 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 1 | _ | 1 | _ | 1 | _ | 1 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 10 | | 11 | | 12 | | 13 | | 15 | |
| Overall | 6375 | 680.3 | 6493 | 693.7 | 6459 | 690.6 | 6710 | 716.6 | 6543 | 698.2 |

 $Living\ with\ diagnosed\ HIV:\ persons\ diagnosed\ with\ HIV\ on\ or\ before\ December\ 31\ and\ resided\ in\ Tennessee\ on\ December\ 31\ , 2019$

For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

[—] represents data not available.

Table 37. Persons living with diagnosed HIV, West public health region, Tennessee, 2015–2019

| | 201 | 15 | 201 | 6 | 201 | 7 | 201 | В | 2019 |) |
|-----------------------------------|-----|-------|-----|-------|-----|-------|-----|-------|------|-------|
| | No. | Rate | No. | Rate | No. | Rate | No. | Rate | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 500 | 191.2 | 502 | 193.5 | 502 | 192.9 | 501 | 192.4 | 543 | 209.3 |
| Cisgender female | 195 | 72.6 | 183 | 68.4 | 194 | 72.6 | 194 | 72.6 | 208 | 77.9 |
| Transgender person | 8 | _ | 10 | _ | 12 | _ | 8 | _ | 8 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 3 | 3.1 | 1 | 1.0 | 1 | 1.1 | 1 | 1.1 | 1 | 1.1 |
| 15–24 | 27 | 39.5 | 26 | 38.7 | 25 | 37.6 | 22 | 33.3 | 27 | 41.6 |
| 25–34 | 123 | 200.6 | 119 | 193.7 | 124 | 198.9 | 119 | 189.9 | 136 | 216.0 |
| 35-44 | 153 | 239.0 | 141 | 226.4 | 141 | 227.6 | 145 | 234.1 | 151 | 244.9 |
| 45–54 | 235 | 322.5 | 228 | 318.1 | 229 | 324.4 | 207 | 299.4 | 186 | 276.4 |
| ≥55 | 162 | 97.2 | 180 | 106.6 | 188 | 109.9 | 209 | 120.4 | 258 | 146.5 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 401 | 457.9 | 394 | 456.8 | 389 | 448.6 | 386 | 445.1 | 420 | 487.4 |
| Non-Hispanic white | 250 | 60.2 | 253 | 61.2 | 268 | 65.0 | 267 | 64.9 | 283 | 69.0 |
| Hispanic | 28 | 187.8 | 26 | 170.7 | 26 | 162.7 | 25 | 152.9 | 29 | 172.1 |
| Other | 24 | 198.9 | 22 | 179.1 | 25 | 198.4 | 25 | 193.2 | 27 | 203.2 |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 287 | _ | 291 | _ | 293 | _ | 290 | _ | 335 | _ |
| Injection drug use (IDU) | 39 | _ | 38 | _ | 39 | _ | 40 | _ | 35 | _ |
| MMS and IDU | 29 | _ | 35 | _ | 34 | _ | 35 | _ | 34 | _ |
| Heterosexual sexual contact | 97 | _ | 97 | _ | 101 | _ | 98 | _ | 99 | _ |
| Perinatal exposure | 5 | _ | 3 | _ | 3 | _ | 3 | _ | 3 | _ |
| Other | 4 | _ | 4 | _ | 4 | _ | 4 | _ | 4 | _ |
| Unknown | 39 | _ | 34 | _ | 28 | _ | 31 | _ | 33 | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | 151 | _ | 141 | _ | 149 | _ | 148 | _ | 159 | _ |
| Injection drug use (IDU) | 23 | _ | 22 | _ | 19 | _ | 19 | _ | 19 | _ |
| Perinatal exposure | 1 | _ | 0 | _ | 1 | _ | 2 | _ | 4 | _ |
| Other | 1 | _ | 1 | _ | 2 | _ | 2 | _ | 2 | _ |
| Unknown | 19 | _ | 19 | _ | 23 | _ | 23 | _ | 24 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 5 | _ | 7 | _ | 10 | _ | 6 | _ | 7 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 1 | _ | 1 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 2 | _ | 2 | _ | 2 | _ | 2 | _ | 1 | _ |
| Overall | 703 | 132.6 | 695 | 131.9 | 708 | 134.2 | 703 | 133.2 | 759 | 144.2 |

 $Living\ with\ diagnosed\ HIV:\ persons\ diagnosed\ with\ HIV\ on\ or\ before\ December\ 31\ and\ resided\ in\ Tennessee\ on\ December\ 31\ ,2019$

For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

[—] represents data not available.

Table 38. Persons living with diagnosed HIV, Jackson/Madison County, Tennessee, 2015–2019

| | 201 | 15 | 201 | 5 | 2017 | | 2018 | | 2019 | |
|-----------------------------------|-----|-------|-----|-------|------|-------|------|-------|------|-------|
| | No. | Rate | No. | Rate | No. | Rate | No. | Rate | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 212 | 459.6 | 215 | 465.7 | 216 | 468.2 | 230 | 497.1 | 186 | 400.7 |
| Cisgender female | 92 | 178.9 | 97 | 189.1 | Χ | Χ | Χ | Χ | Χ | > |
| Transgender person | X | _ | Χ | _ | Χ | _ | Χ | _ | Χ | _ |
| Age group (years) | | | | | | | | | | |
| <15 | Х | Χ | Х | Χ | Х | Χ | Χ | Χ | Χ | > |
| 15–24 | 20 | 137.6 | 24 | 167.8 | 15 | 106.0 | 20 | 143.7 | 9 | 65.1 |
| 25-34 | 63 | 522.2 | 62 | 513.1 | 65 | 535.2 | 65 | 524.5 | 56 | 446.9 |
| 35-44 | 64 | 562.1 | 65 | 581.4 | 71 | 639.2 | 75 | 676.6 | 62 | 557. |
| 45-54 | 91 | 707.6 | 90 | 710.4 | 80 | 638.6 | 79 | 648.7 | 59 | 498. |
| ≥55 | 62 | 219.3 | 69 | 238.4 | 72 | 246.0 | 82 | 274.9 | 77 | 252. |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 192 | 530.3 | 200 | 551.0 | 203 | 556.0 | 208 | 38.4 | 179 | 488. |
| Non-Hispanic white | 85 | 153.6 | 84 | 153.1 | 76 | 139.5 | 88 | 4.7 | 63 | 115. |
| Hispanic | 18 | 511.1 | 19 | 518.0 | 17 | 451.8 | 17 | 14.5 | 14 | 350. |
| Other | Χ | Χ | Χ | Х | Х | X | Χ | Χ | Χ | |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 139 | _ | 141 | _ | 151 | _ | 162 | _ | 127 | _ |
| Injection drug use (IDU) | 13 | _ | 13 | _ | 10 | _ | 9 | _ | 8 | _ |
| MMS and IDU | 11 | _ | 11 | _ | 7 | _ | 10 | _ | Χ | _ |
| Heterosexual sexual contact | 34 | _ | 35 | _ | 30 | _ | 33 | _ | 29 | _ |
| Perinatal exposure | X | _ | Χ | _ | Х | _ | Χ | _ | Χ | _ |
| Other | Χ | _ | Χ | _ | Х | _ | Χ | _ | Χ | _ |
| Unknown | 11 | _ | 10 | _ | 14 | _ | 12 | _ | 14 | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | 59 | _ | 64 | _ | 58 | _ | 61 | _ | 52 | _ |
| Injection drug use (IDU) | 14 | _ | 14 | _ | 13 | _ | 13 | _ | 13 | _ |
| Perinatal exposure | Χ | _ | Х | _ | X | _ | X | _ | Χ | _ |
| Other | X | _ | Χ | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 15 | _ | 15 | _ | 15 | _ | 14 | _ | 10 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | Х | _ | Χ | _ | Χ | _ | Х | _ | Х | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | | 0 | _ | 0 | _ |
| Overall | X | Х | X | Х | X | Х | X | Х | X |) |

 $Living with \ diagnosed \ HIV: persons \ diagnosed \ with \ HIV \ on \ or \ before \ December \ 31 \ and \ resided \ in \ Tennessee \ on \ December \ 31, 2019$

For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

[—] represents data not available.

Table 39. Persons living with diagnosed HIV, South Central public health region, Tennessee, 2015–2019

| | 201 | 15 | 201 | 16 | 201 | 7 | 201 | 8 | 2019 | 9 |
|-----------------------------------|-----|-------|-----|-------|----------|-------|----------|-------|------|-------|
| | No. | Rate | No. | Rate | No. | Rate | No. | Rate | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | Χ | Х | Χ | Χ | 276 | 138.7 | 277 | 137.3 | 408 | 199.9 |
| Cisgender female | 90 | 45.2 | 94 | 46.7 | Χ | Χ | Χ | Χ | 122 | 58.2 |
| Transgender person | Χ | _ | Χ | _ | Χ | _ | Χ | _ | X | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 0 | 0.0 | 0 | 0.0 | Χ | Χ | Χ | Χ | Χ | Χ |
| 15–24 | 8 | 16.9 | 11 | 23.3 | 11 | 23.2 | 9 | 18.9 | 14 | 29.2 |
| 25–34 | 44 | 91.9 | 43 | 86.7 | 51 | 99.8 | 52 | 99.2 | 81 | 151.4 |
| 35-44 | 66 | 136.5 | 70 | 144.9 | 73 | 149.0 | 67 | 134.6 | 104 | 206.8 |
| 45-54 | 105 | 194.3 | 118 | 218.5 | 117 | 216.7 | 112 | 207.7 | 165 | 309.0 |
| ≥55 | 101 | 84.8 | 112 | 92.1 | 118 | 94.9 | 129 | 101.7 | 167 | 128.7 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 75 | 283.5 | 84 | 313.5 | 102 | 371.2 | 101 | 360.9 | 155 | 545.2 |
| Non-Hispanic white | 223 | 66.1 | 238 | 70.0 | 239 | 69.5 | 236 | 67.9 | 327 | 93.3 |
| Hispanic | 21 | 116.7 | 26 | 138.5 | 24 | 120.6 | 24 | 113.7 | 39 | 176.9 |
| Other | 5 | 47.4 | 6 | 54.3 | X | X | X | X | X | X |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 143 | _ | 155 | _ | 161 | _ | 166 | _ | 265 | _ |
| Injection drug use (IDU) | 18 | _ | 19 | _ | 22 | _ | 18 | _ | 28 | _ |
| MMS and IDU | 16 | _ | 17 | _ | 22 | _ | 20 | _ | 27 | _ |
| Heterosexual sexual contact | 35 | _ | 44 | _ | 43 | _ | 43 | _ | 55 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | X | _ | X | _ | X | _ |
| Other | X | _ | X | _ | X | _ | X | _ | X | _ |
| Unknown | 19 | _ | 22 | _ | 22 | _ | 24 | _ | 28 | _ |
| Cisgender female | 1,5 | | | | | | | | 20 | |
| Heterosexual sexual contact | 63 | _ | 67 | _ | 67 | _ | 67 | _ | 86 | _ |
| Injection drug use (IDU) | 13 | _ | 15 | _ | 18 | _ | 13 | _ | 17 | _ |
| Perinatal exposure | X | _ | X | _ | 0 | _ | 0 | _ | X | _ |
| Other | X | _ | X | _ | X | _ | X | _ | X | _ |
| Unknown | 11 | _ | 9 | _ | 7 | _ | 9 | _ | 15 | _ |
| Transgender person | | | , | | , | | , | | 13 | |
| Any sexual contact | Х | _ | Х | _ | Х | _ | Х | _ | Х | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| | | | 354 | | X | | X | | X | |
| Overall | 324 | 82.6 | | 89.2 | | Х | X | Х | Х. | Х |

Living with diagnosed HIV: persons diagnosed with HIV on or before December 31 and resided in Tennessee on December 31, 2019

For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

— represents data not available.

Table 40. Persons living with diagnosed HIV, Mid-Cumberland public health region, Tennessee, 2015–2019

| | 20 | 15 | 2016 | | 2017 | | 2018 | | 2019 | |
|-----------------------------------|------|-------|------|-------|------|-------|------|-------|------|-------|
| | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 1114 | 186.2 | 1116 | 181.9 | 1154 | 183.0 | 1244 | 192.9 | 1439 | 218.8 |
| Cisgender female | 295 | 48.0 | 317 | 50.3 | 336 | 52.0 | 349 | 52.7 | 426 | 63.0 |
| Transgender person | 11 | _ | 12 | _ | 13 | _ | 16 | _ | 16 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 13 | 5.1 | 10 | 3.9 | 10 | 3.8 | 13 | 4.8 | 17 | 6.2 |
| 15–24 | 78 | 45.9 | 63 | 36.5 | 60 | 34.2 | 69 | 38.8 | 70 | 38.9 |
| 25–34 | 242 | 150.7 | 257 | 153.9 | 293 | 168.9 | 329 | 185.2 | 358 | 197.3 |
| 35-44 | 304 | 182.6 | 309 | 182.9 | 290 | 167.2 | 313 | 175.7 | 360 | 197.1 |
| 45-54 | 483 | 284.3 | 466 | 269.1 | 466 | 265.4 | 455 | 257.2 | 506 | 285.6 |
| ≥55 | 300 | 102.9 | 340 | 112.1 | 384 | 121.7 | 430 | 131.2 | 570 | 167.4 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 489 | 419.6 | 523 | 429.4 | 555 | 430.2 | 626 | 461.4 | 719 | 506.8 |
| Non-Hispanic white | 796 | 82.2 | 793 | 80.4 | 801 | 79.8 | 829 | 81.3 | 978 | 94.8 |
| Hispanic | 91 | 127.1 | 84 | 111.6 | 102 | 127.6 | 100 | 118.0 | 112 | 125.7 |
| Other | 44 | 77.2 | 45 | 75.2 | 45 | 70.5 | 54 | 80.2 | 72 | 101.3 |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 768 | _ | 777 | _ | 809 | _ | 869 | _ | 1017 | _ |
| Injection drug use (IDU) | 61 | _ | 64 | _ | 65 | _ | 66 | _ | 61 | _ |
| MMS and IDU | 70 | _ | 64 | _ | 62 | _ | 70 | _ | 71 | _ |
| Heterosexual sexual contact | 118 | _ | 121 | _ | 131 | _ | 133 | _ | 158 | _ |
| Perinatal exposure | 3 | _ | 3 | _ | 1 | _ | 1 | _ | 4 | _ |
| Other | 4 | _ | 4 | _ | 4 | _ | 4 | _ | 8 | _ |
| Unknown | 90 | _ | 83 | _ | 82 | _ | 101 | _ | 120 | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | 210 | _ | 223 | _ | 231 | _ | 245 | _ | 301 | _ |
| Injection drug use (IDU) | 32 | _ | 39 | _ | 41 | _ | 36 | _ | 43 | _ |
| Perinatal exposure | 10 | _ | 10 | _ | 11 | _ | 13 | _ | 14 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 1 | _ |
| Unknown | 43 | _ | 45 | _ | 53 | _ | 55 | _ | 67 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 8 | _ | 9 | _ | 10 | _ | 13 | _ | 12 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 0 | _ | 0 | _ | 1 | _ | 1 | _ | 2 | _ |
| Perinatal exposure | 1 | _ | 1 | _ | 1 | _ | 1 | _ | 1 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 2 | _ | 2 | _ | 1 | _ | 1 | _ | 1 | _ |
| Overall | 1420 | 117.0 | 1445 | 116.2 | 1503 | 117.7 | 1609 | 123.1 | 1881 | 141.0 |

Living with diagnosed HIV: persons diagnosed with HIV on or before December 31 and resided in Tennessee on December 31, 2019

For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

⁻ represents data not available.

Table 41. Persons living with diagnosed HIV, Nashville/Davidson County, Tennessee, 2015-2019

| | 201 | 15 | 201 | 6 | 2017 | 7 | 2018 | | 2019 | |
|-----------------------------------|------|--------|------|--------|------|--------|------|--------|------|--------|
| | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 3232 | 986.3 | 3213 | 972.3 | 3176 | 958.8 | 3196 | 960.3 | 2994 | 895.5 |
| Cisgender female | 898 | 255.0 | 886 | 249.3 | 879 | 247.0 | 864 | 241.5 | 751 | 208.7 |
| Transgender person | 44 | _ | 40 | _ | 45 | _ | 57 | _ | 49 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 20 | 15.9 | 18 | 14.3 | 18 | 14.5 | 19 | 15.4 | 7 | 5.7 |
| 15–24 | 153 | 170.7 | 144 | 160.9 | 125 | 141.5 | 129 | 146.5 | 108 | 122.4 |
| 25-34 | 693 | 524.6 | 683 | 504.7 | 713 | 518.2 | 709 | 505.5 | 713 | 499.4 |
| 35-44 | 874 | 939.8 | 821 | 883.2 | 795 | 850.9 | 768 | 810.7 | 715 | 743.1 |
| 45-54 | 1430 | 1712.0 | 1380 | 1657.7 | 1280 | 1556.9 | 1202 | 1496.6 | 1010 | 1286.9 |
| ≥55 | 1004 | 644.1 | 1093 | 686.8 | 1169 | 724.6 | 1290 | 787.7 | 1241 | 747.4 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 2165 | 1159.0 | 2163 | 1149.1 | 2165 | 1152.1 | 2151 | 1149.6 | 2045 | 1097.2 |
| Non-Hispanic white | 1613 | 419.2 | 1585 | 409.6 | 1557 | 402.5 | 1556 | 400.7 | 1347 | 344.5 |
| Hispanic | 274 | 401.6 | 271 | 391.1 | 252 | 358.2 | 273 | 381.7 | 275 | 380.8 |
| Other | 122 | 305.0 | 120 | 290.2 | 126 | 299.7 | 137 | 314.6 | 127 | 285.2 |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 2262 | _ | 2264 | _ | 2244 | _ | 2282 | _ | 2158 | _ |
| Injection drug use (IDU) | 220 | _ | 216 | _ | 206 | _ | 197 | _ | 180 | _ |
| MMS and IDU | 163 | _ | 154 | _ | 139 | _ | 134 | _ | 122 | _ |
| Heterosexual sexual contact | 248 | _ | 249 | _ | 248 | _ | 246 | _ | 228 | _ |
| Perinatal exposure | 15 | _ | 15 | _ | 15 | _ | 17 | _ | 14 | _ |
| Other | 12 | _ | 13 | _ | 13 | _ | 11 | _ | 5 | _ |
| Unknown | 312 | _ | 302 | _ | 311 | _ | 309 | _ | 287 | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | 603 | _ | 612 | _ | 603 | _ | 593 | _ | 520 | _ |
| Injection drug use (IDU) | 160 | _ | 145 | _ | 145 | _ | 139 | _ | 118 | _ |
| Perinatal exposure | 14 | _ | 13 | _ | 14 | _ | 13 | _ | 10 | _ |
| Other | 5 | _ | 5 | _ | 4 | _ | 5 | _ | 4 | _ |
| Unknown | 116 | _ | 111 | _ | 113 | _ | 114 | _ | 99 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 36 | _ | 33 | _ | 38 | _ | 48 | _ | 43 | _ |
| Injection drug use (IDU) | 1 | _ | 1 | _ | 1 | _ | 1 | _ | 1 | _ |
| Any sexual contact and IDU | 4 | _ | 3 | _ | 3 | _ | 4 | _ | 2 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 3 | | 3 | | 3 | | 4 | | 3 | |
| Overall | 4174 | 614.0 | 4139 | 603.5 | 4100 | 596.7 | 4117 | 596.2 | 3794 | 546.6 |

Living with diagnosed HIV: persons diagnosed with HIV on or before December 31 and resided in Tennessee on December 31, 2019

For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

[—] represents data not available.

Table 42. Persons living with diagnosed HIV, Upper Cumberland public health region, Tennessee, 2015–2019

| | 20 | 15 | 20 ⁻ | 16 | 20 ⁻ | 17 | 20 ⁻ | 18 | 201 | 19 |
|-----------------------------------|-----|--------|-----------------|-------|-----------------|--------|-----------------|--------|-----|-------|
| | No. | Rate | No. | Rate | No. | Rate | No. | Rate | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Χ |
| Cisgender female | 72 | 41.1 | 80 | 45.4 | 81 | 45.5 | 84 | 46.7 | 70 | 38.4 |
| Transgender person | Χ | _ | Χ | _ | Χ | _ | Χ | _ | Χ | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | Χ | Χ | Χ | X |
| 15–24 | 15 | 33.7 | 18 | 41.0 | 15 | 34.3 | 14 | 31.8 | 7 | 15.8 |
| 25-34 | 50 | 128.8 | 51 | 127.7 | 50 | 121.8 | 63 | 150.8 | 40 | 93.4 |
| 35-44 | 85 | 213.8 | 95 | 240.9 | 83 | 210.3 | 86 | 217.2 | 66 | 165.1 |
| 45-54 | 138 | 298.8 | 131 | 283.5 | 132 | 286.6 | 131 | 284.6 | 111 | 245.0 |
| ≥55 | 99 | 85.8 | 107 | 91.1 | 124 | 103.2 | 142 | 115.6 | 128 | 101.5 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 50 | 1028.4 | 47 | 925.6 | 55 | 1039.7 | 70 | 1278.1 | 37 | 657.2 |
| Non-Hispanic white | 297 | 93.3 | 314 | 98.3 | 307 | 95.2 | 318 | 97.8 | 274 | 83.3 |
| Hispanic | 35 | 238.8 | 36 | 235.7 | 34 | 211.8 | 36 | 216.6 | 33 | 192.4 |
| Other | 5 | 66.1 | 5 | 63.7 | 8 | 98.1 | Χ | Χ | Χ | Χ |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 190 | _ | 199 | _ | 203 | _ | 218 | _ | 179 | _ |
| Injection drug use (IDU) | 36 | _ | 30 | _ | 33 | _ | 34 | _ | 29 | _ |
| MMS and IDU | 27 | _ | 31 | _ | 29 | _ | 31 | _ | 25 | _ |
| Heterosexual sexual contact | 38 | _ | 36 | _ | 30 | _ | 38 | _ | 29 | _ |
| Perinatal exposure | Х | _ | Χ | _ | Χ | _ | Χ | _ | Χ | _ |
| Other . | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 22 | _ | 23 | _ | 24 | _ | 27 | _ | 20 | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | 49 | _ | 51 | _ | 57 | _ | 57 | _ | 41 | _ |
| Injection drug use (IDU) | 12 | _ | 17 | _ | 13 | _ | 13 | _ | 15 | _ |
| Perinatal exposure | Х | _ | Х | _ | Χ | _ | Χ | _ | Χ | _ |
| Other | Х | _ | Χ | _ | Χ | _ | Χ | _ | Χ | _ |
| Unknown | 8 | _ | 9 | _ | 8 | _ | 9 | _ | 9 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | Х | _ | Х | _ | Х | _ | Х | _ | Х | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 0 | _ | X | _ | X | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | X | _ | 0 | _ |
| Overall | 387 | 112.1 | 402 | 115.6 | 404 | 114.8 | X | Х | X | Х |

Living with diagnosed HIV: persons diagnosed with HIV on or before December 31 and resided in Tennessee on December 31, 2019

For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

- represents data not available.

Table 43. Persons living with diagnosed HIV, Southeast public health region, Tennessee, 2015–2019

| | 201 | 15 | 201 | 6 | 201 | 7 | 2018 | 3 | 2019 | , |
|-----------------------------------|-----|-------|-----|-------|-----|-------|------|-------|------|-------|
| | No. | Rate | No. | Rate | No. | Rate | No. | Rate | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | Χ | Χ | 206 | 126.0 | 208 | 126.4 | 216 | 130.0 | 266 | 158.6 |
| Cisgender female | 59 | 35.4 | Χ | Χ | Χ | Χ | Χ | Χ | 75 | 43.8 |
| Transgender person | 0 | _ | Χ | _ | Χ | _ | Χ | _ | X | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 0 | 0.0 | Χ | Х | Х | Х | Х | Х | Х | Х |
| 15–24 | Χ | Χ | 9 | 21.2 | 11 | 25.8 | 8 | 18.6 | 6 | 14.0 |
| 25–34 | 22 | 58.5 | 26 | 67.6 | 24 | 61.5 | 24 | 60.4 | 44 | 108.1 |
| 35-44 | 68 | 166.6 | 65 | 161.3 | 64 | 159.9 | 64 | 160.6 | 77 | 194.6 |
| 45-54 | 110 | 239.3 | 95 | 206.7 | 89 | 194.8 | 95 | 208.4 | 96 | 211.8 |
| ≥55 | 60 | 57.6 | 74 | 69.8 | 78 | 72.2 | 83 | 75.2 | 119 | 105.3 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 34 | 288.6 | 27 | 224.4 | 31 | 250.5 | 33 | 261.7 | 59 | 458.7 |
| Non-Hispanic white | 210 | 70.9 | 216 | 72.8 | 216 | 72.6 | 221 | 73.8 | 262 | 87.1 |
| Hispanic | 16 | 126.4 | 18 | 136.5 | 15 | 108.5 | 15 | 103.3 | 15 | 98.2 |
| Other | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Х | Х |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 152 | _ | 144 | _ | 138 | _ | 141 | _ | 169 | _ |
| Injection drug use (IDU) | 16 | _ | 15 | _ | 13 | _ | 16 | _ | 19 | _ |
| MMS and IDU | 13 | _ | 14 | _ | 14 | _ | 15 | _ | 16 | _ |
| Heterosexual sexual contact | 12 | _ | 16 | _ | 21 | _ | 22 | _ | 34 | |
| Perinatal exposure | 0 | _ | Χ | _ | Χ | _ | Χ | _ | Χ | |
| Other | Χ | _ | Χ | _ | Χ | _ | X | _ | Χ | |
| Unknown | 14 | _ | 14 | _ | 19 | _ | 19 | _ | 22 | |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | 41 | _ | 47 | _ | 45 | _ | 43 | _ | 47 | _ |
| Injection drug use (IDU) | 12 | _ | 9 | _ | 6 | _ | 8 | _ | 13 | |
| Perinatal exposure | 0 | _ | Χ | _ | Χ | _ | Χ | _ | 0 | |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | |
| Unknown | 6 | _ | 6 | _ | 6 | _ | 5 | _ | 15 | |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 0 | _ | Χ | _ | Χ | _ | Х | _ | Х | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Overall | Х | Х | Х | Х | Х | Х | Х | Х | Х | Х |

Living with diagnosed HIV: persons diagnosed with HIV on or before December 31 and resided in Tennessee on December 31, 2019

For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

[—] represents data not available.

Table 44. Persons living with diagnosed HIV, Chattanooga/Hamilton County, Tennessee, 2015-2019

| | 20 | 15 | 201 | 16 | 20 | 17 | 20 | 18 | 201 | 19 |
|-----------------------------------|------|-------|------|-------|-----|-------|-----|-------|------|-------|
| | No. | Rate | No. | Rate | No. | Rate | No. | Rate | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | Χ | Χ | Χ | Χ | 847 | 486.2 | 887 | 503.9 | 785 | 442.1 |
| Cisgender female | 266 | 145.2 | 267 | 144.2 | 273 | 146.1 | 277 | 147.1 | 247 | 129.8 |
| Transgender person | Χ | _ | X | _ | Χ | _ | X | _ | 5 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 5 | 8.0 | 5 | 8.0 | Χ | Χ | Х | Х | 5 | 7.9 |
| 15–24 | 37 | 83.2 | 45 | 101.9 | 34 | 77.3 | 28 | 63.8 | 17 | 38.6 |
| 25-34 | 181 | 365.7 | 173 | 338.6 | 177 | 338.3 | 194 | 365.0 | 173 | 319.6 |
| 35-44 | 219 | 496.3 | 221 | 501.4 | 232 | 524.8 | 214 | 477.7 | 192 | 423.6 |
| 45-54 | 387 | 823.1 | 386 | 819.7 | 365 | 778.2 | 368 | 793.4 | 315 | 687.5 |
| ≥55 | 267 | 251.1 | 294 | 270.3 | 317 | 286.4 | 363 | 322.1 | 335 | 291.8 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 476 | 690.5 | 494 | 712.6 | 499 | 716.9 | 514 | 737.0 | 464 | 663.7 |
| Non-Hispanic white | 547 | 216.4 | 554 | 217.1 | 555 | 216.1 | 584 | 225.8 | 493 | 189.1 |
| Hispanic | 59 | 318.7 | 62 | 318.3 | 57 | 278.8 | 59 | 276.6 | 62 | 279.4 |
| Other | 14 | 104.2 | 14 | 101.7 | Χ | Χ | Х | Х | 18 | 120.5 |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 558 | _ | 560 | _ | 575 | _ | 603 | _ | 544 | _ |
| Injection drug use (IDU) | 45 | _ | 47 | _ | 49 | _ | 47 | _ | 39 | _ |
| MMS and IDU | 35 | _ | 44 | _ | 32 | _ | 43 | _ | 32 | _ |
| Heterosexual sexual contact | 79 | _ | 86 | _ | 84 | _ | 88 | _ | 79 | _ |
| Perinatal exposure | Χ | _ | Х | _ | Χ | _ | Х | _ | Х | _ |
| Other | 5 | _ | 5 | _ | Χ | _ | Х | _ | Х | _ |
| Unknown | 94 | _ | 102 | _ | 101 | _ | 101 | _ | 85 | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | 167 | _ | 169 | _ | 175 | _ | 180 | _ | 159 | _ |
| Injection drug use (IDU) | 32 | _ | 33 | _ | 35 | _ | 29 | _ | 26 | _ |
| Perinatal exposure | Χ | _ | Х | _ | Χ | _ | Х | _ | Х | _ |
| Other | Χ | _ | Χ | _ | Χ | _ | Х | _ | Х | _ |
| Unknown | 63 | _ | 61 | _ | 59 | _ | 64 | _ | 58 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 11 | _ | 9 | _ | 8 | _ | 5 | _ | Χ | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | Χ | _ | Х | _ | Χ | _ | Х | _ | Х | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Overall | 1096 | 309.9 | 1124 | 314.2 | X | Х | X | Х | 1037 | 281.9 |

Living with diagnosed HIV: persons diagnosed with HIV on or before December 31 and resided in Tennessee on December 31, 2019

For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

[—] represents data not available.

Table 45. Persons living with diagnosed HIV, East public health region, Tennessee, 2015–2019

| | 20° | 15 | 20° | 16 | 20° | 17 | 201 | 18 | 201 | 19 |
|-----------------------------------|-----|-------|-----|-------|-----|-------|-----|-------|-----|-------|
| | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 435 | 117.3 | 481 | 128.8 | 499 | 132.6 | 495 | 130.6 | 575 | 150.5 |
| Cisgender female | 95 | 24.7 | 94 | 24.3 | 98 | 25.2 | 106 | 27.1 | 145 | 36.8 |
| Transgender person | 4 | _ | 6 | _ | 4 | _ | 5 | _ | 6 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 3 | 2.3 | 4 | 3.1 | 4 | 3.1 | 4 | 3.1 | 5 | 3.9 |
| 15–24 | 14 | 15.8 | 19 | 21.6 | 19 | 21.6 | 16 | 18.2 | 28 | 31.9 |
| 25–34 | 53 | 63.0 | 56 | 65.1 | 59 | 67.1 | 66 | 73.7 | 95 | 104.0 |
| 35–44 | 116 | 127.1 | 128 | 143.1 | 109 | 123.5 | 110 | 125.6 | 122 | 139.5 |
| 45–54 | 199 | 185.1 | 197 | 183.3 | 218 | 203.0 | 207 | 194.6 | 221 | 210.9 |
| ≥55 | 149 | 58.7 | 177 | 68.3 | 192 | 72.7 | 203 | 75.3 | 255 | 92.4 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 46 | 286.5 | 64 | 393.0 | 68 | 411.1 | 56 | 335.2 | 68 | 400.2 |
| Non-Hispanic white | 444 | 64.3 | 467 | 67.4 | 475 | 68.2 | 488 | 69.8 | 584 | 83.1 |
| Hispanic | 29 | 95.7 | 34 | 107.8 | 39 | 118.9 | 44 | 128.8 | 54 | 152.2 |
| Other | 15 | 80.5 | 16 | 83.5 | 19 | 95.2 | 18 | 87.5 | 20 | 94.3 |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 314 | _ | 324 | _ | 345 | _ | 342 | _ | 398 | _ |
| Injection drug use (IDU) | 20 | _ | 33 | _ | 31 | _ | 24 | _ | 28 | _ |
| MMS and IDU | 26 | _ | 27 | _ | 28 | _ | 30 | _ | 41 | _ |
| Heterosexual sexual contact | 47 | _ | 57 | _ | 54 | _ | 63 | _ | 67 | _ |
| Perinatal exposure | 3 | _ | 4 | _ | 4 | _ | 5 | _ | 6 | _ |
| Other | 1 | _ | 2 | _ | 2 | _ | 2 | _ | 1 | _ |
| Unknown | 24 | _ | 34 | _ | 35 | _ | 29 | _ | 34 | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | 62 | _ | 59 | _ | 63 | _ | 66 | _ | 100 | _ |
| Injection drug use (IDU) | 19 | _ | 21 | _ | 20 | _ | 25 | _ | 27 | _ |
| Perinatal exposure | 4 | _ | 5 | _ | 5 | _ | 5 | _ | 6 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 10 | _ | 9 | _ | 10 | _ | 10 | _ | 12 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 2 | _ | 4 | _ | 3 | _ | 4 | _ | 4 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 1 | _ | 1 | _ | 0 | _ | 0 | _ | 1 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 1 | _ | 1 | _ | 1 | _ | 1 | _ | 1 | _ |
| | 534 | 70.7 | 581 | 76.5 | 601 | 78.5 | 606 | 78.6 | 726 | 93.5 |

 $Living\ with\ diagnosed\ HIV:\ persons\ diagnosed\ with\ HIV\ on\ or\ before\ December\ 31\ and\ resided\ in\ Tennessee\ on\ December\ 31\ ,2019$

For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

[—] represents data not available.

Table 46. Persons living with diagnosed HIV, Knoxville/Knox County, Tennessee, 2015-2019

| | 20 ⁻ | 15 | 20 ⁻ | 16 | 20 ⁻ | 17 | 201 | 18 | 201 | 19 |
|-----------------------------------|-----------------|-------|-----------------|-------|-----------------|-------|-----|-------|-----|-------|
| | No. | Rate | No. | Rate | No. | Rate | No. | Rate | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 772 | 351.9 | 817 | 368.7 | 809 | 360.6 | 845 | 372.8 | 764 | 334.0 |
| Cisgender female | 208 | 89.7 | 218 | 93.0 | 233 | 98.2 | 233 | 97.3 | Χ | Χ |
| Transgender person | Χ | _ | 7 | _ | 7 | _ | Χ | _ | 9 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | Χ | Х | 5 | 6.2 | 5 | 6.2 | Х | Х | Х | Х |
| 15–24 | 34 | 47.4 | 36 | 50.2 | 39 | 54.2 | 41 | 56.6 | 40 | 55.4 |
| 25–34 | 122 | 202.5 | 145 | 236.7 | 149 | 237.4 | 171 | 268.6 | 155 | 239.0 |
| 35-44 | 230 | 407.4 | 216 | 380.7 | 219 | 381.3 | 214 | 366.8 | 197 | 332.9 |
| 45-54 | 356 | 597.0 | 360 | 603.2 | 332 | 557.9 | 341 | 580.3 | 305 | 525.8 |
| ≥55 | 242 | 196.2 | 280 | 221.7 | 305 | 236.6 | 316 | 239.7 | 305 | 226.4 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 253 | 638.9 | 271 | 678.7 | 276 | 685.0 | 285 | 701.9 | 275 | 671.8 |
| Non-Hispanic white | 659 | 176.1 | 689 | 182.6 | 692 | 181.9 | 714 | 186.3 | 642 | 166.5 |
| Hispanic | 45 | 250.3 | 50 | 267.8 | 50 | 253.3 | 56 | 270.7 | 55 | 256.2 |
| Other | Χ | Χ | 32 | 158.3 | 31 | 147.4 | Χ | Χ | Χ | Χ |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 555 | _ | 598 | _ | 585 | _ | 624 | _ | 555 | _ |
| Injection drug use (IDU) | 50 | _ | 46 | _ | 42 | _ | 42 | _ | 41 | _ |
| MMS and IDU | 31 | _ | 33 | _ | 36 | _ | 43 | _ | 38 | _ |
| Heterosexual sexual contact | 99 | _ | 103 | _ | 101 | _ | 97 | _ | 96 | _ |
| Perinatal exposure | Χ | _ | Χ | _ | Χ | _ | Χ | _ | Χ | _ |
| Other | Χ | _ | X | _ | Χ | _ | Χ | _ | Χ | _ |
| Unknown | 30 | _ | 31 | _ | 39 | _ | 33 | _ | 30 | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | 149 | _ | 155 | _ | 171 | _ | 171 | _ | 160 | _ |
| Injection drug use (IDU) | 38 | _ | 41 | _ | 38 | _ | 36 | _ | 46 | _ |
| Perinatal exposure | Χ | _ | X | _ | Χ | _ | Χ | _ | Χ | _ |
| Other | Χ | _ | Χ | _ | Χ | _ | Χ | _ | 0 | _ |
| Unknown | 17 | _ | 18 | _ | 19 | _ | 21 | _ | 22 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 8 | _ | 7 | _ | 7 | _ | 9 | _ | 7 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | Χ | _ |
| Any sexual contact and IDU | 0 | _ | 0 | _ | 0 | _ | Χ | _ | Χ | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Overall | Х | Х | 1042 | 228.5 | 1049 | 227.3 | Х | Х | Х | Х |

Living with diagnosed HIV: persons diagnosed with HIV on or before December 31 and resided in Tennessee on December 31, 2019

For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

[—] represents data not available.

Table 47. Persons living with diagnosed HIV, Northeast public health region, Tennessee, 2015–2019

| | 20 ⁻ | 15 | 201 | 16 | 20 ⁻ | 17 | 201 | 18 | 201 | 19 |
|-----------------------------------|-----------------|-------|-----|-------|-----------------|-------|-----|-------|-----|-------|
| | No. | Rate | No. | Rate | No. | Rate | No. | Rate | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | Χ | Χ | Х | Х | Χ | Χ | Х | Х | Χ | Χ |
| Cisgender female | Χ | Χ | Χ | Χ | Χ | Χ | X | Χ | Χ | Χ |
| Transgender person | 5 | _ | Χ | _ | Χ | _ | X | _ | 5 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | Χ | Χ | Χ | Х | Χ | Χ | Х | Х | 0 | 0.0 |
| 15–24 | 18 | 39.7 | 15 | 33.3 | 13 | 29.2 | 11 | 24.6 | 9 | 20.3 |
| 25-34 | 39 | 96.8 | 47 | 114.7 | 43 | 103.7 | 42 | 100.1 | 49 | 115.4 |
| 35–44 | 78 | 183.9 | 81 | 195.3 | 81 | 198.8 | 77 | 191.3 | 70 | 176.1 |
| 45-54 | 147 | 298.7 | 144 | 293.1 | 138 | 281.6 | 133 | 273.3 | 135 | 280.8 |
| ≥55 | 90 | 77.4 | 107 | 90.3 | 125 | 103.9 | 152 | 124.0 | 165 | 132.1 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 59 | 677.7 | 71 | 799.2 | 70 | 775.5 | 71 | 767.7 | 63 | 683.9 |
| Non-Hispanic white | 300 | 92.6 | 309 | 95.3 | 314 | 96.9 | 324 | 99.8 | 340 | 104.6 |
| Hispanic | 14 | 158.9 | 15 | 163.2 | 14 | 145.0 | 17 | 170.2 | 20 | 194.9 |
| Other | Χ | Χ | Χ | Χ | Χ | Χ | Х | Х | 5 | 52.9 |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 208 | _ | 214 | _ | 228 | _ | 236 | _ | 236 | _ |
| Injection drug use (IDU) | 20 | _ | 22 | _ | 23 | _ | 21 | _ | 21 | _ |
| MMS and IDU | 17 | _ | 21 | _ | 19 | _ | 23 | _ | 28 | _ |
| Heterosexual sexual contact | 38 | _ | 39 | _ | 35 | _ | 39 | _ | 37 | _ |
| Perinatal exposure | 5 | _ | 5 | _ | 5 | _ | 5 | _ | 5 | _ |
| Other | Χ | _ | Χ | _ | Χ | _ | Χ | _ | Χ | _ |
| Unknown | 10 | _ | 11 | _ | 9 | _ | 6 | _ | 5 | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | 46 | _ | 52 | _ | 50 | _ | 52 | _ | 59 | _ |
| Injection drug use (IDU) | 13 | _ | 13 | _ | 14 | _ | 13 | _ | 15 | _ |
| Perinatal exposure | Χ | _ | Χ | _ | Χ | _ | Χ | _ | Χ | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 8 | _ | 10 | _ | 13 | _ | 13 | _ | 11 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | Х | _ | Χ | _ | Χ | _ | Χ | _ | Χ | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | Х | _ | Х | _ | 0 | _ | 0 | _ | Χ | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Overall | X | Х | X | Х | X | Х | X | Х | 428 | 120.9 |

Living with diagnosed HIV: persons diagnosed with HIV on or before December 31 and resided in Tennessee on December 31, 2019

For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

[—] represents data not available.

Table 48. Persons living with diagnosed HIV, Blountville/Sullivan County public health region, Tennessee, 2015–2019

| | 201 | 15 | 201 | 6 | 201 | 7 | 201 | 8 | 2019 | , |
|-----------------------------------|-----|-------|-----|-------|-----|-------|-----|--------|------|-------|
| | No. | Rate | No. | Rate | No. | Rate | No. | Rate | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 148 | 195.3 | 166 | 218.9 | 171 | 224.2 | 186 | 242.6 | 162 | 210.2 |
| Cisgender female | Χ | Χ | Χ | Χ | 38 | 47.1 | 42 | 51.9 | X | Χ |
| Transgender person | 0 | _ | Χ | _ | Χ | _ | X | _ | Χ | _ |
| Age group (years) | | | | | | | | | | |
| <15 | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Χ | Χ |
| 15–24 | 5 | 28.2 | 10 | 57.0 | 14 | 80.6 | 11 | 63.6 | 5 | 29.0 |
| 25–34 | 24 | 141.0 | 27 | 154.7 | 33 | 184.2 | 33 | 178.8 | 33 | 174.4 |
| 35-44 | 40 | 213.7 | 34 | 187.2 | 31 | 172.9 | 40 | 225.5 | 27 | 153.1 |
| 45–54 | 60 | 266.4 | 69 | 307.4 | 54 | 242.0 | 56 | 253.5 | 50 | 229.5 |
| ≥55 | 52 | 94.3 | 61 | 109.7 | 77 | 136.6 | 89 | 155.7 | 76 | 131.0 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 25 | 741.0 | 27 | 796.5 | 28 | 827.2 | 35 | 1012.7 | 31 | 877.2 |
| Non-Hispanic white | 150 | 102.4 | 167 | 114.2 | 172 | 117.2 | 186 | 126.5 | 153 | 103.7 |
| Hispanic | Χ | Χ | 7 | 246.3 | 8 | 268.5 | 6 | 195.3 | 8 | 248.4 |
| Other | 0 | 0.0 | Χ | Χ | Χ | Χ | X | Χ | Χ | Χ |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 115 | _ | 130 | _ | 133 | _ | 138 | _ | 122 | _ |
| Injection drug use (IDU) | 6 | _ | 7 | _ | 6 | _ | 9 | _ | 8 | _ |
| MMS and IDU | 9 | _ | 11 | _ | 13 | _ | 16 | _ | 11 | _ |
| Heterosexual sexual contact | 13 | _ | 14 | _ | 14 | _ | 15 | _ | 14 | _ |
| Perinatal exposure | Χ | _ | Χ | _ | Χ | _ | X | _ | Χ | _ |
| Other | Χ | _ | Χ | _ | Χ | _ | X | _ | Χ | _ |
| Unknown | Χ | _ | Χ | _ | Χ | _ | 6 | _ | 5 | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | 26 | _ | 26 | _ | 28 | _ | 30 | _ | 20 | _ |
| Injection drug use (IDU) | 5 | _ | 5 | _ | 5 | _ | 7 | _ | 7 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | Χ | _ | Χ | _ | 5 | _ | 5 | _ | X | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 0 | _ | Χ | _ | 0 | _ | Χ | _ | Χ | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 0 | _ | 0 | _ | Χ | _ | Χ | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | |
| Overall | Х | Х | Х | Х | Х | Х | Х | Х | Х | Х |

Living with diagnosed HIV: persons diagnosed with HIV on or before December 31 and resided in Tennessee on December 31, 2019

For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

- represents data not available.

Appendix H: HIV community planning region data

Table 5. Persons newly diagnosed with HIV, Southwest HIV community planning region, Tennessee, 2015–2019

| | 20 | 15 | 20 ⁻ | 16 | 20 | 17 | 20 | 18 | 20 | 19 |
|-----------------------------------|-----|------|-----------------|------|-----|------|-----|------|-----|------|
| | No. | Rate | No. | Rate | No. | Rate | No. | Rate | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 217 | 43.8 | 212 | 42.8 | 219 | 44.3 | 233 | 47.1 | 210 | 42.4 |
| Cisgender female | 63 | 11.6 | 55 | 10.1 | 46 | 8.5 | 59 | 10.9 | 54 | 9.9 |
| Transgender person | 5 | _ | 6 | _ | 2 | _ | 11 | _ | 5 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 3 | 1.4 | 2 | 0.9 | 0 | 0.0 | 3 | 1.4 | 1 | 0.5 |
| 15–24 | 85 | 58.4 | 79 | 55.4 | 79 | 56.8 | 87 | 63.8 | 81 | 60.5 |
| 25-34 | 89 | 60.8 | 93 | 62.9 | 89 | 59.5 | 108 | 71.2 | 85 | 55.3 |
| 35-44 | 45 | 34.3 | 44 | 34.1 | 39 | 30.3 | 48 | 37.2 | 40 | 31.0 |
| 45-54 | 41 | 29.9 | 31 | 22.9 | 31 | 23.3 | 32 | 24.5 | 35 | 27.4 |
| ≥55 | 22 | 8.4 | 24 | 9.0 | 29 | 10.7 | 25 | 9.0 | 27 | 9.6 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 243 | 46.6 | 248 | 47.5 | 228 | 43.6 | 258 | 49.2 | 211 | 40.1 |
| Non-Hispanic white | 28 | 6.7 | 14 | 3.4 | 26 | 6.3 | 27 | 6.6 | 29 | 7.2 |
| Hispanic | 12 | 20.1 | 6 | 9.9 | 11 | 17.7 | 15 | 23.5 | 24 | 36.8 |
| Other | 2 | 4.9 | 5 | 12.2 | 2 | 4.8 | 3 | 7.0 | 5 | 11.3 |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 128 | _ | 130 | _ | 146 | _ | 125 | _ | 115 | _ |
| Injection drug use (IDU) | 3 | _ | 0 | _ | 1 | _ | 1 | _ | 2 | _ |
| MMS and IDU | 0 | _ | 0 | _ | 1 | _ | 5 | _ | 1 | _ |
| Heterosexual sexual contact | 42 | _ | 64 | _ | 33 | _ | 36 | _ | 13 | _ |
| Perinatal exposure | 1 | _ | 0 | _ | 0 | _ | 2 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 43 | _ | 18 | _ | 38 | _ | 64 | _ | 79 | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | 41 | _ | 51 | _ | 30 | _ | 32 | _ | 20 | _ |
| Injection drug use (IDU) | 5 | _ | 1 | _ | 1 | _ | 1 | _ | 3 | _ |
| Perinatal exposure | 2 | _ | 2 | _ | 0 | _ | 1 | _ | 1 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 15 | _ | 1 | _ | 15 | _ | 25 | _ | 30 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 5 | _ | 6 | _ | 2 | _ | 10 | _ | 3 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 1 | _ | 2 | _ |
| Overall | 285 | 27.5 | 273 | 26.3 | 267 | 25.8 | 303 | 29.2 | 269 | 25.9 |

Source: Tennessee enhanced HIV/AIDS Reporting System (eHARS), accessed July 13, 2020.

New HIV diagnoses: persons diagnosed with HIV during January 1–December 31, 2019 and resided in Tennessee at the time of diagnosis For new diagnoses and concurrent diagnoses, age group refers to the age at the time of HIV diagnosis. For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

⁻ represents data not available.

Table 6. Persons newly diagnosed with HIV, West HIV community planning region, Tennessee, 2015–2019

| | 20° | 15 | 20° | 16 | 20° | 17 | 20° | 18 | 201 | 19 |
|-----------------------------------|-----|------|-----|------|-----|------|-----|------|-----|------|
| | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 33 | 12.8 | 32 | 12.5 | 28 | 10.9 | 26 | 10.1 | 23 | 9.0 |
| Cisgender female | 6 | 2.2 | 6 | 2.2 | 11 | 4.1 | 6 | 2.2 | 4 | 1.5 |
| Transgender person | 1 | _ | 1 | _ | 1 | _ | 0 | _ | 1 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| 15-24 | 10 | 14.2 | 11 | 15.9 | 12 | 17.5 | 5 | 7.4 | 9 | 13.5 |
| 25–34 | 14 | 22.8 | 18 | 29.3 | 11 | 17.7 | 13 | 20.8 | 10 | 15.9 |
| 35-44 | 7 | 11.1 | 5 | 8.2 | 11 | 18.1 | 7 | 11.5 | 5 | 8.3 |
| 45-54 | 7 | 9.8 | 4 | 5.7 | 2 | 2.9 | 6 | 8.9 | 3 | 4.6 |
| ≥55 | 2 | 1.2 | 1 | 0.6 | 4 | 2.4 | 1 | 0.6 | 1 | 0.6 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 22 | 39.3 | 22 | 21.9 | 24 | 23.8 | 18 | 17.8 | 17 | 16.9 |
| Non-Hispanic white | 15 | 5.1 | 13 | 3.3 | 16 | 4.1 | 12 | 3.1 | 8 | 2.1 |
| Hispanic | 1 | 13.6 | 4 | 24.6 | 0 | 0.0 | 1 | 5.8 | 1 | 5.6 |
| Other | 2 | 6.7 | 0 | 0.0 | 0 | 0.0 | 1 | 7.7 | 2 | 15.0 |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 24 | _ | 25 | _ | 19 | _ | 18 | _ | 16 | _ |
| Injection drug use (IDU) | 1 | _ | 0 | _ | 2 | _ | 1 | _ | 1 | _ |
| MMS and IDU | 1 | _ | 1 | _ | 1 | _ | 1 | _ | 1 | _ |
| Heterosexual sexual contact | 4 | _ | 6 | _ | 5 | _ | 4 | _ | 2 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other . | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 3 | _ | 0 | _ | 1 | _ | 2 | _ | 3 | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | 5 | _ | 5 | _ | 8 | _ | 6 | _ | 4 | _ |
| Injection drug use (IDU) | 1 | _ | 1 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other . | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 3 | _ | 0 | _ | 0 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 0 | _ | 1 | _ | 1 | _ | 0 | _ | 1 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 1 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Overall | 40 | 7.6 | 39 | 7.4 | 40 | 7.6 | 32 | 6.1 | 28 | 5.4 |

New HIV diagnoses: persons diagnosed with HIV during January 1–December 31, 2019 and resided in Tennessee at the time of diagnosis For new diagnoses and concurrent diagnoses, age group refers to the age at the time of HIV diagnosis. For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

⁻ represents data not available.

Table 51. Persons newly diagnosed with HIV, Middle HIV community planning region, Tennessee, 2015–2019

| | 20 ⁻ | 15 | 20 ⁻ | 16 | 20 ⁻ | 17 | 20 | 18 | 20 ⁻ | 19 |
|-----------------------------------|-----------------|------|-----------------|------|-----------------|------|-----|------|-----------------|------|
| | No. | Rate | No. | Rate | No. | Rate | No. | Rate | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 218 | 16.9 | 200 | 15.3 | 219 | 16.4 | 210 | 15.5 | 239 | 17.4 |
| Cisgender female | 44 | 3.3 | 39 | 2.9 | 36 | 2.6 | 39 | 2.8 | 43 | 3.0 |
| Transgender person | 5 | _ | 5 | _ | 4 | _ | 7 | _ | 5 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 4 | 0.8 | 1 | 0.2 | 3 | 0.6 | 1 | 0.2 | 0 | 0.0 |
| 15–24 | 70 | 19.9 | 65 | 18.4 | 59 | 16.6 | 56 | 15.7 | 45 | 12.5 |
| 25-34 | 102 | 26.9 | 80 | 20.4 | 96 | 23.8 | 103 | 25.0 | 123 | 29.2 |
| 35-44 | 41 | 11.8 | 49 | 14.0 | 40 | 11.3 | 51 | 14.1 | 46 | 12.5 |
| 45-54 | 34 | 9.6 | 36 | 10.1 | 40 | 11.2 | 27 | 7.6 | 40 | 11.3 |
| ≥55 | 16 | 2.3 | 13 | 1.9 | 21 | 2.9 | 18 | 2.4 | 33 | 4.3 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 126 | 39.3 | 108 | 31.6 | 115 | 32.9 | 113 | 31.7 | 127 | 35.1 |
| Non-Hispanic white | 109 | 5.1 | 112 | 5.5 | 115 | 5.6 | 97 | 4.7 | 119 | 5.7 |
| Hispanic | 20 | 13.6 | 16 | 9.0 | 18 | 9.7 | 24 | 12.4 | 30 | 15.0 |
| Other | 12 | 6.7 | 8 | 6.7 | 11 | 8.8 | 22 | 16.8 | 11 | 8.0 |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 173 | _ | 148 | _ | 170 | _ | 151 | _ | 196 | _ |
| Injection drug use (IDU) | 8 | _ | 4 | _ | 2 | _ | 3 | _ | 8 | _ |
| MMS and IDU | 9 | _ | 11 | _ | 6 | _ | 8 | _ | 4 | _ |
| Heterosexual sexual contact | 18 | _ | 25 | _ | 13 | _ | 31 | _ | 22 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 10 | _ | 12 | _ | 28 | _ | 17 | _ | 9 | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | 32 | _ | 33 | _ | 24 | _ | 32 | _ | 25 | _ |
| Injection drug use (IDU) | 2 | _ | 4 | _ | 2 | _ | 0 | _ | 11 | _ |
| Perinatal exposure | 3 | _ | 1 | _ | 2 | _ | 1 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 7 | _ | 1 | _ | 8 | _ | 6 | _ | 7 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 5 | _ | 4 | _ | 4 | _ | 5 | _ | 4 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 0 | _ | 1 | _ | 0 | _ | 0 | _ | 1 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 2 | _ | 0 | _ |
| Overall | 267 | 10.1 | 244 | 9.1 | 259 | 9.5 | 256 | 9.3 | 287 | 10.2 |

New HIV diagnoses: persons diagnosed with HIV during January 1–December 31, 2019 and resided in Tennessee at the time of diagnosis For new diagnoses and concurrent diagnoses, age group refers to the age at the time of HIV diagnosis. For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

⁻ represents data not available.

Table 52. Persons newly diagnosed with HIV, Southeast HIV community planning region, Tennessee, 2015–2019

| | 20° | 15 | 20 | 16 | 20 | 17 | 20 | 18 | 20° | 19 |
|-----------------------------------|-----|------|-----|------|-----|---------|-----|------|-----|------|
| | No. | Rate | No. | Rate | No. | Rate | No. | Rate | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 50 | 15.0 | 55 | 16.4 | 45 | 13.3 | 48 | 14.0 | 53 | 15.4 |
| Cisgender female | 8 | 2.3 | 13 | 3.7 | 11 | 3.1 | 11 | 3.1 | 13 | 3.6 |
| Transgender person | 1 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 1 | 0.8 | 1 | 0.8 | 0 | 0.0 | 0 | 0.0 | 1 | 0.8 |
| 15-24 | 11 | 12.6 | 16 | 18.5 | 12 | 13.9 | 6 | 6.9 | 7 | 8.1 |
| 25-34 | 20 | 23.0 | 18 | 20.1 | 19 | 20.8 | 26 | 28.0 | 27 | 28.5 |
| 35-44 | 13 | 15.3 | 17 | 20.1 | 10 | 11.9 | 10 | 11.8 | 17 | 20.0 |
| 45-54 | 11 | 11.8 | 13 | 14.0 | 8 | 8.6 | 6 | 6.5 | 9 | 9.9 |
| ≥55 | 3 | 1.4 | 3 | 1.4 | 7 | 3.2 | 11 | 4.9 | 5 | 2.2 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 27 | 39.3 | 24 | 29.5 | 23 | 28.1 | 26 | 31.6 | 27 | 32.6 |
| Non-Hispanic white | 24 | 5.1 | 39 | 7.1 | 33 | 6.0 | 31 | 5.6 | 33 | 5.9 |
| Hispanic | 8 | 13.6 | 4 | 12.2 | 0 | 0.0 | 2 | 5.6 | 5 | 13.3 |
| Other | 0 | 6.7 | 1 | 4.4 | 0 | 0.0 | 0 | 0.0 | 1 | 4.0 |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 26 | _ | 36 | _ | 27 | _ | 30 | _ | 34 | _ |
| Injection drug use (IDU) | 4 | _ | 4 | _ | 5 | _ | 2 | _ | 3 | _ |
| MMS and IDU | 3 | _ | 4 | _ | 1 | _ | 4 | _ | 4 | _ |
| Heterosexual sexual contact | 7 | _ | 5 | _ | 3 | _ | 8 | _ | 9 | _ |
| Perinatal exposure | 0 | _ | 1 | _ | 0 | _ | 0 | _ | 1 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 10 | _ | 5 | _ | 9 | _ | 4 | _ | 2 | _ |
| Cisgender female | | | | | - | | | | | |
| Heterosexual sexual contact | 3 | _ | 11 | _ | 5 | _ | 7 | _ | 6 | _ |
| Injection drug use (IDU) | 1 | _ | 1 | _ | 2 | _ | 2 | _ | 5 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 4 | _ | 1 | _ | 4 | _ | 2 | _ | 2 | _ |
| Transgender person | • | | · | | • | | _ | | _ | |
| Any sexual contact | 1 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Overall | | 8.6 | 68 | 9.9 | 56 | 8.1 | | 8.4 | 66 | 9.3 |

New HIV diagnoses: persons diagnosed with HIV during January 1–December 31, 2019 and resided in Tennessee at the time of diagnosis For new diagnoses and concurrent diagnoses, age group refers to the age at the time of HIV diagnosis. For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

⁻ represents data not available.

Table 53. Persons newly diagnosed with HIV, East HIV community planning region, Tennessee, 2015–2019

| | 201 | 15 | 20 | 16 | 20° | 17 | 20° | 18 | 201 | 19 |
|-----------------------------------|-----|------|-----|------|-----|------|-----|------|-----|------|
| | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 68 | 8.1 | 81 | 9.6 | 76 | 8.9 | 83 | 9.7 | 93 | 10.8 |
| Cisgender female | 26 | 3.0 | 13 | 1.5 | 26 | 2.9 | 22 | 2.5 | 32 | 3.6 |
| Transgender person | 0 | _ | 1 | _ | 1 | _ | 2 | _ | 1 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 1 | 0.3 | 2 | 0.7 | 1 | 0.3 | 0 | 0.0 | 0 | 0.0 |
| 15–24 | 16 | 7.2 | 24 | 10.8 | 26 | 11.7 | 21 | 9.4 | 23 | 10.4 |
| 25–34 | 30 | 14.9 | 31 | 15.1 | 30 | 14.3 | 45 | 21.1 | 44 | 20.2 |
| 35-44 | 20 | 9.6 | 11 | 5.3 | 20 | 9.8 | 16 | 7.8 | 30 | 14.7 |
| 45-54 | 18 | 7.5 | 17 | 7.1 | 13 | 5.5 | 16 | 6.8 | 19 | 8.2 |
| ≥55 | 9 | 1.6 | 10 | 1.8 | 13 | 2.3 | 9 | 1.5 | 10 | 1.7 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 17 | 39.3 | 22 | 32.1 | 26 | 37.5 | 21 | 30.0 | 25 | 35.4 |
| Non-Hispanic white | 72 | 5.1 | 64 | 4.2 | 68 | 4.4 | 70 | 4.5 | 83 | 5.3 |
| Hispanic | 5 | 13.6 | 6 | 9.6 | 6 | 9.2 | 13 | 19.1 | 13 | 18.5 |
| Other | 0 | 6.7 | 3 | 5.8 | 3 | 5.6 | 3 | 5.4 | 5 | 8.7 |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 50 | _ | 55 | _ | 50 | _ | 60 | _ | 58 | _ |
| Injection drug use (IDU) | 2 | _ | 4 | _ | 7 | _ | 5 | _ | 9 | _ |
| MMS and IDU | 4 | _ | 8 | _ | 7 | _ | 3 | _ | 7 | _ |
| Heterosexual sexual contact | 7 | _ | 13 | _ | 8 | _ | 13 | _ | 17 | _ |
| Perinatal exposure | 0 | _ | 1 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 5 | _ | 0 | _ | 4 | _ | 2 | _ | 2 | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | 16 | _ | 10 | _ | 16 | _ | 16 | _ | 17 | _ |
| Injection drug use (IDU) | 8 | _ | 2 | _ | 5 | _ | 5 | _ | 14 | _ |
| Perinatal exposure | 0 | _ | 1 | _ | 1 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 2 | _ | 0 | _ | 4 | _ | 1 | _ | 1 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 0 | _ | 1 | _ | 1 | _ | 2 | _ | 0 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 1 | _ |
| Any sexual contact and IDU | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Overall | 94 | 5.5 | 95 | 5.5 | 103 | 5.9 | 107 | 6.1 | 126 | 7.2 |

New HIV diagnoses: persons diagnosed with HIV during January 1–December 31, 2019 and resided in Tennessee at the time of diagnosis For new diagnoses and concurrent diagnoses, age group refers to the age at the time of HIV diagnosis. For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

⁻ represents data not available.

Table 54. Persons concurrently diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of diagnosis, Southwest HIV community planning region, Tennessee, 2015–2019

| - | 20 | 15 | 20 | 16 | 20 | 17 | 20 | 18 | 20 | 19 |
|-----------------------------------|-----|------|-----|------|-----|------|-----|------|-----|------|
| | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 38 | 7.7 | 37 | 7.5 | 45 | 9.1 | 53 | 10.7 | 40 | 8.1 |
| Cisgender female | 6 | 1.1 | 10 | 1.8 | 12 | 2.2 | 13 | 2.4 | 10 | 1.8 |
| Transgender person | 1 | _ | 1 | _ | 1 | _ | 0 | _ | 0 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 1 | 0.5 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| 15–24 | 6 | 4.1 | 7 | 4.9 | 6 | 4.3 | 10 | 7.3 | 6 | 4.5 |
| 25-34 | 10 | 6.8 | 13 | 8.8 | 19 | 12.7 | 20 | 13.2 | 15 | 9.8 |
| 35-44 | 10 | 7.6 | 9 | 7.0 | 13 | 10.1 | 14 | 10.9 | 10 | 7.7 |
| 45-54 | 12 | 8.8 | 10 | 7.4 | 13 | 9.8 | 13 | 10.0 | 7 | 5.5 |
| ≥55 | 6 | 2.3 | 9 | 3.4 | 7 | 2.6 | 9 | 3.3 | 12 | 4.3 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 35 | 6.7 | 40 | 7.7 | 47 | 9.0 | 51 | 9.7 | 35 | 6.7 |
| Non-Hispanic white | 4 | 1.0 | 3 | 0.7 | 6 | 1.5 | 8 | 2.0 | 7 | 1.7 |
| Hispanic | 5 | 8.4 | 2 | 3.3 | 5 | 8.0 | 6 | 9.4 | 5 | 7.7 |
| Other | 1 | 2.5 | 3 | 7.3 | 0 | 0.0 | 1 | 2.3 | 3 | 6.8 |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 18 | _ | 18 | _ | 22 | _ | 25 | _ | 19 | _ |
| Injection drug use (IDU) | 1 | _ | 0 | _ | 0 | _ | 0 | _ | 1 | _ |
| MMS and IDU | 0 | _ | 0 | _ | 0 | _ | 3 | _ | 0 | _ |
| Heterosexual sexual contact | 10 | _ | 13 | _ | 13 | _ | 12 | _ | 4 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 9 | _ | 6 | _ | 10 | _ | 13 | _ | 16 | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | 3 | _ | 10 | _ | 10 | _ | 8 | _ | 5 | _ |
| Injection drug use (IDU) | 1 | _ | 0 | _ | 0 | _ | 0 | _ | 1 | _ |
| Perinatal exposure | 1 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 1 | _ | 0 | _ | 2 | _ | 5 | _ | 4 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 1 | _ | 1 | _ | 1 | _ | 0 | _ | 0 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Overall | 45 | 4.3 | 48 | 4.6 | 58 | 5.6 | 66 | 6.4 | 50 | 4.8 |

Concurrent diagnoses: persons who were diagnosed with HIV 12 months or less before being diagnosed as Stage 3 HIV (AIDS)

For new diagnoses and concurrent diagnoses, age group refers to the age at the time of HIV diagnosis. For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

⁻ represents data not available.

Table 55. Persons concurrently diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of diagnosis, West HIV community planning region, Tennessee, 2015–2019

| | 20 ⁻ | 15 | 20 ⁻ | 16 | 20 ⁻ | 17 | 20 | 18 | 201 | 9 |
|-----------------------------------|-----------------|------|-----------------|------|-----------------|------|-----|------|-----|------|
| | No. | Rate | No. | Rate | No. | Rate | No. | Rate | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 7 | 2.7 | 10 | 3.9 | 4 | 1.6 | 6 | 2.3 | 3 | 1.2 |
| Cisgender female | 1 | 0.4 | 2 | 0.7 | 3 | 1.1 | 1 | 0.4 | 2 | 0.8 |
| Transgender person | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| 15–24 | 2 | 2.8 | 4 | 5.8 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| 25-34 | 2 | 3.3 | 3 | 4.9 | 3 | 4.8 | 1 | 1.6 | 1 | 1.6 |
| 35-44 | 1 | 1.6 | 2 | 3.3 | 1 | 1.6 | 3 | 4.9 | 2 | 3.3 |
| 45-54 | 2 | 2.8 | 2 | 2.9 | 1 | 1.5 | 3 | 4.5 | 1 | 1.5 |
| ≥55 | 1 | 0.6 | 1 | 0.6 | 2 | 1.2 | 0 | 0.0 | 1 | 0.6 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 6 | 5.9 | 8 | 8.0 | 4 | 4.0 | 4 | 4.0 | 3 | 3.0 |
| Non-Hispanic white | 1 | 0.3 | 3 | 0.8 | 3 | 0.8 | 3 | 0.8 | 1 | 0.3 |
| Hispanic . | 1 | 6.3 | 1 | 6.1 | 0 | 0.0 | 0 | 0.0 | 1 | 5.6 |
| Other | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 6 | _ | 7 | _ | 4 | _ | 5 | _ | 1 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 1 | _ |
| MMS and IDU | 0 | _ | 1 | _ | 0 | _ | 0 | _ | 0 | _ |
| Heterosexual sexual contact | 1 | _ | 2 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 1 | _ | 1 | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | 1 | _ | 1 | _ | 2 | _ | 1 | _ | 2 | _ |
| Injection drug use (IDU) | 0 | _ | 1 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 1 | _ | 0 | _ | 0 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Overall | 8 | 1.5 | 12 | 2.3 | 7 | 1.3 | 7 | 1.3 | 5 | 1.0 |

Concurrent diagnoses: persons who were diagnosed with HIV 12 months or less before being diagnosed as Stage 3 HIV (AIDS)

For new diagnoses and concurrent diagnoses, age group refers to the age at the time of HIV diagnosis. For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

⁻ represents data not available.

Table 56. Persons concurrently diagnosed with HIV Stages 0-2 and Stage 3 (AIDS) within 12 months of diagnosis, Middle HIV community planning region, Tennessee, 2015-2019

| | 20 |)15 | 2 | 016 | | 2017 | | 2018 | | 2019 |
|-----------------------------------|-----|------|-----|------|-----|------|-----|------|-----|------|
| | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 49 | 3.8 | 34 | 2.6 | 37 | 2.8 | 42 | 3.1 | 46 | 3.3 |
| Cisgender female | 13 | 1.0 | 7 | 0.5 | 5 | 0.4 | 7 | 0.5 | 9 | 0.6 |
| Transgender person | 1 | _ | 0 | _ | 0 | _ | 1 | _ | 0 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 1 | 0.2 | 0 | 0.0 | 0 | 0.0 | 1 | 0.2 | 0 | 0.0 |
| 15–24 | 5 | 1.4 | 6 | 1.7 | 5 | 1.4 | 5 | 1.4 | 3 | 0.8 |
| 25-34 | 20 | 5.3 | 11 | 2.8 | 12 | 3.0 | 22 | 5.3 | 13 | 3.1 |
| 35-44 | 13 | 3.7 | 13 | 3.7 | 10 | 2.8 | 13 | 3.6 | 16 | 4.3 |
| 45-54 | 17 | 4.8 | 10 | 2.8 | 12 | 3.4 | 5 | 1.4 | 11 | 3.1 |
| ≥55 | 7 | 1.0 | 1 | 0.1 | 3 | 0.4 | 4 | 0.5 | 12 | 1.6 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 27 | 8.1 | 19 | 5.6 | 16 | 4.6 | 23 | 6.5 | 24 | 6.6 |
| Non-Hispanic white | 30 | 1.5 | 16 | 0.8 | 18 | 0.9 | 17 | 0.8 | 21 | 1.0 |
| Hispanic | 5 | 2.9 | 5 | 2.8 | 5 | 2.7 | 5 | 2.6 | 8 | 4.0 |
| Other | 1 | 0.9 | 1 | 0.8 | 3 | 2.4 | 5 | 3.8 | 2 | 1.5 |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 34 | _ | 22 | _ | 26 | _ | 28 | _ | 36 | _ |
| Injection drug use (IDU) | 3 | _ | 1 | _ | 1 | _ | 0 | _ | 1 | _ |
| MMS and IDU | 2 | _ | 2 | _ | 2 | _ | 2 | _ | 0 | _ |
| Heterosexual sexual contact | 5 | _ | 8 | _ | 5 | _ | 11 | _ | 8 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 5 | _ | 1 | _ | 3 | _ | 1 | _ | 1 | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | 9 | _ | 6 | _ | 4 | _ | 6 | _ | 8 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 1 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 1 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 4 | _ | 1 | _ | 1 | _ | 0 | _ | 0 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 1 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 1 | _ | 0 | _ |
| Overall | 63 | 2.4 | 41 | 1.5 | 42 | 1.5 | 50 | 1.8 | 55 | 2.0 |

Concurrent diagnoses: persons who were diagnosed with HIV 12 months or less before being diagnosed as Stage 3 HIV (AIDS)

For new diagnoses and concurrent diagnoses, age group refers to the age at the time of HIV diagnosis. For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

⁻ represents data not available.

Table 57. Persons concurrently diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of diagnosis, Southeast HIV community planning region, Tennessee, 2015–2019

| | 20 ⁻ | 15 | 20 ⁻ | 16 | 20 ⁻ | 17 | 20 ⁻ | 18 | 201 | 9 |
|-----------------------------------|-----------------|------|-----------------|------|-----------------|------|-----------------|------|-----|------|
| | No. | Rate | No. | Rate | No. | Rate | No. | Rate | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 11 | 3.3 | 16 | 4.8 | 10 | 3.0 | 10 | 2.9 | 12 | 3.5 |
| Cisgender female | 1 | 0.3 | 2 | 0.6 | 3 | 0.8 | 2 | 0.6 | 2 | 0.6 |
| Transgender person | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| 15-24 | 3 | 3.4 | 2 | 2.3 | 2 | 2.3 | 0 | 0.0 | 1 | 1.2 |
| 25-34 | 1 | 1.1 | 6 | 6.7 | 4 | 4.4 | 3 | 3.2 | 7 | 7.4 |
| 35-44 | 4 | 4.7 | 3 | 3.6 | 3 | 3.6 | 2 | 2.4 | 1 | 1.2 |
| 45-54 | 4 | 4.3 | 6 | 6.4 | 2 | 2.2 | 1 | 1.1 | 2 | 2.2 |
| ≥55 | 0 | 0.0 | 1 | 0.5 | 2 | 0.9 | 6 | 2.7 | 3 | 1.3 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 7 | 8.7 | 5 | 6.1 | 5 | 6.1 | 5 | 6.1 | 6 | 7.2 |
| Non-Hispanic white | 4 | 0.7 | 12 | 2.2 | 8 | 1.4 | 6 | 1.1 | 5 | 0.9 |
| Hispanic | 1 | 3.2 | 1 | 3.1 | 0 | 0.0 | 1 | 2.8 | 3 | 8.0 |
| Other | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 4 | _ | 11 | _ | 6 | _ | 4 | _ | 8 | _ |
| Injection drug use (IDU) | 0 | _ | 1 | _ | 1 | _ | 0 | _ | 0 | _ |
| MMS and IDU | 1 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Heterosexual sexual contact | 1 | _ | 2 | _ | 1 | _ | 4 | _ | 3 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 5 | _ | 2 | _ | 2 | _ | 2 | _ | 1 | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | 1 | _ | 2 | _ | 0 | _ | 2 | _ | 1 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 1 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 3 | _ | 0 | _ | 0 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Overall | 12 | 1.8 | 18 | 2.6 | 13 | 1.9 | 12 | 1.7 | 14 | 2.0 |

Concurrent diagnoses: persons who were diagnosed with HIV 12 months or less before being diagnosed as Stage 3 HIV (AIDS)

For new diagnoses and concurrent diagnoses, age group refers to the age at the time of HIV diagnosis. For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

⁻ represents data not available.

Table 58. Persons concurrently diagnosed with HIV Stages 0–2 and Stage 3 (AIDS) within 12 months of diagnosis, East HIV community planning region, Tennessee, 2015–2019

| | 2015 | | 20 | 2016 2017 | | 17 | 20 | 18 | 20 | 19 |
|-----------------------------------|------|------|-----|-----------|-----|------|-----|------|-----|------|
| | No. | Rate | No. | Rate | No. | Rate | No. | Rate | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 21 | 2.5 | 21 | 2.5 | 16 | 1.9 | 26 | 3.0 | 19 | 2.2 |
| Cisgender female | 5 | 0.6 | 3 | 0.3 | 10 | 1.1 | 5 | 0.6 | 3 | 0.3 |
| Transgender person | 0 | _ | 0 | _ | 0 | _ | 1 | _ | 0 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |
| 15–24 | 2 | 0.9 | 3 | 1.3 | 1 | 0.5 | 3 | 1.3 | 1 | 0.5 |
| 25-34 | 7 | 3.5 | 5 | 2.4 | 6 | 2.9 | 12 | 5.6 | 8 | 3.7 |
| 35-44 | 8 | 3.8 | 4 | 1.9 | 5 | 2.4 | 5 | 2.5 | 1 | 0.5 |
| 45-54 | 5 | 2.1 | 8 | 3.4 | 7 | 2.9 | 7 | 3.0 | 8 | 3.4 |
| ≥55 | 4 | 0.7 | 4 | 0.7 | 7 | 1.2 | 5 | 0.9 | 4 | 0.7 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 4 | 5.9 | 3 | 4.4 | 4 | 5.8 | 6 | 8.6 | 2 | 2.8 |
| Non-Hispanic white | 20 | 1.3 | 19 | 1.2 | 18 | 1.2 | 21 | 1.4 | 18 | 1.2 |
| Hispanic | 2 | 3.3 | 2 | 3.2 | 3 | 4.6 | 4 | 5.9 | 1 | 1.4 |
| Other | 0 | 0.0 | 0 | 0.0 | 1 | 1.9 | 1 | 1.8 | 1 | 1.7 |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 14 | _ | 15 | _ | 12 | _ | 16 | _ | 11 | _ |
| Injection drug use (IDU) | 1 | _ | 1 | _ | 2 | _ | 3 | _ | 1 | _ |
| MMS and IDU | 2 | _ | 1 | _ | 0 | _ | 0 | _ | 0 | _ |
| Heterosexual sexual contact | 3 | _ | 4 | _ | 1 | _ | 6 | _ | 6 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 1 | _ | 0 | _ | 1 | _ | 1 | _ | 1 | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | 3 | _ | 2 | _ | 5 | _ | 3 | _ | 2 | _ |
| Injection drug use (IDU) | 1 | _ | 1 | _ | 2 | _ | 1 | _ | 1 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 1 | _ | 0 | _ | 3 | _ | 1 | _ | 0 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 0 | _ | 0 | _ | 0 | _ | 1 | _ | 0 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Overall | 26 | 1.5 | 24 | 1.4 | 26 | 1.5 | 32 | 1.8 | 22 | 1.3 |

Concurrent diagnoses: persons who were diagnosed with HIV 12 months or less before being diagnosed as Stage 3 HIV (AIDS)

For new diagnoses and concurrent diagnoses, age group refers to the age at the time of HIV diagnosis. For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

⁻ represents data not available.

Table 59. Persons living with diagnosed HIV, Southwest HIV community planning region,
Tennessee, 2015–2019

| | 20 | 15 | 20 | 16 | 20 |)17 | 2018 | | 2019 | |
|-----------------------------------|------|--------|------|--------|------|--------|------|--------|------|--------|
| | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 4426 | 892.8 | 4508 | 910.8 | 4515 | 913.7 | 4713 | 952.4 | 4620 | 932.9 |
| Cisgender female | 2030 | 374.4 | 2048 | 377.8 | 2019 | 372.1 | 2051 | 377.3 | 1986 | 364.6 |
| Transgender person | 72 | _ | 84 | _ | 83 | _ | 100 | _ | 96 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 38 | 17.5 | 37 | 17.2 | 29 | 13.5 | 32 | 14.9 | 29 | 13.5 |
| 15-24 | 368 | 252.9 | 339 | 237.9 | 336 | 241.7 | 326 | 238.9 | 312 | 232.9 |
| 25-34 | 1370 | 935.7 | 1401 | 947.1 | 1354 | 904.9 | 1421 | 936.5 | 1331 | 865.7 |
| 35-44 | 1629 | 1242.0 | 1587 | 1228.7 | 1564 | 1214.7 | 1601 | 1241.9 | 1547 | 1198.3 |
| 45-54 | 1834 | 1339.7 | 1826 | 1349.7 | 1799 | 1352.8 | 1783 | 1366.5 | 1710 | 1339.2 |
| ≥55 | 1289 | 494.4 | 1450 | 544.3 | 1535 | 565.7 | 1701 | 615.4 | 1773 | 630.3 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 5398 | 1035.3 | 5531 | 1058.3 | 5513 | 1053.8 | 5721 | 1090.5 | 5582 | 1061.9 |
| Non-Hispanic white | 741 | 178.0 | 725 | 175.7 | 719 | 175.5 | 742 | 182.2 | 713 | 176.1 |
| Hispanic | 164 | 274.6 | 168 | 276.2 | 169 | 271.5 | 179 | 280.3 | 195 | 299.3 |
| Other | 225 | 556.7 | 216 | 527.7 | 216 | 519.1 | 222 | 519.7 | 212 | 480.9 |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 2764 | _ | 2814 | _ | 2835 | _ | 2935 | _ | 2888 | _ |
| Injection drug use (IDU) | 111 | _ | 108 | _ | 101 | _ | 107 | _ | 104 | _ |
| MMS and IDU | 101 | _ | 98 | _ | 97 | _ | 104 | _ | 90 | _ |
| Heterosexual sexual contact | 756 | _ | 791 | _ | 794 | _ | 822 | _ | 774 | _ |
| Perinatal exposure | 31 | _ | 30 | _ | 28 | _ | 29 | _ | 31 | _ |
| Other | 15 | _ | 14 | _ | 14 | _ | 12 | _ | 12 | _ |
| Unknown | 648 | _ | 653 | _ | 646 | _ | 704 | _ | 721 | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | 1568 | _ | 1585 | _ | 1565 | _ | 1565 | _ | 1486 | _ |
| Injection drug use (IDU) | 72 | _ | 74 | _ | 74 | _ | 75 | _ | 73 | _ |
| Perinatal exposure | 49 | _ | 48 | _ | 49 | _ | 53 | _ | 52 | _ |
| Other | 2 | _ | 2 | _ | 2 | _ | 2 | _ | 2 | _ |
| Unknown | 339 | _ | 339 | _ | 329 | _ | 356 | _ | 373 | _ |
| Transgender person | 555 | | 555 | | 025 | | 550 | | 0.0 | |
| Any sexual contact | 60 | _ | 71 | _ | 69 | _ | 85 | _ | 80 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 1 | _ | 1 | _ | 1 | _ | 1 | _ | 0 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 11 | _ | 12 | _ | 13 | _ | 14 | _ | 16 | _ |
| Overall | 6528 | 629.0 | 6640 | 640.3 | 6617 | 638.3 | 6864 | 661.0 | 6702 | 644.5 |

Living with diagnosed HIV: persons diagnosed with HIV on or before December 31 and resided in Tennessee on December 31, 2019

For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

⁻ represents data not available.

Table 60. Persons living with diagnosed HIV, West HIV community planning region, Tennessee, 2015–2019

| | 20 ⁻ | 15 | 20 ⁻ | 16 | 20 | 17 | 2018 | | | 2019 | |
|-----------------------------------|-----------------|-------|-----------------|-------|-----|-------|------|-------|-----|-------|--|
| | No. | Rate | No. | Rate | No. | Rate | No. | Rate | No. | Rate | |
| Gender | | | | | | | | | | | |
| Cisgender male | 609 | 236.1 | 614 | 240.1 | 609 | 237.6 | 622 | 242.8 | 615 | 241.0 | |
| Cisgender female | 239 | 88.9 | 238 | 88.8 | 238 | 89.1 | 242 | 90.7 | 241 | 90.5 | |
| Transgender person | 8 | _ | 10 | _ | 10 | _ | 8 | _ | 9 | _ | |
| Age group (years) | | | | | | | | | | | |
| <15 | 7 | 7.3 | 5 | 5.3 | 5 | 5.3 | 3 | 3.2 | 3 | 3.2 | |
| 15–24 | 39 | 55.5 | 41 | 59.4 | 34 | 49.7 | 39 | 57.6 | 34 | 51.0 | |
| 25–34 | 147 | 239.2 | 144 | 234.4 | 153 | 246.0 | 147 | 234.7 | 158 | 251.1 | |
| 35-44 | 183 | 290.6 | 175 | 285.7 | 176 | 289.3 | 188 | 309.2 | 171 | 282.8 | |
| 45-54 | 285 | 400.2 | 280 | 400.2 | 267 | 387.2 | 251 | 372.9 | 214 | 326.9 | |
| ≥55 | 195 | 118.3 | 217 | 130.0 | 222 | 131.7 | 244 | 142.9 | 285 | 164.8 | |
| Race/ethnicity | | | | | | | | | | | |
| Non-Hispanic Black | 486 | 478.0 | 493 | 491.0 | 489 | 484.3 | 494 | 489.8 | 500 | 498.2 | |
| Non-Hispanic white | 300 | 75.5 | 300 | 76.0 | 297 | 75.6 | 309 | 78.9 | 295 | 75.6 | |
| Hispanic | 43 | 271.5 | 42 | 258.2 | 41 | 242.1 | 40 | 230.9 | 42 | 235.8 | |
| Other | 27 | 224.6 | 27 | 217.5 | 30 | 235.5 | 29 | 222.5 | 28 | 209.5 | |
| Transmission risk | | | | | | | | | | | |
| Cisgender male | | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 369 | _ | 368 | _ | 378 | _ | 389 | _ | 390 | _ | |
| Injection drug use (IDU) | 49 | _ | 49 | _ | 46 | _ | 43 | _ | 41 | _ | |
| MMS and IDU | 38 | _ | 44 | _ | 36 | _ | 37 | _ | 31 | _ | |
| Heterosexual sexual contact | 108 | _ | 113 | _ | 110 | _ | 113 | _ | 108 | _ | |
| Perinatal exposure | 5 | _ | 5 | _ | 6 | _ | 6 | _ | 6 | _ | |
| Other | 4 | _ | 4 | _ | 3 | _ | 4 | _ | 4 | _ | |
| Unknown | 36 | _ | 31 | _ | 30 | _ | 30 | _ | 35 | _ | |
| Cisgender female | | | | | | | | | | | |
| Heterosexual sexual contact | 169 | _ | 170 | _ | 169 | _ | 173 | _ | 174 | _ | |
| Injection drug use (IDU) | 35 | _ | 33 | _ | 29 | _ | 30 | _ | 29 | _ | |
| Perinatal exposure | 3 | _ | 3 | _ | 4 | _ | 4 | _ | 4 | _ | |
| Other | 2 | _ | 2 | _ | 2 | _ | 2 | _ | 2 | _ | |
| Unknown | 30 | _ | 30 | _ | 34 | _ | 33 | _ | 32 | _ | |
| Transgender person | | | | | | | | | | | |
| Any sexual contact | 6 | _ | 8 | _ | 9 | _ | 7 | _ | 9 | _ | |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ | |
| Any sexual contact and IDU | 1 | _ | 1 | _ | 0 | _ | 0 | _ | 0 | _ | |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ | |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ | |
| Unknown | 1 | _ | 1 | _ | 1 | _ | 1 | _ | 0 | _ | |
| Overall | 856 | 162.5 | 862 | 164.6 | 857 | 163.7 | 872 | 166.7 | 865 | 165.8 | |

Living with diagnosed HIV: persons diagnosed with HIV on or before December 31 and resided in Tennessee on December 31, 2019

For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

- represents data not available.

Table 61. Persons living with diagnosed HIV, Middle HIV community planning region, Tennessee, 2015–2019

| | 201 | 15 | 20° | 16 | 20° | 17 | 201 | 2019 | | |
|-----------------------------------|------|-------|------|-------|------|-------|------|-------|------|-------|
| | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 4893 | 379.4 | 4908 | 374.3 | 4926 | 369.1 | 5067 | 373.9 | 5125 | 372.9 |
| Cisgender female | 1355 | 101.0 | 1377 | 101.1 | 1390 | 100.4 | 1388 | 98.7 | 1369 | 95.9 |
| Transgender person | 57 | _ | 55 | _ | 62 | _ | 79 | _ | 70 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 33 | 6.4 | 28 | 5.4 | 29 | 5.5 | 35 | 6.6 | 30 | 5.6 |
| 15–24 | 254 | 72.2 | 236 | 66.8 | 211 | 59.4 | 221 | 61.8 | 199 | 55.2 |
| 25-34 | 1029 | 271.2 | 1034 | 263.9 | 1107 | 274.5 | 1153 | 279.8 | 1192 | 283.4 |
| 35-44 | 1329 | 382.3 | 1295 | 370.4 | 1241 | 349.2 | 1234 | 340.6 | 1245 | 337.3 |
| 45-54 | 2156 | 609.7 | 2095 | 587.5 | 1995 | 557.5 | 1900 | 532.0 | 1792 | 505.7 |
| ≥55 | 1504 | 220.5 | 1652 | 235.5 | 1795 | 248.9 | 1991 | 268.6 | 2106 | 276.2 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 2779 | 830.4 | 2817 | 823.9 | 2877 | 822.7 | 2948 | 827.5 | 2956 | 815.9 |
| Non-Hispanic white | 2929 | 145.8 | 2930 | 144.1 | 2904 | 141.1 | 2939 | 141.3 | 2926 | 139.2 |
| Hispanic | 421 | 244.1 | 417 | 233.5 | 412 | 221.2 | 433 | 223.2 | 459 | 228.9 |
| Other | 176 | 152.9 | 176 | 146.5 | 185 | 147.3 | 214 | 163.0 | 223 | 162.9 |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 3363 | _ | 3395 | _ | 3417 | _ | 3535 | _ | 3619 | _ |
| Injection drug use (IDU) | 335 | _ | 329 | _ | 326 | _ | 315 | _ | 298 | _ |
| MMS and IDU | 276 | _ | 266 | _ | 252 | _ | 255 | _ | 245 | _ |
| Heterosexual sexual contact | 439 | _ | 450 | _ | 452 | _ | 460 | _ | 470 | _ |
| Perinatal exposure | 19 | _ | 19 | _ | 21 | _ | 24 | _ | 23 | _ |
| Other | 18 | _ | 19 | _ | 19 | _ | 17 | _ | 15 | _ |
| Unknown | 443 | _ | 430 | _ | 439 | _ | 461 | _ | 455 | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | 925 | _ | 953 | _ | 958 | _ | 962 | _ | 948 | _ |
| Injection drug use (IDU) | 217 | _ | 216 | _ | 217 | _ | 201 | _ | 193 | _ |
| Perinatal exposure | 27 | _ | 26 | _ | 27 | _ | 30 | _ | 31 | _ |
| Other | 8 | _ | 8 | _ | 7 | _ | 8 | _ | 7 | _ |
| Unknown | 178 | _ | 174 | _ | 181 | _ | 187 | _ | 190 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 46 | _ | 44 | _ | 51 | _ | 66 | _ | 60 | _ |
| Injection drug use (IDU) | 1 | _ | 1 | _ | 1 | _ | 1 | _ | 1 | _ |
| Any sexual contact and IDU | 4 | _ | 4 | _ | 5 | _ | 5 | _ | 4 | _ |
| Perinatal exposure | 1 | _ | 1 | _ | 1 | _ | 1 | _ | 1 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 5 | _ | 5 | _ | 4 | _ | 6 | _ | 4 | _ |
| Overall | 6305 | 239.7 | 6340 | 237.1 | 6378 | 234.6 | 6534 | 236.6 | 6564 | 234.3 |

Living with diagnosed HIV: persons diagnosed with HIV on or before December 31 and resided in Tennessee on December 31, 2019

For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

- represents data not available.

Table 62. Persons living with diagnosed HIV, Southeast HIV community planning region, Tennessee, 2015–2019

| | 201 | 15 | 20 | 16 | 20 ⁻ | 17 | 201 | 18 | 2019 | |
|-----------------------------------|------|-------|------|-------|-----------------|-------|------|-------|------|-------|
| | No. | Rate | No. | Rate | No. | Rate | No. | Rate | No. | Rate |
| Gender | | | | | | | | | | |
| Cisgender male | 1027 | 308.0 | 1053 | 313.2 | 1055 | 311.4 | 1103 | 322.3 | 1051 | 304.5 |
| Cisgender female | 325 | 92.9 | 330 | 93.6 | 331 | 93.2 | 334 | 93.2 | 322 | 89.1 |
| Transgender person | 12 | _ | 11 | _ | 10 | _ | 9 | _ | 8 | _ |
| Age group (years) | | | | | | | | | | |
| <15 | 5 | 4.2 | 6 | 5.0 | 5 | 4.2 | 5 | 4.1 | 7 | 5.8 |
| 15-24 | 45 | 51.5 | 54 | 62.3 | 45 | 52.0 | 36 | 41.5 | 23 | 26.5 |
| 25-34 | 203 | 233.0 | 199 | 222.2 | 201 | 220.1 | 218 | 234.7 | 217 | 228.8 |
| 35-44 | 287 | 337.9 | 286 | 338.9 | 296 | 351.4 | 278 | 328.4 | 269 | 316.8 |
| 45–54 | 497 | 534.5 | 481 | 517.0 | 454 | 490.3 | 463 | 503.4 | 411 | 451.0 |
| ≥55 | 327 | 155.3 | 368 | 171.4 | 395 | 180.5 | 446 | 199.9 | 454 | 199.3 |
| Race/ethnicity | | | | | | | | | | |
| Non-Hispanic Black | 510 | 631.9 | 521 | 640.4 | 530 | 646.5 | 547 | 664.3 | 523 | 631.9 |
| Non-Hispanic white | 757 | 137.8 | 770 | 139.5 | 771 | 139.1 | 805 | 144.3 | 755 | 134.4 |
| Hispanic | 75 | 240.6 | 80 | 244.9 | 72 | 210.1 | 74 | 206.4 | 77 | 205.5 |
| Other | 22 | 99.4 | 23 | 101.1 | 23 | 97.9 | 20 | 82.6 | 26 | 104.3 |
| Transmission risk | | | | | | | | | | |
| Cisgender male | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 710 | _ | 704 | _ | 713 | _ | 744 | _ | 713 | _ |
| Injection drug use (IDU) | 61 | _ | 62 | _ | 62 | _ | 63 | _ | 58 | _ |
| MMS and IDU | 48 | _ | 58 | _ | 46 | _ | 58 | _ | 48 | _ |
| Heterosexual sexual contact | 91 | _ | 102 | _ | 105 | _ | 110 | _ | 113 | _ |
| Perinatal exposure | 2 | _ | 4 | _ | 3 | _ | 3 | _ | 6 | _ |
| Other | 7 | _ | 7 | _ | 6 | _ | 5 | _ | 6 | _ |
| Unknown | 108 | _ | 116 | _ | 120 | _ | 120 | _ | 107 | _ |
| Cisgender female | | | | | | | | | | |
| Heterosexual sexual contact | 208 | _ | 216 | _ | 220 | _ | 223 | _ | 206 | _ |
| Injection drug use (IDU) | 44 | _ | 42 | _ | 41 | _ | 37 | _ | 39 | _ |
| Perinatal exposure | 2 | _ | 3 | _ | 3 | _ | 3 | _ | 2 | _ |
| Other | 2 | _ | 2 | _ | 2 | _ | 2 | _ | 2 | _ |
| Unknown | 69 | _ | 67 | _ | 65 | _ | 69 | _ | 73 | _ |
| Transgender person | | | | | | | | | | |
| Any sexual contact | 11 | _ | 10 | _ | 9 | _ | 7 | _ | 6 | _ |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Any sexual contact and IDU | 1 | _ | 1 | _ | 1 | _ | 2 | _ | 2 | _ |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ |
| Unknown | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | |
| Overall | 1364 | 199.6 | 1394 | 202.4 | 1396 | 201.2 | 1446 | 206.4 | 1381 | 195.4 |

Living with diagnosed HIV: persons diagnosed with HIV on or before December 31 and resided in Tennessee on December 31, 2019

For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

- represents data not available.

Table 63. Persons living with diagnosed HIV, East HIV community planning region, Tennessee, 2015–2019

| | 20° | 15 | 201 | 16 | 20° | 17 | 2018 | | | 2019 | | |
|-----------------------------------|------|-------|---------|-------|------|-------|------|-------|------|-------|--|--|
| | No. | Rate | No. | Rate | No. | Rate | No. | Rate | No. | Rate | | |
| Gender | | | | | | | | | | | | |
| Cisgender male | 1655 | 197.4 | 1778 | 210.7 | 1799 | 211.6 | 1859 | 217.1 | 1836 | 212.9 | | |
| Cisgender female | 407 | 46.6 | 426 | 48.5 | 447 | 50.5 | 461 | 51.7 | 495 | 55.2 | | |
| Transgender person | 17 | _ | 18 | _ | 16 | _ | 20 | _ | 21 | _ | | |
| Age group (years) | | | | | | | | | | | | |
| <15 | 11 | 3.8 | 13 | 4.5 | 12 | 4.1 | 11 | 3.8 | 10 | 3.5 | | |
| 15-24 | 71 | 31.8 | 80 | 36.0 | 85 | 38.3 | 79 | 35.5 | 82 | 37.0 | | |
| 25-34 | 238 | 118.0 | 275 | 133.6 | 284 | 135.2 | 312 | 146.1 | 332 | 152.6 | | |
| 35-44 | 464 | 222.2 | 459 | 223.0 | 440 | 215.3 | 441 | 216.2 | 416 | 203.9 | | |
| 45-54 | 762 | 319.0 | 770 | 322.5 | 742 | 311.5 | 737 | 312.4 | 711 | 305.6 | | |
| ≥55 | 533 | 97.2 | 625 | 111.7 | 699 | 122.7 | 760 | 130.7 | 801 | 135.0 | | |
| Race/ethnicity | | | | | | | | | | | | |
| Non-Hispanic Black | 383 | 565.5 | 433 | 632.2 | 442 | 638.3 | 447 | 638.4 | 437 | 618.3 | | |
| Non-Hispanic white | 1553 | 101.2 | 1632 | 105.9 | 1653 | 106.8 | 1712 | 110.1 | 1719 | 110.1 | | |
| Hispanic | 95 | 158.7 | 106 | 170.3 | 111 | 170.4 | 123 | 181.1 | 137 | 194.5 | | |
| Other | 48 | 96.1 | 51 | 98.7 | 56 | 104.5 | 58 | 104.6 | 59 | 103.2 | | |
| Transmission risk | | | | | | | | | | | | |
| Cisgender male | | | | | | | | | | | | |
| Male-to-male sexual contact (MMS) | 1192 | _ | 1266 | _ | 1291 | _ | 1340 | _ | 1311 | _ | | |
| Injection drug use (IDU) | 96 | _ | 108 | _ | 102 | _ | 96 | _ | 98 | _ | | |
| MMS and IDU | 83 | _ | 92 | _ | 96 | _ | 112 | _ | 118 | _ | | |
| Heterosexual sexual contact | 197 | _ | 213 | _ | 204 | _ | 214 | _ | 214 | _ | | |
| Perinatal exposure | 13 | _ | 14 | _ | 14 | _ | 15 | _ | 15 | _ | | |
| Other | 7 | _ | 7 | _ | 6 | _ | 8 | _ | 6 | _ | | |
| Unknown | 67 | _ | , 78 | _ | 86 | _ | 74 | _ | 74 | _ | | |
| Cisgender female | 0, | | , 0 | | 00 | | , , | | , , | | | |
| Heterosexual sexual contact | 283 | _ | 292 | _ | 312 | _ | 319 | _ | 339 | _ | | |
| Injection drug use (IDU) | 75 | _ | 80 | _ | 77 | _ | 81 | _ | 95 | _ | | |
| Perinatal exposure | 10 | _ | 12 | _ | 10 | _ | 11 | _ | 13 | _ | | |
| Other | 1 | _ | 1 | _ | 1 | _ | 1 | _ | 0 | _ | | |
| Unknown | 38 | _ | 41 | _ | 47 | _ | 49 | _ | 48 | _ | | |
| Transgender person | 50 | | 7. | | 7, | | 7,5 | | 70 | | | |
| Any sexual contact | 14 | _ | 15 | _ | 14 | _ | 17 | _ | 16 | _ | | |
| Injection drug use (IDU) | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 10 | _ | | |
| Any sexual contact and IDU | 2 | _ | 2 | _ | 1 | _ | 2 | _ | 3 | _ | | |
| Perinatal exposure | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ | | |
| Other | 0 | _ | 0 | _ | 0 | _ | 0 | _ | 0 | _ | | |
| Unknown | 1 | _ | 1 | _ | 1 | _ | 1 | _ | 1 | _ | | |
| Overall | 2079 | 121.4 | 2222 | 129.0 | 2262 | 120.2 | 2340 | 133.9 | 2352 | 133.7 | | |
| Overall | | | | | | 130.3 | 2340 | 155.9 | 2352 | 155./ | | |

Living with diagnosed HIV: persons diagnosed with HIV on or before December 31 and resided in Tennessee on December 31, 2019

For persons living with diagnosed HIV, age group refers to age as of December 31, 2019.

Hispanics can be of any race.

Transmission risk categories are mutually exclusive; heterosexual sexual contact includes high risk heterosexuals and persons who had sexual contact with someone of the opposite sex and said no to injecting drugs; other includes blood transfusion and hemophilia; unknown indicates no identified risk (NIR) and no reportable risk (NRR).

X represents suppressed data. See technical notes for suppression rules.

[—] represents data not available.